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ABSTRACT 
Background 
Currently evidence regarding influence of the HER tyrosine kinase family - EGFR, 
HER2, HER3 and HER4 - during disease progression in prostate adenocarcinoma is 
conflicting – both poor prognosis and no influence on outcome are reported. A small 
cohort  pilot  study  of  paired  hormone  sensitive  (HSPC)  and  refractory  (HRPC) 
specimens demonstrated HER2/HER4 as positively prognostic in HSPC. Heregulin 
(HRG),  a  principle  HER  family  ligand,  has  previously  been  noted  to  have  a 
differential  effect  on  HSPC  (decreased  proliferation)  and  HRPC  (increased 
proliferation) cell lines. This study determines influence of HER family and HRG in a 
larger  HSPC  cohort  and  whether  influence  mechanisms  involve  proliferation  or 
apoptosis. 
 
Patients and Methods 
Immunohistochemical  staining  for  HRG,  KI67  (proliferation),  TUNEL  (apoptosis) 
was  performed  on  pilot  study  specimens.  Further  IHC  for  EGFR,  HER2,  HER3, 
HER4,  HRG,  KI67  and  TUNEL  was  performed  on  HSPC  tissue  microarrays. 
Correlations between target protein expression and the outcomes time to biochemical 
relapse and overall survival were determined. 
 
Result 
High expression of HER/HRG was correlated with improved prognosis particularly in 
androgen deprivation treated subcohort (e.g. high EGFR and longer time to relapse 
p=0.02, high HER2 and delayed relapse p=0.002, high HRG and delayed relapse-
p=0.004).  High  expression  of  multiple  markers  increased  association  significance   2 
(e.g. high HER1-4 and delayed relapse p=0.001). No correlations between HER and 
proliferation or apoptosis were seen. 
 
Conclusion 
The HER family and HRG are positively prognostic in prostate adenocarcinoma. This 
has implications for the use of HER family as outcome predictors to guide 
management. 
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CHAPTER 1: BACKGROUND 
1.1 PROSTATE ADENOCARCINOMA 
Prostate Carcinoma (CaP) is a significant and growing health issue in the UK and the 
rest of the developed world and the focus of many areas of research. Adenocarcinoma 
comprises over 95% of CaP (Tanagho et al. 2004) arising primarily in the peripheral 
zone (85%) or transitional zone (15%) of the prostate. 
 
In the UK incidence of CaP has risen significantly to become the most commonly 
diagnosed cancer in males. There were 31 900 CaP diagnoses in the UK in 2003 
(Cancer Research UK: UK Prostate Cancer Statistics) representing 23% of new male 
cancers and 12% cancers overall. Incidence varied between UK regions with 110/100 
000 in England, 140/100 000 in Wales 95/100 000 in Scotland and 86/100 000 in 
Northern Ireland (Cancer Research UK: UK Prostate Cancer Statistics). There has 
been a rise in UK incidence from ~34/100 000 in 1975 to 109/100 000 in 2003. This 
increase  may  be  due  to  a  combination  of  implementation  of  widespread  Prostate 
Specific Antigen (PSA) testing and the generally aging demographic of the Western 
world.  Age  remains  the  principle  risk  factor  for  development  of  CaP  rising  from 
extremely few cases diagnosed below the age of 50 increasing to 120/100 000 at 55-
59, 450/100 000 at 75-79 to just under 900/100 00 at over 85 (Selley et al 1997).  
 
 
Worldwide the USA has the highest incidence in CaP with over 120/100 000 males 
compared to 54/100 000 males in the UK in 2002 (Ferlay et al 2002). Post mortem 
analysis indicates a 40% lifetime risk of CaP development (Tanagho et al. 2004). 
   23 
UK CaP mortality has also increased over the past 30 years however not to the same 
extent as incidence. In 2005 there were 10 000 CaP deaths (34/100 000) again varying 
between the regions England 34/100 000, Wales 36/100 000, Scotland 31/100 000, 
Northern Ireland 26/100 000 (Cancer Research UK: UK Prostate Cancer Statistics) 
This represents 13% male cancer deaths, the 2
nd most frequent cause of cancer death 
behind lung. As with incidence, mortality rises sharply with age from virtually no 
patients below the age of 50 to 800/100 000 at over 85 years old. UK age standardised 
mortality was 25/100 000 in 2005 compared to 20/100 000 in 1975 however the rise 
took place in the 1980s and now appears to have been a slight fall since the early 
1990s (Majeed et al. 2000). Similar falls have been seen in the USA (Tarone et al. 
2000) and Europe (Levi et al. 2000), this has been attributed to increased screening, 
treatment improvement (Hankey et al. 1999) and changes in cancer death attribution 
or coding (Feuer et al. 1999, Swerdlow et al. 2001) but a definite explanation has yet 
to emerge. 
 
1.1.1  HORMONAL TREATMENT OF PROSTATE ADENOCARCINOMA 
Treatment options for CaP are determined by stage as defined by the TNM staging 
system. For local organ-confined CaP (T1-2) there are several potentially curative 
options including radical prostatectomy, radical radiotherapy and brachytherapy. In 
general the mainstay of locally advanced (T3-4) or nodal/distant metastatic disease is 
endocrine therapy alone or combined with radiotherapy (at this time prostatectomy 
also an option in low grade T3a disease). While clinical trials are ongoing there are 
few chemotherapeutic agents e.g. Docetaxel (Tannock et al. 2004), that have been 
shown to be effective in prostate cancer, certainly none that are more effective with a 
better side effect profile than endocrine therapy in newly diagnosed CaP. In patients   24 
with  low  grade,  low  volume  disease  a  strategy  of  watchful  waiting  –  delaying 
treatment until biochemical progression occurs – can also be employed 
 
1.1.1.1 HORMONAL REGULATION 
Endocrine  treatment  is  based  on  the  interaction  of  CaP  cells  with  the  androgen 
production axis (Fig. 1). Production of Testosterone, the principle androgen in men, is 
coordinated centrally via the hypothalamic-pituitary-gonadal axis and feedback loop. 
The  axis  is  initiated  by  release  of  gonadotrophin-releasing  hormone  (GnRH,  also 
termed  Luteinising  Hormone  Releasing  Hormone)  by  the  hypothalamus.  GnRH  is 
released  in  pulsatile,  circadian  and  seasonal  manner  as  well  as  variation  at  key 
developmental times of life such as puberty. GnRH acts on the anterior pituitary gland 
stimulating production and release of luteinising hormone (LH) into the circulation. In 
a parallel system corticotrophin-releasing hormone released from the hypothalamus 
stimulates adrenocorticotropic hormone (ACTH) secretion by the pituitary. LH acts 
on Leydig cells in the testes stimulating production of testicular testosterone which 
makes up 95% of circulating testosterone. Testosterone is also produced in the adrenal 
gland in response to ACTH, in both testis and adrenals it is produced via the gamma-5 
metabolic pathway of steroid hormone synthesis. 
 
Circulating testosterone is mainly bound to sex hormone binding globulin with only a 
small  fraction  free.  Testosterone  enters  prostatic  cells  by  passive  diffusion  and  is 
converted  to  the  more  potent  dihydrotestosterone  (DHT)  by  5-α-reductase  or  to 
oestradiol by 5-α-aromatase. DHT has multiple cellular functions but also acts as a 
negative  feedback  agent  acting  on  the  hypothalamus  to  reduce  GnRH  production 
completing a negative feedback loop. Oestradiol also forms a negative feedback loop   25 
acting at the pituitary to reduce LH secretion. Endocrine therapies for CaP act via 
interference with the androgen production axis (see below) 
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1.1.1.2 THE ANDROGEN RECEPTOR 
Prostatic testosterone and DHT both act by binding to the androgen receptor (AR) 
(Fig. 1.2); DHT has a 10 times greater affinity than testosterone (Suzuki et al. 2003). 
The AR is a steroid hormone receptor encoded by a gene on the long arm of the X 
chromosome and comprises 4 main functional domains (Culig et al. 2002); 
·  Amino-terminal regulatory domain – contains the activation function region 
AF-1 which allows binding of multiple co-factors and protein kinase pathway 
members  and  is  important  in  transactivation/transcription  regulation. 
(Rochette-Egly 2003) 
·  DNA-binding  domain  (DBD)  –  includes  2  zinc  finger  motifs  that  bind  to 
androgen  response  elements  (ARE)  nucleotide  sequences  in  the  promoter 
regions  contained  within  target  androgen  regulated  genes  (Lee  and  Chang 
2003) 
·  Dimerisation/Hinge domain – responsible for dimerisation and translocation to 
the  nucleus  following  ligand  binding.  Contains  nuclear  localisation  signal 
(NLS) region that facilitates this. Phosphorylation of this region may cause 
inactivation of the AR. (Rochette-Egly 2003) 
·  Ligand-binding  domain  –  contains  the  site  for  DHT/testosterone  binding 
causing  AR  activation  and  the  activation  function  AF-2  region  which  also 
interacts with cofactors influencing transcription (Rochette-Egly 2003)   27 
 
 
Pre-activation AR is bound to heat shock proteins which prevent degradation. Ligand 
binding  induces  a  conformational  change  and  dissociation  from  these  heat  shock 
proteins. This is followed by phosphorylation of AR stabilising the ligand-receptor 
complex which then dimerises (Lee and Chang 2003) and translocates to the nucleus 
where  the  DNA-binding  region  binds  to  AREs  initiating  androgen  directed 
transcription. After binding transcription is further regulated by co-factors which bind 
to AR aiding formation of a stable pre-initiation complex facilitating transcription.  
Androgen  directed  transcription  results  in  an  increase  in  cell  proliferation  and 
decrease in apoptosis stimulating prostatic tissue growth amongst other effects. 
 
1.1.1.3 METHODS OF HORMONAL TREATMENT OF PROSTATE 
            ADENOCARCINOMA 
Hormonal treatment of  CaP also termed Androgen  Deprivation Therapy  (ADT) is 
based  on  the  principle  that,  in  a  similar  fashion  to  breast  cancer  cells  expressing 
oestrogen/progesterone  receptors,  CaP  cells  express  AR  making  CaP  androgen 
dependent. Androgen suppression as a treatment for CaP has been noted since 1941 
when  Huggins  et  al.  demonstrated  reduction  in  CaP  related  symptoms  following 
surgical castration or diethylsilboestrol (DES) therapy after which survival benefits of 
NH2  COOH 
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Figure 1.2: Structure of the Androgen Receptor. Bands in the amino 
terminal region represent polymorphic trinucleotide repeats e.g.CAG   28 
endocrine treatment in metastatic CaP were shown (Nesbit et al. 1950). The oestrogen 
DES acts on the pituitary (Fig 1.3) to reduce pituitary LH production in response to 
hypothalamic GnRH as oestrogens act naturally as negative feedback agents in the 
androgen  production  axis.  With  reduced  LH  production  stimulation  of  testicular 
testosterone production falls (Blackard et al. 1970). As mentioned above endocrine 
therapy is utilised where curative radical therapy is inappropriate either due to the 
nature  of  the  cancer  –  local  or  distant  metastasis,  or  the  patient  –  elderly  and/or 
significant  comorbidities.  Additionally  hormone  therapy  is  used  as  neoadjuvant 
treatment with radiotherapy in T3 disease and as second line therapy in patients who 
suffer recurrence after prostatectomy/radiotherapy. 
Since  its  inception  methods  of  hormonal  therapy  have  developed  with  neither 
orchidectomy nor DES remaining first line. The sites of action of ADT agents are 
shown in Fig.1.3 Common agents include 
·  Androgen  Antagonists  (also  known  as  antiandrogens)  –  interfere  with 
activation of AR androgen-androgen receptor complex formation directly in 
tumour cells by competitive binding to AR or inactivating androgens before 
binding.  Target  androgens  whether  the  source  is  testicular  or  adrenal. 
Examples include 2-hydroxyflutamide, the metabolite of the agent flutamide, 
bicalutamide and cyproterone acetate. Antiandrogens can be used as single 
agents (Wellington et al. 2006) but are more commonly used in combination 
with other medications or orchidectomy. While antagonistic to CaP in most 
cases antiandrogens have stimulated cell proliferation in certain CaP cell lines 
and conversion from antagonist to agonist activity may be one mechanism 
behind hormone escape (see below).   29 
·  Gonadotrophin  Releasing  Hormone  Agonists  –  target  the  hypothalamic-
pituitary-gonadal hormone axis to reduce circulating androgen concentrations. 
These act at the pituitary by first stimulating LHRH receptors but ultimately 
causing receptor downregulation and thereby blocking hypothalamic-pituitary 
signaling and gonadotrophin secretion (Schally et al. 1992). GnRH agonists 
such as Goserelin therefore block the production of testicular but not adrenal 
testosterone. The agonistic nature of theses agents entails a brief flare-up with 
increased testosterone risking a transient worsening of disease hence a short 
course of antiandrogen is often used to cover the first dose of GnRH inhibitor. 
Side  effect  profile  includes  impotence,  loss  of  libido,  hot  flashes, 
gynaecomastia  and  osteoporosis;  it  does  not  include  the  increased  risk  of 
cardiovascular complications of DES and is considerably better than that of 
cytotoxic chemotherapeutic agents. 
·  Maximal  Androgen  Blockade  –  Antiandrogen  with  GnRH  analogue  or 
orchidectomy 
Rate of response to hormonal therapy as assessed by symptom relief, reduction in 
primary  tumour  size  or  fall  in  acid  phosphatase/PSA  varies  40-80%  between 
studies (Murphy et al. 1980, Wein 2007). Endocrine treatment is not considered 
curative although at least one study has claimed this (Johansson et al. 1981)). A 
complete response with disappearance of all detectable disease is seen in only 5-
10% (Murphy et al 1980). Progression despite hormonal treatment, also known as 
hormone escape or progression from hormone sensitive CaP (HSPC) to hormone 
refractory/resistant CaP (HSPC) occurs almost universally (Feldman et al. 2001) 
with time to progression   30 
 
 
18  –  36  months  varying  between  studies  (Trachtenberg  et  al  2002,  Wein  2007). 
Hormone escape occurs in 2 stages, a transition stage with tumour cells still requiring 
androgen to proliferate but not requiring androgen to survive then an outgrowth phase 
with androgen required neither for survival nor growth (Craft & Chhor). Progression 
can  be  defined  as  either  physically  –  by  increase  in  size  of  lesion/s  by  25%  or 
appearance of new lesion (Wein 2007) or biochemically – by rise in acid phosphatase 
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or,  much  more  frequently,  PSA  from  a  nadir  achieved  after  commencement  of 
hormone therapy. 
 
Prognosis in CaP is much reduced following hormone escape with mean time to death 
from escape 9-12 months (Henry et al. 1999). Much research in prostate cancer has 
focussed  on  factors  contributing  to  hormone  escape  and  potential  treatments  for 
HRPC.  Current  available  strategies  involve  further  hormonal  manipulation  e.g. 
removal of antiandrogen (20-30% demonstrate secondary PSA response)/conversion 
to maximal androgen blockade and cytotoxic chemotherapy e.g. Docetaxel. 
 
1.1.2  MOLECULAR  BIOLOGY  OF  PROSTATE  ADENOCARCINOMA;  AN 
OVERVIEW 
Many  genes and gene products have been investigated for their influence on CaP 
development, in particular oncogenes, the androgen receptor, growth factors, growth 
factor receptors and their transcription pathways. 
 
9% CaP can be linked to one of a number of genes which increase likelihood of CaP 
development inherited in an autosomal dominant fashion. Such inheritance is seen 
more frequently in tumours presenting at a younger age (Carter et al. 1992). Deletion 
of  Tumour  Suppressor  Genes  at  several  chromosomal  loci  (Isaacs  et  al.  1995) 
including 8p, 10q, 13q (Retinoblastoma-Bookstein et al 1990), 16q (Breast Cancer 
Antioestrogen Receptor 1 (Fromont et al. 2007), 17p and 18q have been linked to 
localised CaP. In particular deletion at 8p22 is found in 70% localized CaP (Macoska 
et al. 1994) and E-cadherin at 16q deleted in 60% of metastatic CaP (Umbas et al. 
1994). As in other cancers p53 mutation is associated with 50% high grade metastatic   32 
CaP (Navone et al. 1993). A Tumour Suppressor Gene mapped to 10q23 which codes 
for  protein  PTEN  (Li  et  al.  1997),  a  tyrosine  phosphatase,  which  appears  to  be 
mutated in a large number of cancer cell lines with a greater proportion CaP cell lines 
(100%) versus other cancer types (31% glioblastoma, 6% breast Ca etc). Mutation of 
PTEN results in loss of expression therefore the PI3K/AKT pathway is upregulated 
(Davies et al. 1999). 
 
Given the importance of androgenic stimulation in normal prostatic development as 
well as CaP (Feldman et al. 2001) and the pivotal role of androgen therapy in CaP 
attention relating to hormone escape has focussed on dysfunction of the androgen 
receptor  (AR)  in  development  of  CaP  and  subsequent  development  of  hormone 
escape. Evidence for AR involvement of AR in HRPC includes high AR expression in 
recurrent CaP (Van der Kwast et al. 1991)) and inhibition of proliferation of hormone 
refractory cell lines by in vitro inhibition of AR. 
Several  mutations  have  been  identified  affecting  the  ligand  binding  region  of  AR 
which  allow  a  number  of  alternative  ligands  even  antiandrogens  such  as 
hydroxyflutamide (Taplin et al. 1999) to stimulate transcriptional activity and tumour 
growth.  Such  mutations  have  been  shown  to  develop  in  response  to  antiandrogen 
therapy itself and form the theoretical basis for the secondary PSA response when 
discontinuing antiandrogen therapy following hormone escape. Additional mutations 
have been noted in the transactivation amino-terminal domain allowing AR stimulated 
transcriptional activity without ligand binding (Wallen et al. 1999). These include a 
CAG  polymorphism  site  where  a  shorter  CAG  repeat  length  is  associated  with 
increased  CaP  risk  (Irvine  et  al.  1995).  More  than  60  AR  mutations  have  been   33 
described in CaP (Debes et al. 2002) however such mutations are only found in 10-
20% CaP in vivo (Suzuki et al 2003, Taplin 2003). 
 
The  rate  of  AR  gene  amplification  has  been  shown  to  be  significantly  higher 
following development of hormone escape (Brown et al. 2002, Edwards et al. 2003). 
Approximately 20-30% of HRPC samples have AR amplification compared to 0-5% 
in HSPC (Edwards et al. 2003) and this study also showed an association between AR 
amplification and reduced survival. While most tumours with AR amplification also 
demonstrated increased AR protein expression increased protein expression did not 
influence  survival  although  this  may  reflect  more  accurate  detection  of  gene 
amplification by FISH than corresponding protein expression by IHC. A xenograft-
model study demonstrated increased AR mRNA expression related to hormone escape 
independent  of  gene  amplification  (Chen  CD  et  al.  2000)  although  this  does  not 
represent the normal mechanism of AR upregulation in prostate cancer. These studies 
indicate that AR gene amplification and consequent increased AR protein expression 
in CAP cells allow a response to the reduced androgen levels in patients on GnRH 
analogues/antiandrogens thereby allowing progression in spite of hormonal therapy. 
 
Increased phosphorylation of  AR via  a number of MAP kinase/AKT kinases also 
increased sensitivity to low androgen levels (Rochette-Egly 2003) and increased MAP 
kinase  correlates  with  CaP  grade  and  stage  (Uzgare  et  al.  2003)  and  is  found  in 
increased levels in HRPC (Bakin et al. 2003). AR phosphorylation is one of a number 
of mechanisms whereby AKT may influence CaP development, higher AKT activity 
is found in CaP than benign prostate disease (Liao et al 2003) and it is higher in 
HRPC  cell  lines  (Ghosh  et  al.  2002).    Activation  of  Akt  has  been  significantly   34 
associated  with  decreased  survival  in  hormone  refractory  tumours  (Edwards  et  al. 
2006) and strongly correlates with phosphorylation of the AR at serine 210 in the 
same patient cohort (McCall et al 2008). 
 
Additionally  the  roles  of  several  cofactors  which  bind  to  AR  and  alter  its 
transcriptional activity have been investigated in relation to CaP and hormone escape. 
Examples  include  CBP  (cAMP  response  element  binding  protein)  which  is 
overexpressed in HRPC and has been shown to allow hydroxyflutamide to activate 
AR in vitro (Gelfanov et al 2001) and ARA70, also upregulated in HRPC, has been 
shown  to  allow  bicalutamide  to  act  as  an  AR  ligand  (Yeh  et  al.  1996).  C-Jun  a 
cofactor which binds to the intracellular AR domain allows ligand independent signal 
transduction (Rochette-Egly 2003). Other cofactors e.g. STAT3 bind with AR and 
effect translocation of AR to the nucleus (Lee SO et al. 2003). The STAT3 pathway 
has been shown to be activated by interleukin-6 accompanied by conversion from 
HSPC to HRPC (Tam et al 2007), in fact IL-6 has been suggested as being linked to 
prostate cancer morbidity for over 10 years (Twillie et al. 1995). 
 
Increased expression of a number of growth factors (EGF, TGF-α, FGF etc.) have 
been linked to the earliest stages of CaP including changes in stromal-epithelial cell 
interactions  and  angiogenesis  necessary  for  tumour  development  and  invasion. 
Increased vascular endothelial growth factor stimulated by other growth factors in 
tumour  epithelial  cells  plays  in  particular  has  been  linked  to  angiogenesis  and 
subsequent invasion (Foster et al. 2002, Bhowmick et al 2004, Chung et al. 2005). 
TGF-α has been reported as having a tumour suppressor function (Kambhampati et al. 
2005).   35 
 
Several  intracellular  signal  transduction  pathways  have  been  implicated  in 
development of HRPC via bypassing AR. In addition to acting on the AR the MAP 
kinase pathway members are upregulated in HRPC and hormone escape has been 
shown  occur  by  transfection  with  Raf  via  the  MAP  kinase  pathway  (Bakin  et  al. 
2003,) independent of AR. C-Jun combines with c-Fos forming transcription factor 
Activated Protein 1 (AP1) which can activate AR targets without AR involvement 
(Edwards, Krishna et al. 2004). Components of the hedgehog signalling cascade are 
upregulated in CaP cell lines compared to normal prostate tissue and may stimulate 
growth in CaP (Karhadkar et al 2004). Several ligands and members of the Wnt/β-
catenin signalling pathway are overexpressed in HSPC and HRPC cell lines (Chen G 
et  al.  2004).  Additionally  several  neuropeptides  acting  via  G-protein-coupled 
receptors influence multiple tumorigenic cascades to upregulate CaP proliferation and 
metastasis (Mimeault et al. 2003). 
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1.2 HER FAMILY 
1.2.1  HER1-4 
The  HER  (Human  Epidermal  Growth  Factor  Receptor)  family  of  transmembrane 
glycoprotein  receptor  molecules  consists  of  4 members;  Epidermal  Growth  Factor 
Receptor (EGFR also termed HER1 and ErbB1), HER2 (ErbB2), HER3 (ErbB3) and 
HER4  (ErbB4)  and  their  variants.  EGFR  was  first  noted  to  be  connected  with 
oncogenesis  in  the  1980s  during  study  of  the  avian  erythroblastosis  tumour  virus 
which encodes an aberrant form of human EGFR (Burden et al 1997). HER2 was then 
identified due to homology to but distinction from EGFR (Schechter et al. 1984) and 
its amplification in mammary carcinoma (King et al. 1985). The gene loci for the 
HER family are EGFR 7p12, HER2 17q11, HER3 12q13, HER4 2q34. Classically the 
EGFR family members  are usually considered as transmembrane  receptors and as 
such are located in the cell membrane unless internalised to the cytoplasm as part of 
signalling cascade (Carraway et al. 2001). One specific pathway involves cleavage of 
HER4  by  tumor  necrosis  factor  α  converting
  enzyme  and  presenilin-dependent 
secretase  allowing  the  cytoplasmic  portion  to  be  internalised  and  accumulate  in 
mitochondria  stimulating  apoptosis  (Vidal  et  al.  2005).  However,  more  recent 
research has revealed that HER3 may also be involved with signaling pathways within 
the cell nucleus (Koumakpayi et al. 2006) associated with oncogenesis.  
HER family members have a common structure (Fig 1.4) with 3 domains;- 
·  Extracellular domain – the ligand binding domain (LBD) containing 2 cysteine 
rich regions and is glycosylated. The ligand specificity of this region varies 
between family members 
·  Transmembrane domain – single helix of 23 hydrophobic amino acids which 
anchors the receptor to the cell membrane   37 
·  Intracellular domain – has tyrosine kinase (TK) activity, responds to ligand 
binding with initiation of signal transduction 
 
 
 
Total  molecular  weight  of  the  EGFR  molecule  is  170  kD  40  kD  of  which  is 
carbohydrate moieties (Ennis et al. 1991). HER2 has a weight of 185 kD. While there 
is a great deal of homology between family members only EGFR and HER4 have all 
domains  fully  functioning  –  HER3  has  impaired  tyrosine  kinase  activity  largely 
relying on heterodimerisation (Guy et al. 1994) (see below) to function, HER2 has no 
known specific ligand (Klapper et al. 1999). 
The mechanisms by which the HER family translate extracellular ligand signalling 
into cell activity is complex and has been termed a layered signalling network (Fig 
1.5)  (Yarden  et  al.  2001).  The  first  or  input  layer  consists  of  the  HER  family 
molecules themselves and their ligands. All HER ligands belong to the Epidermal 
Growth  Factor (EGF) family  containing a 60  amino acid EGF-like domain and 3 
disulphide-bonded  intramolecular  loops.  Ligands  binding  to  EGFR  include  EGF, 
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Figure 1.4: Generic structure of HER family member.   38 
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heparin  binding  EGF-like  growth  factor,  epiregulin,  TGFα,  amphiregulin  and 
betacellulin (Warren et al. 2006). HER3 and HER4 ligands are termed neuregulins 
(NRG) a large family made up of splice variants of 4 NRG genes (Falls et al. 2003). 
Heregulins (HRG) are one subtype of NRGs. Some ligands have narrow specificity 
e.g. EGF, NRG4 while others can bind to 2 receptor types e.g. epiregulin (Jones et al. 
1999). 
 
Ligand binding initially stimulates dimerisation of HER family members, both hetero- 
and  homodimers  are  formed  with  HER2  being  the  most  common  co-receptor  in 
heterodimers (Mass et al. 2004, Graus et al. 1997) and HER2-HER3 the strongest 
dimer combination (Slikowski et al. 1994). Several factors are thought to make HER2 
the preferred choice in heterodimers. HER2 increases the ligand binding affinity of its 
heterodimer partner (Slikowski 1994) and the specific crystal structure of HER2 is 
dimer favourable (Garret et al. 2003). HER2 heterodimers have greater activity than 
others due to decreased ligand dissociation rate (Karunagaran et al. 1996), defective 
ubiquitin  degradation  (Lenferink  et  al.  1998)  (see  below)  and  multiple  pathway 
activation by the HER2-HER3 heterodimer (Ben-Levey et al. 1994). 
Specific inter-receptor binding and dimer makeup are mediated by ligands but also by 
relative availability of HER family molecules for example while HER2 has no direct 
ligand, overexpression increases HER2 participation in heterodimer formation. Indeed 
this can change cellular ligand specificity as ligands better at recruiting HER2 as a co-
receptor will be favoured (Yarden 2001). HER2 does not typically form homodimers 
but can do in the case of mutation or overexpression (Brennan et al. 2000, Penuel et 
al. 2002). The precise mechanism of dimerisation has not been fully defined as each   40 
of the 3 domains has been shown to be involved and none fully responsible for dimer 
linkage (Warren et al. 2006). 
 
The signal-processing layer is the next layer in the signal network and consists of an 
array  of  enzymes,  proteins  and  secondary  messengers  involved  in  multiple  inter-
related transduction cascades. Which messengers are involved depends on the initial 
ligand,  the  structure  and  effector  sites  of  HER  family  dimer  and  the  types  and 
availability  of  phosphotyrosine-binding  proteins  associated  with  the  tails  of  HER 
molecules following dimerisation. Signals resulting from different dimers have been 
shown  to  be  different  (Wilkinson  et  al.  2002).    The  initial  phosphorylation  is  of 
tyrosine residues within the intracellular domain of the HER dimer itself these sites 
then allow protein substrate binding and further phosphorylation. The first substrates 
are adaptors such as Src, PI3K, jak, Ras etc. which then activate an array of signal 
transduction cascades. Different HER molecules activate different adapters e.g. EGFR 
activates c-Cbl, Grb2 amongst others whereas HER3 does not but instead activates 
Shc and Grb7 (Yarden 2001). 
 
The Ras activated MAP kinase pathway is a target of all HER family members and 
PI3K/AKT  pathway  components  couple  directly  with  HER3/HER4  and  indirectly 
with  EGFR/HER2  with  consequently  differing  levels  of  activation  (Soltoff  et  al. 
1996). Other cascades recruited by HER family members including Protein Kinase C 
and  stress  activated  protein  kinase  translate  into  nuclear  transcription  pathways 
involving  fos,  jun,  myc  and  zinc  finger  containing  transcription  factors  (Yarden  
2001). 
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The  final  output  layer  refers  to  the  cellular  outcomes  generate  by  the  signalling 
cascade  principally  cell  growth,  division,  migration,  adhesion,  differentiation  and 
apoptosis.  In  addition  to  original  ligand  and  HER  receptor  involved  cell  context 
determines outcome (Yarden 2001). Heterodimers particularly those including HER2 
are known to be more mitogenic (Reese et al 1995). 
HER family tyrosine kinase molecule levels are regulated via 2 main mechanisms, 
endocytosis of receptors with subsequent degradation and alteration of receptors with 
modulator  proteins  (Sweeney  et  al.  2004).  The  mechanism  by  which  EGFR  is 
endocytosed and degraded has been the subject of much study. The initial step is 
ligand stimulated localisation of membranous EGFR to clathrin coated pits via EGFR 
interacting with clathrin by way of AP2 adapters mediated by epsin (Warren 2006) 
following which the pits are internalised. Recent studies have shown the ubiquitin 
ligase cbl to play a vital role in this process (Shtiegman et al. 2003); stimulation by 
EGF  causes  phosphorylation  of  EGFR’s  intracellular  domain  tyrosine  residues 
including  a  binding  site  to  which  cbl  is  recruited  subsequently  being  tyrosine 
phosphorylated activating its ubiquitin ligase activity (Levkowitz et al. 1999). Cbl 
then stimulates attachment of monoubiquitin moieties which are thought to induce 
internalisation via endocytosis (Mosesson et al. 2003) although other studies suggest 
endocytosis  can  occur  without  ubiquitylation.  Once  internalised  endosomal  EGFR 
will undergo lysosomal degradation if already ubiqutinylated otherwise it is returned 
to the surface (Duan et al. 2003). Thereby ligands that stimulate EGFR activity also 
reduce  EGFR  levels.  HER2-4  do  not  undergo  ligand  mediated  endocytosis  to  the 
same extent as cbl does not attach to them as efficiently (Levkowitz et al. 1996). 
Degradation related mechanisms of controlling HER2-4 levels are less well defined 
however  E3  ubiquitin  ligases  may  be  involved  (Diamonti  et  al.  2003,  Qiu  et  al.   42 
2002);- Nrdp1 binds to HER3 and HER4 whether ligand stimulated or not marking 
receptors  for  endocytosis  and  degradation.  Overexpression  of  both  cbl  and  Nrdp1 
downregulate  HER  expression  at  the  cell  membrane.  Mechanisms  controlling  E3 
ligase levels are poorly defined. HER4 is internalised and functions as a cytoplasmic 
protein for longer than EGFR. It is regulated by 2 separate pathways cleaved by a 
PKC dependent proteolytic pathway and by the PKC independent tumour necrosis 
alpha converting enzyme (TACE) (Rio et al. 2000) 
 
Negative modulator proteins interact with receptors to alter their response to ligand 
binding negatively regulating receptor activity. Examples include splice variants of 
HER family extracellular domains herstatin, a HER2 splice variant, which binds to 
and inhibits EGFR and HER2 (Azios et al. 2001, Doherty et al. 1999). A similar 
variant exists for HER3; other negative modulators include potato carboxypeptidase 
inhibitor (Blanco-Aparicio et al. 1998). 
 
The  layered  signalling  network  of  the  HER  family  interacts  with  other  signalling 
networks. Interaction from a variety of signals including hormones and cytokines is 
generally  mediated  by  protein  kinases  which  phosphorylate  HER  family  members 
thereby altering activity in response to their usual ligands (Carpenter et al. 1999). One 
example is G-protein coupled receptors some of whose ligands (e.g. lysophosphatidic 
acid, carbachol, thrombin) require transactivation of the HER network. GPCRs act via 
matrix metalloproteinases or Pyk2/Src cascade increasing tyrosine phosphorylation of 
EGFR/HER2 increasing downstream signalling and magnifying the mitogenic effects 
of the original ligand. Another example is the growth hormone activation of tyrosine 
kinase  jak2  which  phosphorylates  EGFR  indirectly  activating  the  MAP  Kinase   43 
pathway.  Other  factors  that  interact  with  the  HER  network  include  Il-6  and  PKC 
(Yarden 2001) 
 
1.2.2  EGFR VARIANT III 
There have been several EGFR variant mutations defined some of which have been 
associated with tumours (Moscatello et al. 1995). It has been postulated by at least 
one author that expression of mutated forms of EGFR explains contradictory findings 
regarding EGFR levels in benign and malignant prostate tissue i.e. while some studies 
indicate no significant difference in expression in malignancy others show decreasing 
expression with malignant transformation (Olapade-Olaopa et al. 2000). Of all the 
mutations of wild type EGFR (EGFR-WT) the most common is termed EGFR variant 
III (EGFRvIII). This variant has a mutation in the external domain which involves 
loss of the first 2 extracellular subdomains but preserves the intracellular signalling 
segments (Wong et al. 1990). No ligand binds to the altered extracellular potion but 
the instead the receptor is constitutively active activating the signal cascade in the 
absence of ligand binding. 
 
EGFRvIII  has  been  detected  in  different  tumour  types  including  CaP  (Olapade-
Olaopa 2000) but has not been detected to the same extent in benign tissue and has 
been postulated as having a role in tumourigenesis. 
 
1.2.3  HEREGULIN 
Heregulins (HRG), also termed neu differentiation factors or glial growth factor, are a 
family of growth factors encoded on chromosome locus 8p12 (Holmes et al. 1992) 
which  contain  an  EGF-like  sequence,  an  immunoglobulin  homology  unit  and  a   44 
cytoplasmic  domain  with  different  family  members  made  up  of  alternative  splice 
variants. Principle HRG variants are α1, α2, α3, β1, β2 and β3 (Lyne et al. 1997) with 
variation in the 3
rd cysteine loop of the EGF-like domain determining α or β isoform 
status (Holmes et al. 1992). 
 
HRG family members, both α and β isoforms, principally act as ligands to HER3 and 
HER4 acting via the HER family signalling cascade to effect cell processes including 
growth, proliferation and differentiation (Leung et al. 1997) with different variants 
having varying potency and different effects on the same cell line (Sartor et al. 2001). 
HRG was initially thought to be a ligand for HER2 but has transpired to activate 
HER2 via its heterodimerisation with HER3 or HER4. HRG activity has been shown 
to be concentration dependent; in breast cell lines AU565 and MDA-MB-453 low 
HRG levels are mitogenic but at high levels HRG initiates differentiation and cell 
growth inhibition (Sartor et al 2001). Response to HRG has also been shown to be 
dependent on receptor (e.g. HER2) density and cell types. 
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1.3 HER FAMILY IN CANCER 
Expression of HER family members has been extensively investigated in a number of 
cancer types with the best known being HER2 in breast Ca as this has given rise to 
both a prognostic test (HercepTest™, DAKO) and an immunotherapeutic treatment 
trastuzamab (Herceptin, Roche). Cancer pathogenesis related to the HER can be due 
to hyperactivity at various levels of the signalling network 
·  Ligand overproduction 
·  Receptor upregulation 
·  Constitutive receptor activity 
Oncogenic  viruses  including  HBV  and  avian  erythroblastosis  virus  act  by 
inappropriate  manipulation  of  the  signalling  network.  HER  network  hyperactivity 
effects oncogenesis by mechanisms including enhanced proliferation of tumour cells – 
clonal expansion, increased cell growth and decreased apoptosis (Yarden 2001). 
 
1.3.1 EGFR 
Overexpression  and  mutations/variants  of  EGFR  has  been  noted  in  many  tumour 
types. EGFR overexpression leading to oncogenesis is more often accompanied by 
concomitant ligand expression than overexpression alone being responsible (Yarden 
2001).  EGFR  overexpression  through  gene  amplification  has  been  noted  in  40% 
gliomas with overexpression associated high grade and poor outcome (Wikstrand et 
al. 1998). In breast cancer EGFR, HER2 and HER3 expression is associated with 
increased cellular proliferation while HER 4 is non- or anti proliferative (Tovey et al. 
2004). HER 1-3 positive tumours have a significantly poorer prognosis than HER 
negative  and  HER  4  positive  tumours  (Witton  et  al.  2003).  Again  EGFR 
overexpression is associated with reduced disease free survival and overall survival   46 
(Tsutsui  et  al.  2002).  Other  tumours  in  which  EGFR  overexpression  has  been 
demonstrated include head and neck squamous cell carcinoma (HNSCC) (Magne et al 
2001),  non-small  cell  lung  carcinoma  (NSCLC),  gastric,  colorectal,  pancreatic 
ovarian, oesophageal, renal and bladder cancers (Saloman et al. 1995, Bellezza et al. 
2006) and is considered a negatively prognostic factor in general (Ennis et al. 1991, 
Nicholson et al. 2001). Tumours which can secrete EGF and other ligands coupled 
with EGFR overexpression can set up an autocrine loop allowing tumour proliferation 
without extraneous stimulation providing a possible mechanism for hormone escape 
(Normanno et al. 1995, Sato et al. 1999). EGFRvIII has been linked to tumours of 
lung, ovary and breast (Moscatello 1995) 
 
1.3.2 HER2 
HER2 is overexpressed in several cancer types most notably ductal breast CA where 
15-30% show significant gene amplification (Slamon et al. 1987). Overexpression is 
correlated with several negative tumour factors – increased size, high grade, greater 
proliferation,  aneuploidy,  lymph  node  spread  and  reduction/absence  of  hormone 
receptors (Ross et al. 1998, Paik et al. 2000) however expression is greater in earlier 
breast  CA  than  advanced.  HER2  amplification  is  associated  with  malignant 
transformation (Hudziak et al 1987. Zhou et al. 2003) significantly poorer prognosis 
(Ross 1998), higher risk of recurrence and disease related death with node negative 
(Press et al. 1997) and node positive (Slamon 1987, Tandon et al. 1989) invasive 
disease and has also been associated with increased risk of resistance to antioestrogen 
therapy (Borg et al. 1994) through cross-talk with the oestrogen receptor complex 
(Schiff  et  al.  2003)  if  present.  HER2  has  been  shown  to  modulate  response  to 
chemotherapy with increased resistance to some (Zhang et al. 2003) regimens and   47 
increased sensitivity to others e.g. anthracycline based agents (Pritchard et al. 2006). 
HER2 oncogene is also amplified in ovarian CA (Edwards and Mukherjee 2004). 
 
HER2 positive tumours can now be identified with the immunohistochemical (IHC) 
Herceptest or fluorescence in-situ hybridisation (FISH) and treated with trastuzamab, 
a  monoclonal  antibody  to  HER2  which  downregulates  HER2  expression  altering 
downstream  signalling  increasing  apoptosis  and  blocking  growth  stimulation  and 
VEGF production (Ferretti et al. 2007) with a consequent significantly increased time 
to disease progression (Slamon 2001). Trastuzamab use is dependent on the result of 
testing  for  HER2  with  its  use  being  indicated  by  strong  immunohistochemical 
staining,  contraindicated  in  weak  or  absent  staining  and  intermediately  stained 
specimens determined by additional Fluorescence in-situ hybridisation testing. 
 
1.3.3 HER3/HER4 
HER3 has been found in several cancer types including breast, gastric, colonic and 
endometrial  adenocarcinomas  (Poller  et  al.  1992)  but  gene  amplification  and 
overexpression are rare (Yarden 2001). Co-expression of HER2 with HER3 or EGFR 
predicts outcome in oral squamous cell carcinoma (Xia et al. 1999). 
 
Conversely to other HER family members HER4 expression which includes nuclear 
expression, is lower in breast CA than in benign tissue and is associated with lower 
grade.  As  mentioned  above  HER4  is  non-  or  antiproliferative  and  positively 
prognostic  in  breast  CA  particularly  when  compared  to  HER1-3  positive  tumours 
(Tovey 2004). In a study of childhood medulloblastoma involving IHC and Western 
blotting for all 4 main family members HER4 co-expressed with HER2 in the HER2-  48 
HER4 heterodimer was shown to prognostic value in terms of 25 year survival. An 
association between HER2-4 and transcription factor AP-1 expression was also noted 
(Gilbertson et al. 1997). 
 
1.3.4 ANTITUMOUR THERAPY 
Given the role of the HER family in several tumour types many agents that target 
HER family members have been investigated as antitumour therapy. The best known 
is Herceptin (trastuzamab), licensed in the UK for HER2 positive breast tumours to 
prevent/postpone  recurrence.  Several  antitumour  agent  types  have  been  developed 
(De Bono et al. 2002) including 
·  Monoclonal antibodies to HER family members 
·  Small molecule tyrosine kinase inhibitors 
·  Conjugates of specific antibodies with cytotoxic agents or radionuclides 
·  Gene therapy 
·  Antisense Oligonucleotides 
 
Monoclonal antibodies (mAb) bind with high affinity to a specified target competing 
with normal ligands. They prevent ligand binding and induce receptor endocytosis 
and  degradation  with  consequent  reduction  in  downstream  signal  transduction 
resulting in delayed tumour growth and spread (Aguilar et al. 1999, Chen X, et al. 
2000). An example of anti-EGFR antibody is Cetuximab (Erbitux, Merck) which has 
a binding affinity to the extracellular domain of EGFR 10 times that of EGF itself. 
Cetuximab binding blocks EGFR signalling cascades causing cell growth arrest in G1 
and  has  been  shown  to  inhibit  growth,  stimulate  apoptosis,  reduce  volume  and 
enhance  the  action  of  cytotoxins  and  radiotherapy  in  EGFR  positive  tumour   49 
xenografts (Baccus et al. 1993, Daly et al. 1997). Cetuximab has been used, either 
alone or in combination with in trials involving multiple tumour types including non-
small cell lung CA, HNSCC, colorectal and pancreatic CA (De Bono et al. 2002). 
Trastuzamab is a mAb with high affinity for the external domain of HER2 used now 
in HER2 positive breast CA. Other antibodies to HER2 include 2C4 used in trials 
against ovarian and lung CA. Antibodies to HER3 and HER4 have not been explored 
to the same extent. 
 
Tyrosine  kinase  inhibitors  (TKI)  bind  to  the  intracellular  domain  of  HER  family 
members  preventing  activation  of  the  next  level  of  the  signalling  cascade.  These 
inhibitors usually target a specific HER family member but can block others through 
inhibition  following  heterodimerisation  (Peles  et  al.  1992).  TKIs  have  a  lesser 
specificity than mAbs and greater concentrations are required however they can be 
oral  agents  (mAbs  must  be  intravenous  and  are  more  likely  to  fail  to  recognise 
receptor  mutations  and  variants  (Bellezza  2006).  Inhibitors  can  be  reversible  or 
irreversible. There are several TKIs targeting EGFR; these include Iressa (Gefitinib, 
AstraZeneca) which competitively binds to ATP binding at the tyrosine kinase site of 
EGFR decreasing CDK2 kinase activity inducing G0/G1 arrest and, at higher doses, 
apoptosis (De Bono 2002) and antiangiogenesis (Bellezza et al. 2006). Gefitinib has 
been used in advanced non-small cell lung carcinoma and in trials concerning breast, 
HNSCC,  colorectal,  uterine  (De  Bono  2002)  and  glioma  cancers  (Mass  2004). 
Tarceva  (OSI-744,  OSI  Pharmaceuticals)  also  targeting  EGFR  has  been  used  in 
studies concerning advanced SCCHN, pancreatic and ovarian CA. Both Gefitinib and 
Tarceva affect HER2 and HER3 signalling via heterodimers with EGFR (De Bono 
2002).  Tyrosine  kinase  inhibitors  that  target  HER2  exist  and  include  GW572016   50 
(colorectal and breast CA). CI-1033 (lung and  breast CA) targets all HER family 
members (Mass 2004). Adenovirus type 5 early region 1 (EA1) gene product has been 
studied as gene therapy designed to target HER2. This has been shown to inhibit 
HER2 transcription acting as a tumour suppressor in HER2 overexpressing ovarian 
cancer  cells  in  mice  prolonging  survival  (Hung  et  al.  2000).  Antisense 
oligonucleotides directed against EGFR used in CaP cell lines in nude mice have been 
shown  to  inhibit  tumour  growth  and  angiogenesis  causing  tumour  necrosis 
(Rubenstein et al. 1996). 
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1.4 HER FAMILY IN PROSTATE ADENOCARCINOMA 
HER  family  members  have  been  found  to  be  expressed  in  prostate  tissue  benign, 
hyperplastic,  precancerous  (prostatic  intraepithelial  neoplasia,  PIN)  and  cancerous 
(Nasu et al. 2006, Rana et al. 2006) but the relationship between levels of and changes 
in expression in relation to malignant transformation, severity of disease, hormone 
escape and overall prognosis remain controversial with conflicting evidence produced 
by different studies. 
 
1.4.1 EGFR  
EGFR is  expressed in prostatic epithelial  cells  with a  greater levels in basal than 
luminal epithelial cells (Maygarden et al. 1994) with EGF also detectable in high 
levels in prostatic tissue and secretions (Elson et al. 1984). EGFR is detectable in up 
to 100% benign tissue (Rana 2006), 29-88% benign hyperplasia (Di Lorenzo et al. 
2004) and in 17 - 100% (Mellon et al. 1992, Di Lorenzo et al. 2002) of prostate 
adenocarcinomas  with  this  high  variability  possibly  due  to  definitions  of  high 
expression varying between studies, heterogeneity in CaP particularly metastasis and 
HRPC specimens or differences in IHC technique (Hernes et al. 2004). EGFR has 
been shown to essential for androgen induced proliferation. EGFR expression has not 
been found to related to Gleason score in most studies in which this has been assessed 
(Moul et al. 1996, Hernes 2004) although this has been shown in at least one (Di 
Lorenzo  2002).  Amount/Intensity  of  staining  in  benign  tissue  and  PIN  has  been 
reported as greater than in CaP (Mellon et al. 1992) in some studies while others 
indicates the converse – significantly greater EGFR expression in CaP and high grade 
PIN than in benign tissue and low grade PIN. EGFR overexpression in metastatic CaP 
has been seen in several studies (Kumar et al. 1996, Kim et al 1999, Di Lorenzo   52 
2002).  Kumar  et  al.  showed  EGFR  messenger  RNA  expression  as  greater  in 
malignant compared to benign prostatic tissue. 
 
As in other cancer types EGFR acts via an array of signal transduction pathways in 
CaP  oncogenesis  including  P13K/Akt,  MAP  Kinase  and  PKC.  Inhibition  of  these 
signalling cascades in HSPC and HRPC cell lines inhibits growth blocking G1 to S 
phase  transition  by  upregulating  p27
KiPI  protein  which  in  turn  inhibits  cyclin-
dependent protein kinases (CDKs) controlling the cell cycle (Mimeault 2003). The 
EGFR  activated  PI3k  cascade  stimulates  growth  and  angiogenic  factors  while 
MAPK/PLC-γ cascades increase cell motility (Graff et al. 2002, Ghosh et al. 2002). 
Another postulated mechanism behind HER carcinogenesis is overexpression of the 
EGFR-HER2 heterodimer compared to other HER dimers which has been noted in 
several  cancer  types.  EGFR-HER2  has  a  greater  affinity  for  EGF  and  lesser 
degradation  compared  EGFR  homodimers  (Xia  1999).  EGF-EGFR  acting  via 
PI3K/Akt within membrane microdomains known as caveolae and rafts also effects 
an antiapoptotic signal maintaining CaP cells in the absence of androgen signalling: 
inhibiting PI3K  causes  apoptosis in these cells although this effect is lessened by 
activating EGFR with EGF suggesting alternative antiapoptotic pathways exist (Lin et 
al.  1999).  In  CaP  EGFR  also  acts  via  reducing  cellular  ceramide  levels  to  effect 
antiapoptotis. 
 
In CaP EGFR and its downstream messengers interact with other signal transduction 
pathway.  In  AR  positive  cell  lines  endocytosis  of  EGFR  is  reduced  altering 
downstream  signalling  via  adaptor  proteins  possibly  accounting  for  reduced 
invasiveness  of  AR  positive  cell  lines  (Bonaccorsi  &  Marchiani  2004).  Several   53 
neuropeptides interact with EGFR pathways via G-protein coupled receptors (Shah 
GV et al. 1994) with the MAP Kinase pathway being the point of convergence. 
 
Previous studies have shown EGFR influence on hormone escape and CaP prognosis. 
Shah RB et al compared EGFR levels in tissue microarrays (TMA) of HSPC and 
HRPC tumours with HRPC status associated with increased expression although it did 
not achieve statistical significance on multivariate analysis. Zellweger et al. (2005) 
similarly  showed  greater  expression  16%  versus  1%  in  hormone  refractory  and 
metastatic CaP compared to localized disease. Several other studies concur with this 
(Glynne-Jones et al 1996, Maddy et al. 1989, Myers et al. 1997)); Di Lorenzo (2002) 
demonstrated  increased  EGFR  expression  in  HRPC  than  in  neoadjuvant  hormone 
treated CaP and greater expression in both than in hormone naïve tissue. In this study 
increased EGFR expression was associated with advanced stage, high Gleason score, 
decreased time to hormone escape and relapse with results more pronounced if EGFR 
and  HER2  overexpression  are  combined.  Additional  studies  further  demonstrated 
poor  prognosis  with  increased  EGFR  expression  (Fowler  et  al.  1998,  De  Miguel 
1999).  In  Bartlett  et  al.  (2005)  a  cohort  of  matched  HSPC  and  HRPC  tumour 
specimens with EGFR gene copies assessed by FISH and EGFR protein expression 
assessed though IHC, no EGFR gene amplification was shown however increased 
EGFR copy number in HRPC was observed and was associated with reduced overall 
survival. This increase in copy number was not associated with gene amplification or 
change in protein expression. Increased EGFR protein expression was observed in 
some patients (~25% showed significant increase in EGFR and/or HER2 expression) 
but  was  not  associated  with  reduced  overall  survival  (OS)  however  patients 
demonstrating  a  rise  in  EGFR  expression  following  hormone  escape  did  show  a   54 
significantly  reduced  time  to  death  following  relapse  (TTDFR)  (p=0.0004).  This 
indicates that while increased EGFR expression may be involved in hormone escape 
and CaP progression this does not occur via gene amplification as is the case with 
HER2 association with breast CA. Hernes (2004) showed a similar significant rise in 
EGFR expression in the HRPC specimen of paired HSPC and HRPC samples. No 
association between EGFR expression and prognosis was found in this study. EGFR 
and EGFR ligand expression is greater in AR negative androgen independent CaP cell 
lines  than  in  AR  positive  again  linking  EGFR  expression  with  more  aggressive 
disease (Vincentini et al. 2003). Alternatively Moul (1996) agrees with Hernes in that 
no correlation between EGFR and outcome is shown. 
 
Several  mechanisms  have  been  suggested  whereby  EGFR  could  effect  hormone 
escape. There is  a high degree of overlap between androgen  and EGFR activated 
changes in gene expression (Oosterhoff et al. 2005) and EGFR is one of a number of 
factors that have been shown to activate AR in the absence of androgenic stimulation 
(Mimeault 2003) indicating the EGFR pathway as a bypass allowing cell proliferation 
during  androgen  suppression.  Further  evidence  is  demonstrated  in  prostate  cancer 
xenografts in mice where castration has been shown to increase concentrations of 
EGF related growth factors (Torring et al. 2005). As in other tumour types EGF and 
TGF-α are secreted by some HRPC cell lines forming an autocrine loop (Fong et al. 
1992,  De  Miguel  1999,  Kim  1999)  independent  of  androgen  influence.  Autocrine 
growth  stimulation  may  involve  upregulation  of  transmembrane  EGF-like  ligand 
cleavage  and  activation  by  matrix  metalloproteinases  (MMPs)  (Marinissen  et  al 
2001). Such loops are not seen in benign prostate and HSPC cell lines (MacDonald et 
al. 1992). The MAP kinase pathway has also been implicated in the autocrine loop as   55 
it is activated by EGFR and stimulates pro-EGF release at the cell surface (Lin et al. 
1999). 
 
Antitumour agents targeting EGFR have been utilised against CaP in trials. Iressa 
(gefitinib) has been used in CaP cell lines with both AR positive cell lines and AR 
negative sensitive to antiproliferative/apoptotic sensitive to it (Vincentini 2003). CaP 
cell line proliferation and metastasis are inhibited in both in vitro assays and in vivo – 
nude mice (Angelucci et al. 2006). Gefitinib has been shown to inhibit invasion and 
proliferation  on  HRPC  cell  lines  via  suppression  of  the  PI3K/Akt  pathway 
(Bonaccorsi  &  Marchiano  2004).  Studies  in  HRPC  cell  lines  have  demonstrated 
gefitinib as having a greater antitumour effect than Herceptin (Formento et al. 2005). 
Additionally  when  gefitinib  is  used  in  conjunction  with  bicalutamide  both  agents 
potentiate each others antiproliferative action (Sirotnak et al. 2002). Unfortunately a 
phase II trial of gefitinib in 40 HRPC patients showed no improvement in PSA or 
objective disease progression and high levels of side effects, principally diarrhoea, 
fatigue and rash, were noted (Canil et al. 2005) with similar lack of effect seen in 
another trial (Rosenthal et al. 2003). It should be noted that these trials did not involve 
populations selected for EGFR expression and studies with gefitinib in Breast Ca have 
demonstrated a much greater response in EGFR selected populations (Polychronis et 
al. 2005). Antitumour agents that targeting both EGFR and HER2 have also been 
explored, despite Formento et al (2004) showing no benefit in targeting both (using 
combination trastuzamab and gefitinib) compared to targeting one alone. GW572016 
(lapatinib, Tykerb, GlaxoSmithKline) a tyrosine kinase inhibitor that targets both has 
been associated with tumour apoptosis and regression of metastases (Spector 2005) 
   56 
1.4.2 HER2 
Evidence  for  HER2  expression  in  the  development  of  CaP  is  contradictory  (Yeh 
1999). Level of HER2 expression in primary CaP varies widely between studies with 
0 -100% (Zhau 1992, Shi et al. 2001, Savainan et al. 2002) immunohistochemically 
positive compared to 0-100% (Lyne 1997, Hernes 2004) in benign prostate tissue. 
Different studies have shown both greater expression of HER2 in CaP than benign 
prostate  tissue  (Okegawa  et  al.  2006,  Hernes  2004)  and  no  significant  difference 
(Mellon et al. 1992). In general HER2 expression in CaP is lower than other tumour 
types  both  in  positivity  rate  and  intensity  (Edwards  2003).  HER2  expression  is 
primarily cytoplasmic or membranous (Ware 1990) with greater expression in basal 
than luminal cells (Lyne 1997). Lara et al. (2002) found HER2 overexpression to be 
infrequent with IHC, FISH and ELISA. HER2 expression is correlated with Gleason 
score and stage in some studies (Ross et al. 1998, Sadasivan et al 1993, Shi 2001) but 
not  in  others  (Mellon  1992,  Lara  2002,  Hernes  2004).  Other  evidence  for  HER2 
involvement in CaP includes high HER2 expression in PIN indicating a role in early 
tumourigenesis (Kuhn et al. 1993, Ware 1991) and Osman et al. (2000) demonstrating 
raised serum HER2 in patients with metastatic CaP. Evidence to the contrary includes 
the absence of HER2 overexpression/gene amplification in several commonly used 
CaP cell lines and xenografts (Ullen et al. 2005). 
 
The relationship between HER2 and CaP hormone escape and prognosis is likewise 
unclear  with conflicting evidence. HER2 expression in HRPC is extremely varied 
from 0 to 85% (Signoretti et al. 2000, Shi 2001, Savainan 2002). Again high variation 
has been put down to varying IHC antibodies and techniques, scoring criteria and/or 
tissue heterogeneity. Several authors have demonstrated greater HER2 expression in   57 
HRPC than HSPC in non-paired samples (Shi 2002, Xie et al. 1995, Signoretti 2001, 
Di Lorenzo 2002), in Shi et al 9% HER expression in untreated CaP compared with 
50% in CaP treated with hormonal therapy and 85% in established HRPC, a similar 
progression  was  shown  by  Signoretti.  Serum  levels  of  HER2  were  higher  in 
metastatic HRPC than in metastatic HSPC patients (Osman 2000). Comparing paired 
HSPC  and  HRPC  samples,  Bartlett  et  al.  (2005)  described  only  low  level  (6.5%) 
HER2  gene  amplification  in  contrast  to  the  25-30%  seen  in  breast  CA.  Previous 
studies in CaP have reported an amplification rate of up to 41% (Reese et al. 1995, 
Ross et al. 1997) however these studies did not include a chromosome 17 probe as 
used in Bartlett et al. allowing no distinction between amplification and increased 
copy number. In other studies amplification has been linked to hormone escape (Craft 
& Shostak 1999). Bartlett et al. concluded that gene amplification was rare in CaP and 
not clinically significant and several other previous studies concur (Fournier et al. 
1995, Mark et al. 1999, Savainan 2002). As with EGFR, increased gene copy number 
(again not associated with gene amplification or change in gene expression) following 
hormone escape was associated with decreased overall survival but the significance of 
this is unclear. Increased copy number is usually due to unstable genome and random 
duplication and is not thought to represent upregulation of gene expression in the 
same manner as gene amplification. It was not considered of clinical importance in 
Bartlett et al.  There was no change in average HER2 expression following hormone 
escape in the full population however increased HER2 expression in the HRPC escape 
for  individual  paired  samples  was  associated  with  significantly  lower  TTDFR 
(p=0.0037) indicating a possible role of HER2 overexpression in hormone escape. In 
this study if patients with increased EGFR and HER2 following hormone escape were 
combined the significance value for reduced TTDFR was even lower (p=0.0003).   58 
 
Hernes  et  al.  (2004)  actually  demonstrated  a  fall  in  HER2  expression  in  paired 
samples which did not achieve statistical significance rather than a rise however high 
HER2  expression  in  the  HRPC  specimen  was  again  significantly  associated  with 
decreased TTDFR. Lara et al. (2002) amongst others (Savainan 2002, Calvo et al. 
2003)  demonstrated  no  link  between  HER2  overexpression  and  hormone  escape. 
Xenograft  studies  in  mice  have  indicated  greater  HER2  expression  in  androgen 
independent compared to androgen dependent human CaP cells (Agus et al. 1999). 
Poor prognosis has been linked to tissue HER2 expression in other studies (Zhau 
1992, Sadasivan et al. 1993, Okegawa 2006) – in Di Lorenzo (2004) et al and Morote 
et  al.  (1999)  the  outcome  demonstrated  was  disease  specific  death,  in  Okegawa 
(2006). risk of biochemical recurrence Serum HER2 is also correlated with increased 
risk of disease specific death (Osman 2000). 2 studies have shown HER2 expression 
as an independent predictor of worse prognosis on multivariate analysis (Veltri et al. 
1994,  Morote  1999)  Other  studies  have  shown  no  relationship  of  HER2  with 
prognosis  on  multivariate  or  univariate  analysis  (Ware  1991,  Mellon,  1992,  Ross 
1997). HER2 expression in these studies was assessed primarily using either IHC or 
FISH. 
 
As noted above androgen signalling pathways and their interaction with/bypass by 
other pathways are key to hormone escape therefore HER2-AR pathway interaction 
provides a mechanism  of HER2 influence over the same phenomenon. Cross talk 
between HER2 and AR pathways shown by Mellinghoff et al. (2004) who used a dual 
EGFR-HER2 inhibitor PKI-166 to demonstrate the inhibitory effect of EGFR/HER2 
acting  via  reduced  AR  transcription.  It  was  further  shown  that  the  HER2-HER3   59 
heterodimer rather than EGFR modulated AR function in the absence of androgens by 
stabilising AR levels and optimising binding of AR to androgen regulated genes. A 
role of the HER2-HER3 heterodimer in hormone escape was therefore suggested.  
 In  Yeh  (1999)  AR  positive  cell  lines  HER2  has  been  shown  to  induce  AR 
transactivation  with  transfection  of  HER2  gene  increasing  PSA  secretion  and 
proliferation rate. This study also indicates HER2 transactivates AR via the MAP 
Kinase pathway and this action is not blocked by antiandrogens indicating a possible 
pathway to hormone escape. HER2 and HER3 expression, stimulated by HRG, have 
been shown to increase AR transactivation and tumour proliferation in a recurrent 
CaP cell line in the absence of androgen (Gregory et al. 2005). As well as direct cross-
talk between HER2 and AR interaction via downstream mediators such as IL-6 (Qiu 
et al. 1998) 
Spontaneous HER2 homodimerisation in the presence of extreme overexpression of 
HER2 has also been shown to induce androgen independent AR transactivation. Wen 
et al. (2000) suggested HER2 induced hormone independence could be mediated via 
the  PI3K/Akt  signalling  pathway  while  Pfeil  et  al.  (2004)  demonstrated  androgen 
ablation therapy causing overexpression and resistance to inhibition of the PI3K/Akt 
pathway itself. Craft et al. (1999) induced HER2 gene expression in a HSPC cell line 
demonstrating  the  consequent  development  of  a  hormone  independent  state. 
Overexpression  of  HER2  has  been  shown  to  be  induced  by  low  androgen 
environments in vitro and in vivo (Berger et al. 2006). 
An  array  of  anti  HER2  agents  have  been  used  in  CaP  trials.  The  HER2  mAb 
trastuzamab when used with HSPC and HRPC cell lines in xenografts models. HRPC 
tumours  had  no  response  but  in  HSPC  tumours  significant  growth  inhibition  was 
observed  (Agus  1999)  and  androgen  dependence  was  proposed  as  required  of   60 
trastuzamab  response.  Li  et  al.  (2004)  correlated  trastuzamab  response  only  with 
HER2  levels.  If  trastuzamab  was  combined  with  the  chemotherapeutic  Paclitaxil 
(Taxil, Bristol-Myers Squibb) in animal models growth inhibition was seen in both 
androgen  dependent  and  independent  tumours  to  a  greater  extent  than  either 
individual agent (Agus 1999). This has not translated into a successful clinical trial; 
one trial with profiling correlation of HER-2 expression, androgen dependence and 
trastuzamab  effect  and  Paclitaxil  used  after  clinical  failure  (Morris  et  al.  2002) 
showed trastuzamab as ineffective with all patients progressing and the combination 
uncertain. 
 
An alternative HER2 mAb 2C4 (Pertuzumab, Genentech) has been shown to inhibit 
growth of HSPC and HRPC cell lines and xenografts based on the same cell line 
(Menodoza et al. 2002) A phase I trial involving multiple types of solid metastatic 
malignancies  at  a  terminal  stage  indicated  some  successful  inhibition  of  HER2 
heterodimerisation and stabilisation of disease. The TKI Lapatinib with action against 
EGFR  and  HER2  has  been  shown  to  significantly  inhibit  HER2/HER3 
proproliferative action on recurrent CaP cell lines. When this cell line was denied 
growth  factors  lapatinib  continued  to  have  an  inhibitory  effect  suggesting  the 
existence of a HER2 autocrine loop (Gregory 2005). 
 
In  summary  while  reported  expression  of  HER2  in  relation  to  HSPC,  HRPC  and 
prognosis is conflicted there is still evidence including HER2-AR interactions, greater 
signalling effects of the HER2-HER3 dimer than EGFR dimers and response to some 
targeted  therapies  that  HER2  has  a  key  and  potentially  targetable  role  in  CaP 
progression.   61 
1.4.3 HER3 
While studied to a lesser extent than EGFR and HER2, HER3 has been consistently 
found to be expressed in both benign and malignant prostatic tissue (Myers et al. 
1994, Prigent et al. 1992). Koumakpayi et al. (2006) demonstrated >90% cytoplasmic 
HER3 expression in all types prostate cancer with no significant difference to benign 
tissue noted on IHC. However nuclear expression was significantly higher in CaP 
than benign prostate tissue with HRPC cell line expression being significantly higher 
than that of HSPC tissue. In this study higher HER3 nuclear expression was correlated 
with higher Gleason score. Another study showed HER3 expression in CaP but not 
benign prostate tissue however there was no relationship between HER3 expression 
and  Gleason  score  (Leung  1997).  Western  blotting  showed  greater  nuclear  HER3 
expression in HSPC cell lines as than HRPC contradicting IHC results. Comparing 
HER3 in paired HSPC and HRPC samples Hernes (2004). demonstrated a greater 
expression  in  HRPC  samples  than  HSPC  21%  vs.  15%  which  did  not  achieve 
significance. One important role of HER3 was suggested by Lee H et al (2001) who 
showed a naturally secreted form of HER3 (p85-sErbB3) as an important negative 
regulator  of  HRG  action  in  stimulation  of  cell  membrane  HER  2-4  acting  via 
competitive binding to HRG. As noted above in Gregory et al. (2005) HER2 and 
HER3 expression, stimulated by HRG, was shown to increase AR transactivation and 
tumour proliferation in a recurrent CaP cell line in the absence of androgen. At least 
one  study  has  linked  HER3  to  poor  prognosis,  Leung  et  al  (1997)  demonstrated 
expression of HER3 and its ligand HRG-α expression in CaP but not benign tissue 
and  indicated  HER3  expression  linked  to  poor  response  to  androgen  therapy  and 
decreased survival. Koumakpayi et al (2006) demonstrated low nuclear HER3 as a 
predictor of biochemical recurrence in CaP.   62 
1.4.4 HER4 
In contrast to the other 3 family members, early studies indicated that HER4 was not 
expressed  in  CaP  at  al  (Grasso  et  al  1997)  however  more  recently  this  has  been 
contradicted  (Hernes  2004,  Lyne  1997).  Lyne  et  al.  demonstrated  high  HER4 
expression 95-100% in benign prostatic basal and luminal cells, 67% in PIN and 23% 
in CaP (prostatectomy). As in HER1-3 Hernes et al compared HER4 expression in 
paired  HSPC  and  HRPC  specimens;  in  this  study  HER4  expression  rose  slightly 
following  hormone  escape  from  24%  to  29%  positivity  but  this  did  not  achieve 
significance. In addition expression of HER4 in the HRPC sample was associated 
with improved 2 year survival to a degree nearly achieving statistical significance 
(p=0.054). This is in contrast to prognosis HER1-3 in this study as expression of these 
was  associated  with  worse  prognosis  (although  of  these  statistical  significance 
occurred only with HER2) but in agreement with prognostic data for HER family in 
breast  CA.  In  vitro,  a  constitutively  active  HER4  mutant  inhibits  formation  of 
colonies in DU-145 and PC-3 CaP cell lines (Williams et al. 2003) . 
 
1.4.5 EGFR VARIANT III 
Several  studies  have  linked  EGFRvIII  expression  and/or  constitutive  EGFR 
expression with development of CaP and androgen resistance (Myers 1997, Sherwood 
et al.1998, Schwartz et al. 1999 Olapade 2000, Di Lorenzo 2002). EGFRvIII has been 
detected only in tumour cells and not in benign prostate tissue (Olapade 2000).  It has 
been speculated that failure to recognise EGFR variants, in particular EGFRvIII, is 
one of the reasons behind the disparate results relating to EGFR-WT expression in 
HSPC and HRPC development. Olapade-Olaopa et al. stained benign and malignant 
prostate tissue for EGFR-WT and EGFRvIII. EGFRvIII was primarily found in the   63 
perinuclear  cytoplasm  rather  than  the  membrane  where  EGFR-WT  was  most 
commonly located. While there was a progressive decrease in EGFR-WT expression 
with increased malignancy (i.e. most in benign tissue, medium in PIN/CaP, least in 
metastatic CaP),  EGFRvIII showed a counterpointing progressive increase – none in 
benign  tissue,  most  in  metastatic  and  poorly  differentiated  disease.  There  was 
significantly greater EGFRvIII expression in HRPC compared to HSPC samples in 
this  study  although  there  was  no  similar  or  opposite  difference  in  EGFR-WT 
expression. In terms of prognosis EGFRvIII expression was found to be significantly 
associated  with  serum  PSA  and  time  to  disease  progression  but  not  on  overall 
survival. This article postulated that as CaP progresses it expresses the constitutively 
active  EGFRvIII  in  preference  to  EGFR-WT  and  that  this  increase  in  ligand 
independent mitogenesis may occur due to loss of usual ligand input e.g. reduced 
androgens/androgen  receptors  with  EGFRvIII  overexpression  effecting  malignant 
progression and hormone escape. EGFRvIII has been found to be associated with anti 
KI67  mAb,  a  marker  of  cell  proliferation,  also  indicating  an  association  with 
increased CaP activity (Olapade-Olaopa et al 2001). 
 
1.4.6 HEREGULIN 
Heregulin expression in benign and malignant prostate tissue was assessed by Lyne 
(1997).  In this study high  expression was found in benign basal  cells  and stroma 
(100%)  with  intermediate  expression  in  benign  luminal  cells  (58%)  and  low 
expression in PIN (5%) and prostatectomy derived CaP (10%). In CaP cell lines some 
HRG mRNA was detectable on Southern Blotting but no HRG protein expression was 
detectable. In vitro HRG-β treatment of androgen sensitive LNCaP prostate cancer 
cells caused inhibition of cell proliferation whereas no such effect was seen in AR   64 
negative cell lines. In a separate study HRG treatment of androgen resistant CWR-R1 
prostate  cancer  cell  lines  increased  proliferation  (Gregory  2005).  Whether  this 
differing  activity  in  androgen  independent  tissue  or  the  concentration  dependent 
mitogenesis/ antiproliferation activity of HRG described above are involved in the 
mechanisms by which the HER family affects cancer progression has not been clearly 
defined.  Lyne  et  al  suggested  that  lack  of  HRG  expression  in  CaP,  coupled  with 
previous reports that the chromosomal locus 8p12-21 which includes the HRG gene is 
often lost in PIN/CaP (Emmett-Buck et al. 1995), indicates HRG acts as a tumour 
suppressor  and  its  loss  is  an  early  stage  in  prostate  oncogenesis.  The  differential 
effects on AR positive and negative tumour lines were also suggested as a driving 
force behind inability to prevent tumour progression at low androgen levels. 
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1.5 PILOT STUDY: HER FAMILY IN PROSTATE ADENOCARCINOMA 
It was speculated that conflicting published results relating to the HER family and 
prostate cancer may be due to a piecemeal approach dealing with one or two family 
members at a time. Very few published studies examine all 4 members of the family ± 
ligands – exceptions are (Hernes 2004) and Grasso (1997). A pilot study has been 
conducted  at  this  centre  involving  all  4  main  members  of  the  family  and  EGFR 
variant III to give a clearer picture of the overall role of HER proteins 
 
Immunohistochemical analysis was use to investigate protein expression of HER 1-4 
and EGFRvIII in matched hormone sensitive and resistant prostate tumours samples 
from 74 patients. These patients all had had a tissue diagnosis of locally advanced or 
metastatic CaP, underwent chemical or surgical (orchidectomy) androgen ablation but 
subsequently  suffered  hormone  escape  as  determined  by  biochemical  relapse  (see 
method  section)  and  had  a  further  pathological  specimen  taken.    Specimens  were 
prepared  as  slides,  stained  with  commercial  antibodies  to  EGFR,  HER2,  HER3, 
HER4  and  EGFRvIII  and  scored  by  2  independent  observers  utilising  a  weighted 
histoscore  technique  (see  method  section).  Scoring  results  were  used  to  divide 
specimens into low score (< 3
rd quartile) and high score (> 3
rd quartile) and were 
analysed to determine effect of histoscore on endpoints time to hormone escape and 
mortality. 
 
This  pilot  study  demonstrated  that  HER3,  HER4,  EGFRvIII  were  expressed  at 
significantly  higher  levels  than  EGFR/  HER2.  Unlike  previous  studies  EGFR 
overexpression was not associated with survival following hormone escape, neither 
was high or low EGFR expression associated with differing time to relapse. High   66 
HER2 expression in hormone sensitive tumours was associated with increased time to 
biochemical  relapse  (p=0.0001).  This  translated  into  longer  overall  survival 
(p=0.0021). 
As previously noted, high HER2 expression in HRPC samples was associated with 
significantly  reduced  time  to  death  following  biochemical  relapse  (p=0.039). 
Additionally, a significant rise in HER2 expression in between the first and second 
matched samples was associated with significantly reduced survival after biochemical 
relapse (p=0.012). Differing HER3 had no significant effect on measured endpoints 
HER4 overexpression in hormone sensitive tumours was associated with longer time 
to  biochemical  relapse  (p=0.042).  EGFRvIII  was  associated  with  shorter  time  to 
biochemical relapse (p=0.037). 
Multivariate analysis involving all 5 family members, Gleason Score and metastasis at 
diagnosis demonstrated HER 2 was an independent positive predictive marker of time 
to  relapse  in  hormone  sensitive  tumours  (p=0.014).  Multivariate  analysis  did  not 
demonstrate any of the 5 family members as significantly influencing overall survival. 
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1.6 SUMMARY, AIMS AND OBJECTIVES 
Published literature concerning the role of the HER family is contradictory in many 
aspects. While there are several indications that the HER family and HRG provide 
opportunities for diagnosis, prognosis and therapy a clear candidate has yet to emerge. 
The pilot study was motivated by the aim to define the roles of the HER family in 
prostate cancer development and progression by examining all HER family members 
and utilising multivariate analysis to clarify the picture. Several interesting results 
have been thrown up by the pilot study most notably a positive prognostic role for 
HER2  in  contradiction  to  much  existing  literature.  Several  avenues  invite  further 
exploration. 
·  Expansion of study numbers  
·  HER family ligands have not been explored – given the concentration and 
androgen level differentiation effects noted above HRG is of greatest interest 
·  There has been little use of markers of proliferation and apoptosis to define 
whether tumourigenesis effects mediated by HER family/HRG occur primarily 
through one or the other process. 
The research questions for this study have been formulated with these in mind with 
the overall objective of determining the role of HER family in CaP development and 
progression. 
 
 
 
 
 
   68 
1.6.1 RESEARCH QUESTIONS 
1.  Are expression of HER 1-4 and EGFRvIII correlated with response to therapy/ 
time to relapse/time to death in prostate cancer? 
2.  Is Heregulin (HRG) involved in mechanisms by which HER family proteins affect 
cancer progression? 
3.  Do HER family proteins effect oncogenesis via cell proliferation or reduced cell 
death? 
4.  Are trends seen in the pilot study borne out with a larger patient base? 
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CHAPTER 2: PATIENTS AND METHODS 
 
2.1 ETHICAL APPROVAL AND FUNDING 
Ethical  approval  for  the  pilot  study  (Edwards  et  al.  2006)  was  obtained  from 
Multicentre  Research  Ethics  Committee  (MREC)  for  Scotland  reference 
MREC/01/0/36. Ethical approval for this study was obtained from the Glasgow Royal 
Infirmary Local Research Ethics Committee (LREC) with application title ‘What is 
the Role of EGFR, HER 2-4, EGFR variant III, Heregulin and Downstream Signalling 
in development/progression of Prostate Adenocarcinoma?’ reference 05/S0704/89.  
 
Funding was kindly provided by the Aileen Lynn Bequest Fund committee based at 
the Royal College of Physicians and Surgeons of Glasgow. 
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2.2 PATIENT COHORTS 
2.2.1 COHORT 1: PILOT STUDY COHORT WITH PAIRED HORMONE 
         SENSITIVE AND HORMONE RESISTANT SPECIMENS 
This is the patient cohort utilised in the pilot study  (Edwards 2006) and includes 
paired single slides of matched androgen sensitive and androgen insensitive samples. 
This cohort was collected from hospitals within the West of Scotland Deanery with 
specimens originally taken between 1984 and 2004. For inclusion within the study 
inclusion and exclusion criteria were;- 
1.  A  pathological  diagnosis  of  prostate  adenocarcinoma  with  a  pathological 
specimen taken at this stage; either a biopsy (usually obtained via trans-rectal 
ultrasound  (TRUS)  sampling  or  shavings  obtained  from  a  trans-urethral 
resection of prostate (TURP) procedure. In all cases this sample was obtained 
before  any  hormonal  therapy  was  commenced  making  it  a  hormone 
naïve/sensitive sample (HSPC). 
2.  The patient commenced on hormonal therapy either an antiandrogen such as 
bicalutamide  (Casodex,  AstraZeneca),  a  gonadotrophin  releasing  hormone 
(GnRH)  agonist  such  as  goserelin  (Zoladex,  AstraZeneca)  or  maximal 
androgen blockade (MAB); a combination of antiandrogen and GnRH agonist. 
Alternatively the patient could have undergone bilateral orchidectomy. 
3.  A significant tumour response to the hormonal therapy as determined by a 
>50%  fall  in  PSA  following  commencement  confirming  the  hormone 
sensitivity of the primary tumour.  
4.  Subsequent tumour hormone escape as determined by two consecutive rises in 
PSA  of  >10%  with  the  initial  PSA  value  above  0.5  despite  continued   71 
hormonal therapy. The tumour is thereafter classified as hormone resistant/ 
refractory (HRPC) 
5.  A further pathological sample of the tumour obtained subsequent to hormone 
escape. Usually this is  a sample obtained by TURP performed to alleviate 
symptoms  of  bladder  outlet  obstruction  secondary  to  the  tumour  and 
constitutes the HRPC sample. 
 
In the pilot study 74 sets of paired samples were utilised. Subsequently to the pilot 
study  7  patients  were  added  to  the  cohort  however  due  to  the  gradual  nature  of 
additions to the cohort coupled with depletion of slides through use in other studies 
staining for each target could not be carried out in all slide pairs. In this study a cohort 
of 81 paired samples were stained for at least one target.  
 
Within this cohort of 81 patients mean age was 70.0 years (SD ± 8.0, range 41.1 – 
98.0). At diagnosis at least 56 (69.1%) patients had locally advanced disease (T3-4). 
Gleason scores in HSPC specimens were low (1-4) in 2 (2.5%) patients, intermediate 
(5-7) in 35 (43.2%), high in 8-10 in 43 (53.8%) and not recorded in the remainder. 18 
(22.2%)  patients  had  known  metastatic  disease  at  diagnosis,  54  (66.7%)  had  no 
metastases with the metastatic status of the remainder unknown. By definition all of 
the patients in this cohort had undergone hormone escape; mean time to relapse was 
36.5 ± 31.3 months. At last known follow up 69 (85.2%) patients were deceased, 8 
(9.9%) patients were alive with the status of the remainder lost to follow up. Mean 
time to death/last follow up was 61.0 months (SD ± 43.1). 
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Table 2.1: Summary Statistics for All Cohort 1 Patients  
N  81 
Age  70 ± 8 years 
Range 41.1 – 98.0 years 
Gleason Score 
￿  Low 
￿  Medium 
￿  High 
 
2 
35 
43 
T Stage at Diagnosis 
￿  T1-T2/unknown 
￿  T3-T4 
 
25 
56 
Metastasis at Diagnosis 
￿  Yes 
￿  No 
￿  Unknown 
 
21 
35 
25 
 
Biochemical Relapse 
￿  Yes 
￿  No 
￿  Unknown 
 
81 
0 
0 
Time to Relapse  36.5 ± 31.3 months 
Final Status 
￿  Alive 
￿  Deceased 
￿  Unknown 
 
69 
8 
4 
Follow up  61.0 ± 43.1 months   
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2.2.2 COHORT 2: EXPANDED COHORT WITH HORMONE SENSITIVE 
         SPECIMENS 
Due to the fact that in the pilot the majority of significant results were found in the 
hormone sensitive samples the decision was made to expand the hormone sensitive 
samples  cohort.  The  criterion  for  this  cohort  was  to  have  had  a  pathologically 
confirmed  diagnosis  of  prostate  adenocarcinoma  with  a  specimen  taken  before 
commencement  of  any  hormonal  therapy.  This  specimen  can  be  obtained  from  a 
biopsy, TURP or radical prostatectomy sample if this was the primary treatment.  
 
Cohort  2  was  made  up  of  the  HSPC  samples  from  cohort  1  supplemented  by 
specimens obtained from Newcastle prepared as tissue microarrays i.e. with multiple 
tumour cores per slide. Where possible there was more than one tumour core per 
patient  on  the  TMAs  to  compensate  for  possible  tissue  heterogeneity.  4  different 
TMAs were utilised including CaP specimens from a total of 276 patients.  
·  TMA1 consisted of samples from 76 patients all obtained from TRUS biopsy 
or  TURP.  There  were  2-3  CaP  samples  per  patient.  A  range  of  treatment 
methods were utilised with only a proportion of patients receiving hormonal 
therapy 
·  TMA2 consisted of samples from patients all obtained from TRUS biopsy or 
TURP. There were 2-3 CaP samples per patient. A range of treatment methods 
were utilised with only a proportion of patients receiving hormonal therapy. 
·  TMA3  consisted  of  samples  from  patients  all  obtained  from  radical 
prostatectomy. There were 4 CaP samples per patient. To our knowledge none 
of these patients underwent hormonal therapy.   74 
·  TMA4 consisted of samples obtained from patients obtained from TURP or 
TRUS biopsy. There was 1 sample per patient, all patients received hormone 
therapy. 
 
Together the patients from cohort 1 and those from the TMAs gave a total of 357 
patients. Within this second cohort of 357 the median age was 70.7 years (range 39.0 
– 103.4  years) mean age was 70.4  years (SD ± 9.2). At diagnosis 65 (18.2%) of 
tumours  were  Stage  T1,  53  (14.8%)  T2,  86  (24.1%)  T3,  30  (8.4%)  T4  with  the 
remainder of unknown/unrecorded stage. Gleason scores in HSPC specimens were 1-
4  in  4  (1.1%),  5-7  in  206  (57.7%),  8-10  in  94  (26.3%)  and  not  recorded  in  the 
remainder.  74  patients  (20.7%)  had  known  metastatic  disease  at  diagnosis,  187 
(52.4%) had no metastases with the metastatic status of the remainder unknown.  
     Patients within the cohort underwent a variety of treatment modalities. 227 patients 
(63.3%) including all those from the pilot study cohort underwent hormone therapy – 
antiandrogens, GnRH analogues, maximal androgen blockade or bilateral 
orchidectomy. At least 45 (12.6%) underwent radical retropubic prostatectomy. Over 
the recorded course of their disease 194 patients (54.3%) suffered biochemical relapse 
as defined above, 64 (17.9%) had no relapse and the relapse status was not recorded 
in 99 patients (27.7%). Mean time to relapse was 35.1 months (SD ± 32.3). At last 
known follow up 213 patients (59.7%) patients were deceased, 110 patients (31.9%) 
were alive with the status of the remainder unclear. Mean time to death/last follow up 
was 69.8 months (SD ± 54.0). 
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Table 2.2: Summary Statistics for All Cohort Patients with Hormone Treated 
Subgroup 
  HORMONE TREATED 
PATIENTS 
ALL PATIENTS 
N  227  357 
Age  71.4 ± 8.6 
(41.1 – 103.4) 
70.4 ± 9.2 
(39.0 – 103.4) 
Gleason Score 
￿  Low 
￿  Medium 
￿  High 
 
4 
116 
69 
 
4 
206 
94 
T Stage at Diagnosis 
￿  T1 
￿  T2 
￿  T3 
￿  T4 
 
34 
26 
31 
25 
 
65 
54 
86 
30 
Metastasis at Diagnosis 
￿  Yes 
￿  No 
￿  Unknown 
 
57 
110 
60 
 
74 
187 
96 
Biochemical Relapse 
￿  Yes 
￿  No 
￿  Unknown 
 
182 
36 
12 
 
194 
64 
99 
Time to Relapse  34.1 ± 32.1 months  35.1 ± 32.3 months 
Final Status 
￿  Alive 
￿  Deceased 
￿  Unknown 
 
43 
167 
17 
 
110 
213 
34 
 
Follow up  73.2 ± 58.6 months  69.8 ± 54.0 months 
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2.3 IMMUNOHISTOCHEMISTRY 
The main principle of immunohistochemistry (IHC) is the use of specific antibodies to 
the  antigen  to  be  detected  to  stain  tissues  prepared  as  slides.  Once  the  primary 
antibody has bound to the antigen of interest, a secondary antibody is utilised which 
binds to the primary and amplifies the staining. This secondary antibody is labelled 
with  an  enzyme  such  as  3,3’-diaminobenzidine  (DAB)  or  visible  marker 
(fluorochrome) which gives a measurable visual representation of the level of binding 
of the primary antibody thus allowing the level of the target antigen to be assessed. 
 
2.3.1  GENERAL STEPS IN IMMUNOHISTOCHEMISTRY 
In this study 6 different specific protein marker antigens were targeted 
·  EGFR 
·  HER2 
·  HER3 
·  HER4 
·  EGFRVIII 
·  HRG 
Additionally, as mentioned in the aims and objectives, the patient cohorts were also 
stained for markers of cell proliferation and apoptosis to assess their relationship with 
the main targets of this study. 
·  KI67-MIB antibody – a marker of cell proliferation 
·  ApopTag®  TUNEL  Assay  (Chemicon  International)–  a  marker  of  cell 
apoptosis 
The IHC staining process of these markers varies somewhat in detail but follows the 
same basic steps in each case. The scoring process for assessing staining levels varies   77 
somewhat between the main study proteins and the proliferation/apoptosis markers 
and will be addressed later in this chapter 
 
Tissue Preparation 
Tissue specimens had previously been prepared as formalin-fixed, wax-embedded 3-
4 m thick sections with size dependent on the source of the sample for single slides 
and  multiple  5mm  diameter  sections  on  TMAs.  Specimens  were  mounted  on  3-
aminopropylethoxysilane coated slides. As the sections on TMAs are small and prone 
to damage/destruction during the IHC process TMAs are heated at 80°C for 5 minutes 
before other tissue preparation as this renders TMA samples less prone to damage. 
This process is not required for larger single slide sections 
 
Before IHC staining tissue sections are dewaxed in 2×2-5 minute xylene baths then 
rehydrated in a series of alcohol baths;- 2×5 minutes 100% alcohol, 1×3 minutes 90% 
alcohol then 1×3 minutes 70% alcohol. 
 
Antigen Retrieval 
This process serves to counter any loss of immunoreactivity that occurs in tissues due 
to formalin-fixation and wax-embedding. During formalin fixation methylene bridges 
can form within tissue sections masking the relevant antigenic sites causing reduced 
or absent antibody-antigen interaction. Antigen retrieval breaks methylene bridges to 
expose  antigenic  sites  (Fig  2.1a)  and  is  achieved  by  incubating  rehydrated  tissue 
sections in a citrate or TRIS buffer at high temperature and/or pressure. The principle 
method used in this study was 1mM citrate buffer (1:100 dilution Epitope Retrieval 
Buffer, DAKO) in a pressure cooker heated in a microwave for 5 minutes followed by   78 
a 20 minute cool down period. Other methods used in this study include heated at 
pressure in Tris EDTA Buffer (10mM Trizma Base, 0.25 mM EDTA), incubated in 
0.1% trypsin in 0.1% calcium chloride at 37°C water bath,  HercepTest™ (DAKO) 
epitope retrieval solution in water bath at 95-99°C and incubation with Protein Kinase 
K 20 g/ml at 25°C. The precise methods of antigen retrieval used for each marker are 
listed in tables 2.3 and 2.4 below. 
 
Blocking of Background Staining 
Endogenous  peroxidase  within  prepared  tissue  sections  can  react  with 
diaminobenzidine (see below) causing non-specific background staining during the 
IHC  process  interfering  with  assessment  of  the  presence  of  the  target  antigen. 
Blocking of this process can be achieved by incubating with 0.3% Hydrogen Peroxide 
(H2O2) for 10-20 mins followed by wash in distilled water. Additionally unintended 
hydrophobic bonds can form between immunoglobins and prepared tissue resulting in 
non-specific  binding  of  both  primary  and  secondary  antibodies  and  further 
background staining. This can be counteracted by incubation with 1.5% horse serum 
(Vector) in Tris Buffered Saline (TBS) for 10 minutes after which the blocking serum 
is poured off but not washed. The relative position of blocking processes and antigen 
retrieval varies between different IHC protocols 
 
Incubation with Primary Antibody 
At this stage the prepared, blocked tissue sections were incubated with the primary 
antibody which binds to the target antigen (Fig 2.1b). The specific concentration and 
duration  and  temperature  of  incubation  for  each  antibody  was  determined  by 
optimisation of the antibody i.e. trial runs with a range of concentrations/durations    79 
Figure 2.1: Schematic Representation of Immunohistochemical Staining using the 
example of the streptavidin-biotin method which relies on the high affinity of avidin 
and biotin to each other. 
 
temperatures  in  samples  known  to  stain  positively  with  the  aim  of  finding  the 
conditions providing the best result – strongest specific staining with the least possible 
background and not overstained so a comparison between low and high expression is 
possible.  The  antibodies  to  EGFR,  EGFRvIII,  HER2,  HER3  and  HER4  were 
optimised during the pilot study and the regimens determined in the pilot study were 
a) antigen retrieval to 
expose antigen 
b) Incubation with primary antibody 
– binds to target antigen 
d) Incubation with strptavidin 
labelled with horse radish 
peroxidase – binds to biotin 
e) Incubation with 3,3’-diamino 
benzidine – binds to peroxidase and 
produces insoluble brown 
precipitate 
c) Incubated with 
biotinylated link antibody 
– binds to primary 
antibody   80 
used. The antibodies to HRG and KI67 were optimised in this study (see below). The 
TUNEL apoptotic assay is provided with specific instruction and is pre-optimised. 
The specific incubation concentrations and conditions used for each antibody in this 
study are listed in tables 2.3 and 2.4. 
 
Quality Control 
Each IHC run performed included both a positive and negative control. The positive 
control used was a tissue section known to stain positively with the specific antibody 
– in most cases a specific tissue section shown to be strongly positive in the pilot 
study. The same positive controls were used in different runs of the same antibody 
although the section used varied between different antibodies.  Positive controls go 
through every single step of a run with the aim of confirming the success or failure of 
staining; specific positive controls used are listed in table 2.5. Negative controls were 
all isotype matched prostatic tissue sections which went through every step of the run 
except incubation with the primary antibody with the aim of checking specificity of 
staining i.e. demonstration of staining in the negative control indicates background 
staining rendering a run unreliable.  
Incubation with Secondary Antibody 
Following incubation with the primary antibody the tissue sections were washed with 
TBS  buffer  for  2×5  minutes  then  incubated  with  a  secondary  antibody  (Fig  2.1c, 
2.1d).  One  secondary  antibody  method  utilised  in  this  study  is  the  labelled 
streptavadin-biotin (LSAB plus-DAKO) visualisation which involves a 2 step process, 
first the specimen is incubated for 15 minutes at 25°C with biotin-attached antibody 
directed at the primary antibody washed in TBS then incubated with avidin affixed to 
a peroxidase for 15 minutes at 25°C and washed again. Avidin has a high affinity for   81 
biotin and the result of this dual incubation is peroxidase bound via avidin, biotin and 
secondary antibody to the primary. Another secondary antibody used in this study was 
Envision™  (DAKO)  which  consists  of  a  dextran  large  molecule  backbone  with 
enzyme molecules including horseradish peroxidase attached as well as antibodies 
which bind to the primary. It is the attached peroxidase which is vital to the next 
stage. Incubation is carried out at room temperature in a humidified chamber usually 
for  30  minutes.  The  envision  system  is  noted  to  have  high  sensitivity  and  low 
background staining. 
 
Visualisation 
Following a further wash in 2×5 minutes TBS the tissue sections were incubated with 
3,3’-diaminobenzidine (DAB) in the form of chromagen DAB substrate (DAKO) in 
specific DAB diluent (DAKO) usually in ratio 1:50. An alternative preparation is 4 
drops DAB stock solution, buffer, 2 drops H2O2, 2 drops buffer in 5mls distilled water 
(Vector).  When  a  substrate  chromagen  binds  to  peroxidase  (Fig  2.1e)  a  colour 
reaction occurs producing a brown colour product with the amount of brown staining 
corresponding to the level of peroxidase present therefore the level of secondary and 
primary  antibody  hence  the  level  of  expression  of  the  target  antigen  in  the  tissue 
section. Incubation with DAB is carried out at room temperature for 5-10 minutes 
followed by washing in water for 10 minutes. 
 
Counterstaining 
Following chromagen staining tissue sections were counterstained to provide contrast 
to the brown colour allowing assessment of the level of positive staining. Slides are 
immersed in haematoxylin for 30-45 seconds, washed then submerged in Scots Tap   82 
Water Substitute for 45 seconds and washed again. Haematoxylin stains tissue not 
already chromagen stained vivid red and the Scots Tap converts this red to a blue 
colour particularly in contrast to chromagen brown. 
 
Dehydration and Mounting 
The final steps in the IHC process prepare the tissue section for viewing under light 
microscope and scoring. The slides are dehydrated in a series of alcohol baths;- 1×1 
minute 70% alcohol, 1×1 minute 90%, 2×1 minute 100% then 2×1 minute xylene. 
Dehydrated slides are then mounted onto cover slips using DPX mountant (Dibutyl 
Phtalate and xylene) as an adhesive.  
 
2.3.2 OPTIMISATION OF HEREGULIN 
As it had neither been used in the pilot study nor as part of any study at this institution 
the antibody for HRG (HRG Clone V10081 (Biomedia)) was optimised for use in this 
study. Identical slides prepared and incubated at varying concentrations of primary 
antibody/durations.  
·  1:100 for 10 mins at 25°C humidified  
·  1:100 for 30 mins at 25°C humidified 
·  1:200 for 10 mins at 25°C humidified 
·  1:200 for 30 mins at 25°C humidified 
The other steps used in HRG staining protocol used are listed in table 3. Incubation 
for  30  mins  at  either  concentration  rendered  slides  too  heavily  stained  to  allow 
differential scoring of expression. Incubation for 10 minutes gave an appropriate level 
of staining with 1:100 stronger than 1:200. Incubation with concentration 1:100 for 10 
minutes was chosen as the optimal method and used thereafter for all HRG staining.   83 
2.3.3 SPECIFIC STEPS IN IMMUNOHISTOCHEMISTRY 
Table 2.3: Specific Antigen Staining Protocols 
Antigen  Tissue 
Preparation 
Blocking  Antigen 
Retrieval 
Primary 
Antibody 
Secondary 
Antibody 
Visualisation  Counterstain  Dehydration 
EGFR  xylene 2×4 
mins, alcohol 
100% 2×4 mins, 
alcohol 90% 
1×2 mins, 
alcohol 70% 
1×2 mins 
Pre-retrieval: 
0.3% H2O2 for 
20 mins 
Post-retrieval: 
1.5% horse 
serum 
Incubated in 
0.1% trypsin 
(Sigma) in 0.1% 
calcium chloride 
at 37°C water 
bath for 10 mins 
EGFR clone 
31G7 (Zymed) 
slides incubated 
1:50 antibody: 
antibody diluent 
(DAKO) 25°C 
for 1 hour 
LSAB Plus  DAB (Vector)  Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene. 
HER2  xylene 2×4 
mins, alcohol 
100% 2×4 mins, 
alcohol 90% 
1×2 mins, 
alcohol 70% 
1×2 mins 
  HercepTest™ 
(DAKO) epitope 
retrieval 
solution in water 
bath at 95-99°C 
 
HercepTest 
7.5g/ml rabbit 
anti-human 
HER2 
polyclonal 
antibody for 30 
mins at 25°C 
humidified 
chamber 
  DAB (Vector)  Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene. 
HER3  xylene 2×4 
mins, alcohol 
100% 2×4 mins, 
alcohol 90% 
1×2 mins, 
alcohol 70% 
1×2 mins 
0.3% H2O2 for 
20 mins. 
avidin/biotin 
blocking kit, 
2.5% horse 
serum for 20 
mins 
none required  HER3 clone 
H3.105.5 (MS-
303-PABX, 
Neomarkers) 
Slides incubated 
in 1:20 
antibody:antibod
y diluent for 2 
hours at 25°C 
humidified 
ImmPRESS 
Anti-mouse Ig 
(peroxidase) kit 
(Vector) 
DAB (Vector)  Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene.   84 
HER4  xylene 2×4 
mins, alcohol 
100% 2×4 mins, 
alcohol 90% 
1×2 mins, 
alcohol 70% 
1×2 mins 
0.3% H2O2 for 
20 mins 
avidin/biotin 
blocking kit, 
serum free 
blocking 
solution 
(DAKO) for 10 
minutes 
none required  HER4 clone 
HFR1 (ME-637-
PO, 
Neomarkers) 
Slides incubated 
in 1:50 
antibody:antibod
y diluent for 2 
hours at 25°C 
LSAB Plus  DAB (Vector)  Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene. 
EGFRvIII  xylene 2×4 
mins, alcohol 
100% 2×4 mins, 
alcohol 90% 
1×2 mins, 
alcohol 70% 
1×2 mins 
 
Pre-retrieval: 
0.3% H2O2 for 
20 mins 
Post-retrieval: 
5% horse serum 
for 1 hour 
Tris EDTA 
Buffer (10mM 
Trizma Base, 
0.25 mMEDTA) 
heated at 
pressure for 
5mins 
EGFRvIII clone 
ZMD.82 
(Zymed) Slides 
incubated in 
1:50 
antibody:antibod
y diluent at 
25°C humidified 
LSAB Plus  DAB (Vector)  Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene.. 
HRG  2×2 mins 
xylene, 2×2 
100% alcohol, 
1×2 mins 90% 
alcohol, 
1×2mins 70% 
alcohol 
Post-retrieval: 
1% H2O2 for 10 
mins 
Citrate Buffer 
heated at 
pressure for 5 
mins, 20 mins 
cooling 
HRG Clone 
V10081 
(Biomedia) 
Slides incubated 
in 1:100 
antibody:antibod
y diluent for 10 
minutes at 25°C 
Envision 
(DAKO) for 30 
mins 
Chromagen 
DAB 1:50 
(DAKO) 
Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene. 
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2.3.4 KI67 ASSAY 
KI67  is  a  nuclear  protein  principally  associated  with  cellular  proliferation.  It  is 
expressed in all active phases of the cell cycle (G1, S, G2 and M) but is not expressed 
in the resting G0 phase. Precise location of KI67 varies with cell cycle phase. In G1 
the  perinucleolar  region,  in  later  phases  throughout  the  nucleus,  being  mainly 
localized to the nuclear matrix., in mitosis, it is present on all chromosomes. KI67 is 
thought to be involved in regulating the cell cycle and cell division. IHC is carried out 
in a similar fashion to other antigens however staining is only in the nucleus.  
The  antibody  used  for  KI67  staining  was  KI67  MIB  Clone  M7240  (DAKO).  For 
optimisation identical slides were prepared and incubated with the antibody at varying 
concentrations 
·  1:50 for 1 hour at 25°C humidified 
·  1:100 for 1 hour at 25°C humidified 
·  1:150 for 1 hour at 25°C humidified 
Steps used in KI67 staining are listed in tale 4. The 1:150 concentration was found to 
have the optimal staining level 
 
2.3.5 TUNEL ASSAY 
As  apoptosis  occurs  many  fundamental  cellular  changes  occur  including  nuclear 
condensation, segmentation, fragmentation and  formation of apoptotic  bodies. The 
TUNEL assay functions by enzymatically labelling the free 3’-OH termini that are 
produced during apoptotic fragmentation of DNA typically located in the nucleus and 
apoptotic  bodies.  These  3’-OH  ends  are  not  seen  in  significant  numbers  in 
normal/proliferative nuclei and this type of DNA cleavage does not typically occur in 
cell necrosis. The TUNEL assay can detect apoptosis at a relatively early stage where   86 
chromatin  condensation  has  occurred  and  DNA  strand  breaks  are  few  but  still 
significantly greater than in normal/proliferative cells. As part of the TUNEL assay 
prepared,  blocked  tissue  sections  are  incubated  in  terminal  deoxynucleotidyl 
transferase  (TdT)  and  reaction  buffer;  nucleotides  in  the  buffer  (which  may  be 
labelled with dioxigenin or unlabelled) are enzymatically added by the TdT to the 3’-
OH terminals. Labelled and unlabelled nucleotides form an oligomer in a random 
sequence but in a ratio promoting binding by anti-dioxigenin antibodies. Secondary 
labelling is incubation with an anti-dioxigenin antibody conjugated with peroxidase 
and further addition of DAB (3,3’diaminobenzidine) produces a visible stain as in 
other IHC processes.  
 
In  lieu  of  optimisation  instructions  from  the  ApopTag  TUNEL  Assay  kit  were 
followed specifically. Specific steps are listed in table 4. 
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Table 2.4: Specific Staining Protocols for KI67 and TUNEL Assay 
Antigen  Tissue 
Preparation 
Antigen 
Retrieval 
Blocking  Primary 
Antibody 
Secondary 
Antibody 
Visualisation  Counterstain  Dehydration 
KI67  2×2 mins 
xylene, 2×2 
100% alcohol, 
1×2 mins 90% 
alcohol, 
1×2mins 70% 
alcohol 
Citrate Buffer 
heated at 
pressure for 5 
mins, 20 mins 
cooling 
Post Retrieval: 
1% H2O2 for 10 
mins 
KI67 MIB 
Clone M7240 
(DAKO) Slides 
incubated in 
1:150 
antibody:antibod
y diluent for 1 
hour at 25°C 
humidified 
Envision 
(DAKO) for 30 
mins 
 
Chromagen 
DAB 1:50 
(DAKO) 
Haematoxylin 
and Scots Tap 
1×1 min 70% 
alcohol, 1×1 
min 90% 
alcohol, 2×1 
min 100% 
alcohol then 2×1 
min xylene. 
TUNEL 
Assay 
3×5mins xylene, 
2×5mins 100% 
alcohol, 
1×3mins 90% 
alcohol, 1×70% 
alcohol 
Incubation with 
Protein Kinase 
K 20 g/ml for 
10 mins at 25°C 
Post-Retrieval 
3% H2O2 for 5 
mins, ApopTag 
Equilibration 
Buffer 
ApopTag TdT 
enzyme 3:7 
reaction buffer 
Slide incubated 
for 1 hour at 
37°C humidified  
 
ApopTag Anti-
Dioxigenin 
Peroxide 
Antibody 
incubated for 30 
mins at 25°C 
humidified 
ApopTag DAB 
Slides incubated 
at in 1:20 DAB 
substrate:diluent 
for 3-6 mins at 
25°humidified 
Methylgreen 
(0.5g 
methylgreen in 
sodium acetate 
(1.36g in 100ml 
dH2O pH 
adjusted to 4)) 
for 10 minutes 
2×20 dips dH2O, 
1×30 seconds 
dH2O, 2×20 dips 
N-Butanol, 1×30 
mins, 3×2 mins 
xylene 
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Table 2.5: Antibodies used in IHC 
TARGET  ANTIBODY  SOURCE  CONCEN-
TRATION 
POSITIVE 
CONTROL 
EGFR  clone 31G7  Zymed  1:50  Specific 
CaP  tissue 
section 
from pilot 
HER2  Anti-human  HER2 
polyclonal antibody 
Rabbit 
HercepTest 
DakoCyto-
mation 
7.5g/ml  Specific 
CaP  tissue 
section 
from pilot 
HER3  H3.105.5  
MS-303-PABX 
Neomarkers  1:20  Specific 
CaP  tissue 
section 
from pilot 
HER4  clone HFR1 
MS-637-PO 
Neomarkers  1:50  Specific 
CaP  tissue 
section 
from pilot 
EGFRVIII  clone ZMD.82  Zymed  1:50  Specific 
CaP  tissue 
section 
from pilot 
HRG  Clone V10081  Biomedia  1:100  CaP 
(Specific 
Sample) 
PROLIFERATION  KI67 MIB  
Clone M7240 
DakoCyto-
mation 
1:150  Prostate 
Tissue 
(specific 
sample) 
APOPTOSIS  TDT Enzyme* 
Anti-Dioxigenin  
(sheep polyclonal) 
TUNEL Assay 
ApopTag 
Chemicon  3:7 in buffer 
As in 
TUNEL kit 
Rodent 
Mammary 
Gland 
* enzymatic addition of labelled nucleotides takes the place of the primary antibody 
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2.4 IMMUNOHISTOCHEMISTRY SCORING 
The principle IHC scoring is assessment of the level of specific protein expression by 
determining the relative levels of the visualisation factor in different samples. Accuracy 
of scoring is ensured by use of 2 independent scorers with agreement in results between 
the 2 scorers correlated. Within this study 2 methods of histoscore; weighted histoscore 
for  target  antibodies  primarily  staining  cytoplasm  and  cell  membrane  and  nuclear 
counting for the cell proliferation and apoptotic markers that primarily stain the nucleus.  
 
2.4.1 SCORING – WEIGHTED HISTOSCORE METHOD 
For each of the target proteins EGFR, HER2, HER3, HER4, EGFRvIII and HRG tissue 
levels were assessed using the weighted histoscore method previously demonstrated in 
multiple  studies including  McCarty et  al  (1986),  Witton  et al.  (2004)  Edwards  et  al. 
(2005) and Kirkegarrd et al (2006). On viewing the full section the prostate tumour cells 
are identified and the level of staining of the cytoplasm, cell membrane and nucleus are 
separately assessed with the intensity of staining categorised as negative (0), weak (1), 
moderate (2), and strong (3) and the percentage of tumour cells within each intensity 
category estimated. The weighted histoscore was calculated using the formula 
Histoscore = (0 × negative tumour cells) + (1 × % weakly stained tumour cells) + (2 
× % moderately stained tumour cells) + (3 × % strongly stained tumour cells) 
This  formula  gives  a  weighted  histoscore  value  (called  the  HSCORE  by  McCarty) 
between minimum 0 and maximum 300. Separate values are calculated for cytoplasm, 
cell membrane and nucleus for each target protein. 
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Accuracy of score was determined by use of 2 independent observers for each target 
protein with the results of the 2 observers correlated. In single slide tissue sections all 
slides are analysed by both observers and the results for each slide compared. Results 
were considered discordant if scores differed by more than 50 and these individual cases 
re-evaluated by both observers. The inter-class correlation coefficient (ICCC) was used to 
assess  variation  in  expression  scoring  between  the  2  observers  for  all  markers.  This 
reliability measure assesses differences between the observers in each case comparing it 
to  the  overall  variation  between  all  scorings.  ICCC  as  a  determinant  of  validity  was 
explored in Kirkegaard et al who stated that an ICCC > 0.7 was a minimum requirement 
for  acceptable  variation  therefore  within  this  current  study  agreement  between  2 
observers was considered satisfactory for a specific marker +if ICCC > 0.7 was achieved. 
Final scores used were the mean of the 2 observer scores. TMAs were scored in full by a 
single observer with a 2
nd independent observer scoring a minimum of 10% of TMA 
specimens and the results of these double scored specimens compared. If ICCC of the 
double scored TMA specimens > 0.7 without adjustment this was taken as confirmation 
of accuracy of the 1
st scorer. If ICCC < 0.7 at least a further 10% were double scored with 
ICCC calculated again with the process repeated until either ICCC > 0.7 or all TMA 
specimens  were double  scored.  It  should  be  noted  that  no  further  specimens  for  any 
marker  required  further  double  scoring  after  the  first  calculation  of  ICCC.  The  final 
histoscores used were the mean of the 2 scorers for double scored specimens and that of 
the 1
st scorer in all others. ICCCs for all markers are listed in the results section below. 
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2.4.2 SCORING – NUCLEAR COUNT METHOD 
Cell proliferation marker KI67 and apoptotic marker TUNEL assay stain only the nuclei 
of proliferating/apoptotic cells respectively with levels of these processes assessed by 
calculating the relative numbers of stained and unstained tumour cell nuclei. In single 
slide  specimens  15  separate  fields  at  20×magnification  which  included  tumour  were 
assessed using a 10 line grid overlying the field. All tumour cell nuclei lying on a grid 
line were assessed as either positive or negative and counted with the aim of counting 
100 nuclei per field therefore 1500 nuclei per specimen. Where fewer than 100 tumour 
nuclei were present on grid lines all tumour nuclei in the field were counted up to a 
maximum of 100 – all tumour cell nuclei present if there were fewer than 100. Where 
there  were  persistently  fewer  than  100  tumour  nuclei  per  field  up  to  20  fields  were 
viewed. Where fewer than 15 separate 20× magnification fields could  be found with 
tumour within a tissue section the maximum of separate 20× magnification fields that 
could be found with tumour in were used. Therefore ~1500 tumour cell nuclei or all those 
present in up to 20 fields of the sample were counted. In TMAs all tumour cell nuclei 
within a sample were counted.  
 
Marker  expression  was  calculated  as  the  percentage  of  all  cells  counted  that  were 
positive. This method has been demonstrated previously in Hilmy et al.  
Positive Nuclear Score = 100 × (Number of Positive Tumour Nuclei/Total Number 
Tumour Nuclei) 
All specimens were assessed by a single scorer with a 2
nd independent scorer double 
scoring at least 10% of samples including TMAs. Positive nuclear scores of the 2 scorers   92 
were compared and the ICCCs calculated for the double scored specimens. If ICCC > 0.7 
without adjustment for the samples assessed this was taken as a confirmation of accuracy 
of the 1
st scorer. If ICCC < 0.7 at least a further 10% samples were double scored and the 
ICCC calculated until ICCC > 0.7 or until all were double scored. It should be noted that, 
due to this method being a count and less subjective than the weighted histoscore method, 
no further double scoring was required after the initial ICCC calculation indeed ICCCs 
calculated by this method were all > 0.9. The final positive nuclear scores used were the 
mean of the 2 scorers for double scored specimens and that of the 1
st scorer in all others. 
ICCCs for all markers are listed in the results section below 
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2.5 WESTERN BLOTTING 
Western blotting is a technique which allows detection, identification and quantification 
of specific proteins within a sample using electrophoresis to divide denatured proteins 
into a spectrum by molecular weights within a gel followed by transfer of the resulting 
proteins to a PVDF membrane. The membrane is then incubated with a primary antibody 
to recognise a specific protein from the spectrum and a secondary antibody to the primary 
which allows visualisation of the protein via chemiluminescence/chemifluorescence/x-
ray film. Use of a known primary antibody allows detection of a specific protein within a 
mixed  sample  (e.g.  one  derived  from  lysed  tissue  sections)  with  confirmation  of 
molecular  weight  thereby  identity  via  comparison  of  a  protein’s  position  following 
electrophoresis  relative  to  proteins  of  known  molecular  weight  in  a  protein  ladder. 
Intensity of signalling following visualisation processes indicates quantity of the target 
protein within the original sample.  
 
A further indication for use of Western  Blotting is confirmation of specificity of the 
primary antibody. If an antibody is truly specific to one protein it will attach only to that 
protein within the spectrum produced by gel electrophoresis with the resultant completion 
of the Western Blotting process resulting in a single band. Conversely an antibody with 
poor specificity will result in multiple bands. Within this study Western Blotting is only 
used for this last indication. At this centre the specificity of EGFR, HER3, HER4 and 
EGFRvIII  had  been  confirmed  in  previous  studies  including  the  pilot  and  HER2 
specificity is assured by use of the commercial HercepTest; however the HRG antibody   94 
(Clone V10081, Biomedia) had never been used here and a Western Blot utilising this 
antibody was performed. 
 
2.5.1 WESTERN BLOTTING OF HEREGULIN ANTIBODY 
Western  Blotting  was  carried  out  using  the  Bio-Rad  Mini-Protean  3  Electrophoresis 
System. The initial step was preparation of 10% resolving gel – polymerisation of the 
acrylamide  and  bis-acrylamide  catalysed  by  TEMED  and  APS  form  the  gel.  Protein 
migration during electrophoresis is determined by size of gel pores which are in turn 
governed  by  the  amount  of  acrylamide-bis  in  the  gel  mixture  –  increased 
acrylamide/increased gel percentage decreases pore size thereby making gel suitable for 
separating smaller proteins. 
Table 2.6: Constituents of 10% Resolving Gel 
REAGENTS  10% RESOLVING GEL 
40% Acrylamide/Bis-Acrylamide (Sigma) 
0.5M EDTA 
2M Tris, pH 8.9 
10% SDS 
dH20 
10% APS 
TEMED 
12.49ml 
330 l 
8.35ml 
500 l 
28.33ml 
300 l 
30  
 
A mould was assembled from 2 spacer plates fixed into a casting frame and gel poured 
into the mould between spacer plates and isopropanol poured on top of the gel which is 
allowed to set over 30 mins. The isopropanol serves to remove air bubbles from and 
flatten the top of the setting gel. Once the gel was set the isopropanol was poured off and 
blotted and 4.5% stacking gel prepared and poured onto the resolving gel filled to the 
level of the top of the spacer plates. A gel comb, which creates the wells into which the   95 
denatured  protein  samples  would  later  be  placed,  was  positioned  in  the  stacking  gel 
which is then allowed to set over 30 minutes. 
Table 2.7: Constituents of 4.5% Stacking Gel 
REAGENTS  4.5% STACKING GEL 
40% Acrylamide/Bis-Acrylamide (Sigma) 
0.5M EDTA 
2M Tris, pH 8.9 
10% SDS 
dH20 
10% APS 
TEMED 
5.63ml 
400 l 
6.35ml 
500 l 
37.22ml 
30 l 
10  
 
After the stacking gel was set the comb was removed and the gel rinsed in 1× running 
buffer 
Table 2.8: Buffer Constituents used in Western Blotting 
BUFFERS IN WESTERN 
BLOTTING 
REAGENTS 
10× Running Buffer  200mM Tris, 2M Glycine, 1% SDS  
(diluted to 1× in dH2O) 
2× Sample Buffer  1ml 0.5M Tris/HCl pH 6.8, 08ml Glycerol, 
1.6ml 10% SDS, 0.4ml 2-MerCaptoethanol, 
0.2ml 0.05% Bromophenol Blue, 4ml dH2O 
10× Transfer Buffer  248mM Tris, 1.3M Glycine, 20% Methanol 
(diluted to 1× in dH2O) 
Gel Loading Buffer  5% 2-merCaptoethanol 
10× TBS  0.1M Tris/HCl, 1.5M NaCl, pH 7.4 
(diluted to 1× in dH2O 
0.001% TTBS  1ml Tween 20 in 1l 1×TBS 
 
Meanwhile protein sample – cell lysate of prostate cancer cells of the LNCaP cell line – 
was prepared via protein denaturation. 2 volumes protein were added to 2× sample buffer 
in  an  Eppendorf  tube  which  was  boiled  at  100°C  for  2  minutes  then  spun  down  to 
separate solid remnants. A molecular weight marker (Biotinylated Protein Ladder – cell   96 
signalling Technology) was also boiled for 2 minutes with gel loading buffer (1 l marker 
in 9 l buffer) in a separate tube.  
 
The  sample  buffer,  specifically  the  SDS  transfers  a  negative  charge  to  the  denatured 
proteins. It is this charge that allows the movement required for electrophoresis as they 
will migrate towards the anode if placed in an electric field. Proteins will migrate through 
the acrylamide gel at a rate determined by molecular weight with lower rates travelling 
more quickly thus proteins are separated.  
 
The set gel was placed between glass plates in an electrode assembly in a mini buffer 
tank surrounded by 1× running buffer. The prepared protein sample and markers were 
loaded into the wells in the stacking gel with a fine tip pipette avoiding overspill from the 
wells. Once loaded the gel was run with a charge of 40mA for 1 hour. The denatured 
proteins migrate from the stacking to the running gel.  
 
The next step is transfer of separated proteins onto a polyvinylidene difluoride (PVDF) 
membrane so that it can be labelled. In this study the Mini-Trans Blot Cell (Bio-Rad) 
system was used. A PVDF membrane cut to be slightly larger than the running gel was 
first pre-treated in 100% methanol for 1 minute then soaked in 1× transfer buffer (table 
2.8) with fibre pads and 3M Whatman paper cut to the same size as the membrane. The 
gel  was  removed from the electrode  assembly,  the stacking portion  removed and the 
running  gel placed in transfer buffer for 15 minutes. A ‘transfer sandwich’ was then 
created  with  the  running  gel  lying  against  the  PVDF  membrane  with  both  packed   97 
between Whatman paper (3 sheets either side), fibre pads and gel cassettes, air bubbles 
are  carefully  removed  by  rolling  with  a  glass  rod.  The  sandwich  was  placed  in  an 
electrode assembly in a mini tank filled with transfer buffer itself placed in a Bio-Ice 
cooling unit with a magnetic stirrer to maintain even buffer temperature. The sandwich 
was incubated overnight (~18 hours) with the electrode assembly set at 10V which causes 
the charged proteins to transfer from the gel to the membrane maintaining the dispersion 
pattern established by electrophoresis. 
 
The next stage in the Western Blotting process is blotting of the membrane to prevent the 
primary antibody binding non-specifically to it. The sandwich was disassembled and the 
membrane incubated in 5% Marvel (non-fat dry milk) blocking solution in TBS-Tween 
(TTBS) (table) for 1 hour at 25°C on an orbital shaker which causes continuous stirring. 
The impregnated, blocked PVDF membrane was incubated with the primary antibody 
HRG antibody (Biomedia) 1:100 in 5% Marvel/TTBS at 4°C overnight on an orbital 
shaker.  
 
Following primary antibody incubation the PVDF membrane was washed in TTBS for 
3×10 mins then incubated with secondary antibody. In this study the secondary antibody 
used was 1:10 000 anti-mouse IgG (Cell Signalling Technology) linked to horseradish 
peroxidase  (HRP)  which  recognises  the  HRG  antibody.  Additionally  HRP-linked 
antibiotin  antibody  (Cell  Signalling  Technology)  1:1000  was  used  to  detect  the 
biotinylated marker ladder. The PVDF membrane was incubated with these secondary 
antibodies for 1 hour at 25°C on an orbital shaker.    98 
 
The  final  step  in  Western  Blotting  is  visualisation.  In  this  study  the  ECL  plus 
(Amersham) chemiluminescent method was utilised; – horse radish peroxidase oxidises 
luminal  into  an  excited  state  which  then  emits  light  during  its  decay 
(chemiluminescence). In ECL plus the chemiluminescent agent substrate is Lumigen PS-
3 Acridan oxidised by HRP to form acridinium ester intermediates which react with the 
peroxidase to produce light emissions at 430nm which can be detected by radiographic 
film. Following incubation with the secondary antibody the membrane was again washed 
in  TTBS  for  3×10  mins  TTBS.  The  ECL  plus  components  were  heated  to  room 
temperature then mixed in amount 3mls solution A: 75 L solution B (40:1). In semi-
darkness  to  prevent  interference  with  chemiluminescence  and  premature  non-specific 
exposure of the radiographic film the membrane was placed protein side up on a sheet of 
saran wrap, the ECL solution pipetted onto it and the membrane incubated for 5 minutes 
at 25°C. After this incubation the ECL reagents were poured off, the membrane blotted 
and wrapped in another piece of saran. The membrane was placed in full darkness with 4 
autoradiographic  films  in  succession  for  different durations;  30  seconds, 1,  5  and  15 
minutes.  
 
The radiographic films were subsequently developed and all showed the marker ladder 
and a single band at 7000Daltons corresponding with cellular Heregulin (Figure 2.2). 
This confirms that the HRG antibody used in this study has the appropriate specificity to 
be used in this study’s IHC.   
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Figure 2.2: Western Blot of HRG antibody (Clone V10081, Biomedia)  
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Protein samples of LNCaP Prostate Cancer Cell Lysate protein mixed with SDS sample buffer (to 
confer a charge to the lysate constituent proteins) are loaded onto a resolving gel block with a separate 
molecular  weight marker ladder and electrophoresed across it to create a dispersion pattern of its 
constituents  delineated  by  decreasing  molecular  weight.  The  proteins  are  transferred  to  a  PVDF 
membrane  while  maintaining  the  dispersion  pattern.  Following  blotting  to  prevent  non-specific 
binding labelled with the PVDF membrane is incubated with 1:100 HRG antibody at 4°C overnight. 
The primary antibody is washed off then the specific proteins labelled by antibody are discerned by 
incubation with secondary antibody anti-mouse IgG which binds to the primary and is also linked to a 
horseradish peroxidase moiety. The HRP labelled PVDF membrane is placed in a chemoluminescent 
agent (Lumigen PS-3 Acridan) and heated which produces light emissions which can be captured on 
radiographic film (pictured). Thus only the specific proteins within the lysate constituent dispersal 
pattern labeled by the primary antibody will ultimately produce a light emission and register on film. 
The HRG antibody produces a single band on Western Blot corresponding to Heregulin confirming its 
specificity as an antibody.  
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2.6 STATISTICS 
As in the pilot study the purpose of the statistics was to determine whether any significant 
association existed between expression of the target markers and the outcome measures;-  
Time to biochemical relapse (TTR) - time elapsed between tissue diagnosis of CaP and 
the occurrence of biochemical relapse as defined above and in the pilot study 
Time to death from relapse (TTDFR) - time elapsed from biochemical relapse as defined 
above to patient death from any cause. This outcome measure was used only for cohort 1  
Overall survival (OS) - time elapsed from tissue diagnosis of CaP to death from any 
cause 
 
Initially Kaplan-Meier regression analysis was performed comparing both above median 
(High)  and  above  upper  quartile  (Very  High)  marker  expression  with  the  outcome 
measures. As usual a p-value < 0.05 was taken as indicating a significant association. For 
those markers that demonstrated a significant association a univariate COX regression 
analysis was also performed to confirm significance and give a value for the hazard ratio 
(increased  risk  factor)  with  confidence  interval.  Multivariate  COX  regression  was 
performed  for  those  markers  demonstrating  significance  to  determine  if  this  was 
independent of Gleason score and metastasis at present. A further multivariate analysis 
was  performed  including  all  markers  maintaining  significance  through  the  first 
multivariate COX to compare the significance of these markers. 
In Cohort 1 when comparing HSPC and HRPC mean expression Wilcoxen analysis was 
used to determine any significant rise or fall after hormone escape as this is linked data 
(before  and  after)  with  a  non-parametric  distribution.  Dividing  the  cohort  into  those   101 
whose individual marker expression had risen or fallen, Kaplan-Meier analysis was again 
used to determine if a rise or fall in expression of a marker had any association with any 
of the outcome measures.  
Correlation analysis was performed on expression of all markers in the HSPC cohort to 
discern any correlations between expression of pairs of markers initially. 
All statistics were performed using the SPSS program. 
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CHAPTER 3: RESULTS – COHORT 1 
 
This chapter records the results obtained from cohort 1 which was used in the pilot study 
and  consists  of  paired  HSPC  and  HRPC  specimens  taken  from  the  same  patient  at 
diagnosis (HSPC) then following established hormone escape (HSPC). The manner in 
which these patients were identified and samples obtained is described in the method 
section.  Results  gathered  from  the  larger  cohort  2  consisting  of  HSPC  samples  are 
described in chapter 4.  
 
3.1 PATIENTS 
In the pilot study 74 sets of paired samples were utilised. Subsequently 7 patients were 
added to the cohort however due to the gradual nature of additions to the cohort coupled 
with depletion of slides through use in other studies staining for each target could not be 
carried out in all slide pairs. In this study a cohort of 81 paired samples were stained for 
at least one target. 
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3.1.1 PATIENT DATA FOR COHORT 1 
Table 3.1: Patient Data for Cohort 1 
N 
 
81 
Age  70 ± 8 years 
Range 41.1 – 98.0 years 
Gleason Score 
￿  Low              (2-4) 
￿  Medium        (5-7)        
￿  High             (8-10) 
 
2 
35 
43 
T Stage at Diagnosis 
￿  T1-T2/unknown 
￿  T3-T4 
 
25 
56 
Metastasis at Diagnosis 
￿  Yes 
￿  No 
￿  Unknown 
 
20 
35 
26 
 
Biochemical Relapse 
￿  Yes 
￿  No 
￿  Unknown 
 
81 
0 
0 
Time to Relapse  36.5 ± 31.3 months 
Final Status 
￿  Alive 
￿  Deceased 
￿  Unknown 
 
8 
69 
4 
Follow up  61.0 ± 43.1 months 
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Table 3.2: Summary of Patient Tissue Samples Within Cohort 1 Stained for each Marker 
in this Study and the Pilot Given Sample Attrition  
 
MARKER  PATIENTS  HSPC 
SAMPLES 
HRPC 
SAMPLES 
PAIRED 
SAMPLES 
EGFR  74  74  74  74 
HER2  52  52  52  52 
HER3  53  50  52  49 
HER4  59  53  54  48 
EGFRvIII  69  63  69  63 
HRG  69  53  61  45 
KI-67  71  61  69  59 
TUNEL 
ASSAY 
62  57  50  45 
 
 
3.1.2 CORRELATION  OF GLEASON SCORE AND METASTASIS  WITH STUDY 
OUTCOMES IN COHORT 1 
In  this  cohort  High  Gleason  score  (8-10)  was  associated  with  reduced  time  to 
biochemical relapse (P<0.001) and overall survival (P=0.002). Metastasis at presentation 
was associated with reduced time to relapse (P=0.045) and survival (P=0.0497). These 
values  are  in  accordance  with  known  prostate  cancer  natural  history  and  thus  help 
validate the database.   105 
Figure  3.1:  Correlation  of  Gleason  Score  and  Metastasis  at  Diagnosis  with  Time  To 
Relapse and Overall Survival in Cohort 1 
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a) Kaplan-Meier plot correlating Gleason Score and Time To Relapse. b) Kaplan-Meier 
plot correlating Gleason Score and Overall Survival. c) Kaplan-Meier plot correlating 
Metastasis  at  Diagnosis  and  Time  To  Relapse.  d)  Kaplan-Meier  plot  correlating 
Metastasis at Diagnosis and Overall Survival 
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3.2 IMMUNOHISTOCHEMICAL EXPRESSION AND INTER-OBSERVER 
      CORRELATION   
As detailed in the method section scoring accuracy was confirmed by double scoring 
conducted  by  2  independent  observers.    For  the  semi-qualitative  weighted  histoscore 
method (i.e. HRG in this study) all full tissue sections were double scored. For the more 
quantitative and objective nuclear staining count at least 10% of samples were double 
scored for each marker with the full scoring set for the first observer accepted if the inter 
class correlation coefficient (ICCC) was > 0.7.  The figure of ICCC > 0.7 was chosen in 
reference to Kirkegaard et al (2006) which stated after multipaper review of IHC scoring 
that an ICCC > 0.7 was a minimum requirement for acceptable variation 
 
3.2.1 HEREGULIN 
3.2.1.1 DESCRIPTION OF STAIN PROFILE 
Within cohort 1 HRG expression was noted in the cytoplasm, cell membrane and nucleus 
with  cytoplasmic  expression  being  most  frequent;-  99%  of  tumours  had  cytoplasmic 
staining seen by at least one observer. Nuclear (54% of tumours) and membranous (46% 
of tumours) expression were seen with lesser frequency. HRG expression was observed 
in at least one cellular location was seen in 99% of tumours analysed. 
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Figure 3.2: Heregulin Immunohistochemistry 
a1) HRG Stained Prostate Tumour          a2) HRG Stained Prostate Tumour 
 
 
b) Negative Control for HRG Staining  
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a1) Prostate  Tumour  Stained  with  HRG  antibody demonstrating  cytoplasmic  and  cell 
membrane  staining.  a2)  Prostate  Tumour  Stained  with  HRG  antibody  demonstrating 
nuclear staining. b) Prostate Tumour Negative for HRG Staining 
c) Histogram showing intensity of HRG cytoplasmic staining in HSPC specimens.  
d) Histogram showing intensity of HRG cytoplasmic staining in HRPC specimens.  
e) Histogram showing intensity of HRG membranous staining in HSPC specimens.  
f) Histogram showing intensity of HRG membranous staining in HRPC specimens.  
g) Histogram showing intensity of HRG nuclear staining in HSPC specimens.  
h) Histogram showing intensity or HRG nuclear staining in HRPC specimens 
 
3.2.1.2 INTER-OBSERVER SCORING VARIATION 
All  tissue  section  stained  for  HRG  were  double  scored  by  2  independent  observers. 
Cytoplasmic staining, the most commonly found, had the lowest ICCC of 0.72 (Pearson 
Coefficient 0.77) with membranous and nuclear staining giving higher ICCC values of   109 
0.83  (Pearson  0.84)  and  0.90  (Pearson  0.90)  respectively.  As  all  ICCC  values  were 
greater than 0.70 scoring of HRG in all areas was considered to be valid. 
Figure 3.3: Inter-Observer Variation in Heregulin Staining between double scored tissue 
sections in Cohort 1 
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a)Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Cytoplasmic  HRG 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Cytoplasmic 
HRG  Staining.  c)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in 
Membranous  HRG  Staining.  d)  Bland-Altman  Plot  demonstrating  Inter-Observer 
Variation  in  Membranous  HRG  Staining.  e)  Scatter  Graph  Plot  demonstrating  Inter-
Observer Variation in Nuclear HRG Staining. f) Bland-Altman Plot demonstrating Inter-
Observer Variation in Nuclear HRG Staining.   
 
 
3.2.2 KI-67 
3.2.2.1 DESCRIPTION OF STAIN PROFILE 
KI-67 was expressed only in the nucleus with no membranous or cytoplasmic expression. 
Positive and negatively stained nuclei were clearly distinguishable allowing assessment 
via nuclear counting method.  
The IHC for KI67 in this study is demonstrated in appendix 1 
 
3.2.2.2 INTER-OBSERVER SCORING VARIATION 
All  tissue  sections  stained  for  KI-67  were  scored  by  one  single  observer  with  40 
specimens out of the 145 (27.6%) stained for KI-67 double scored by an independent 
observer to confirm accuracy of the first observer. ICCC score for double scored KI-67 
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sections  was  0.95  (Pearson  0.96)  confirming  the  accuracy  of  the  first  observer  and 
reflecting the less subjective nature of nuclear counting compared to weighted histoscore.  
Graphs demonstrating this are in appendix 1 
 
3.2.3 TUNEL ASSAY 
3.2.3.1 DESCRIPTION OF STAIN PROFILE 
As  described  in  the  ApopTag®  instruction  manual  (Chemicon)  the  TUNEL  assay 
primarily causes staining only in the nucleus although there was some minor non-specific 
background staining. Positive and negatively stained nuclei were clearly distinguishable 
allowing  assessment  via  nuclear  counting  method.  TUNEL  IHC  is  demonstrated  in 
appendix 1 
 
3.2.3.2 INTER-OBSERVER SCORING VARIATION  
All TUNEL Assay stained tissue sections and TMAs were viewed as a single group and 
scored by one observer with 10% double scored by an independent observer to ensure 
accuracy. Double scoring demonstrated an ICCC of 0.95 (Pearson 0.95) (see appendix 1) 
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3.2.4 SUMMARY OF COHORT 1 INTER-OBSERVER CORRELATIONS OF THIS 
         STUDY AND THE PILOT  
Table 3.3: ICCCs for Dual Scored Markers in this study and the pilot 
Marker  2 Standard 
Deviations 
Inter Class 
Correlation 
Coefficient 
Pearson 
Coefficient 
EGFR 
Cytoplasm* 
26  0.87  0.89 
EGFR 
Membrane* 
28  0.89  0.89 
HER2 
Membrane* 
26  0.91  0.90 
HER3 
Cytoplasm* 
49  0.93  0.97 
HER3 
Membrane* 
48  0.95  0.96 
HER4 
Cytoplasm* 
47  0.90  0.91 
HER4 
Membrane* 
32  0.91  0.93 
EGFRvIII* 
 
69  0.85  0.85 
HRG 
Cytoplasm 
57.2  0.72  0.77 
HRG 
Membrane 
46.9  0.83  0.84 
HRG 
Nucleus 
32.2  0.90  0.90 
KI67 
 
10.2  0.95  0.96 
TUNEL 
 
13.5  0.95  0.95 
* Data from pilot study 
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3.3 MARKER EXPRESSION IN HORMONE SENSITIVE PROSTATE CANCER 
       SPECIMENS 
Levels of staining of HRG (cytoplasmic, membranous and nuclear), KI-67 and TUNEL 
assay  were  assessed  separately  in  HSPC  and  HRPC  samples.  The  results  for  HSPC 
samples are listed in table 3.4. Expression levels for each marker were then analysed to 
determine any association between expression and High Gleason Score (8-10), metastasis 
at presentation and patient outcome measures i.e. time to relapse, time to death from 
relapse and overall survival.  
Table 3.4: Median and lower/upper quartile expression of HRG, KI67 and TUNEL assay 
in HSPC samples 
Marker  HSPC Expression  
HRG Cytoplasm  75 
(50–100) 
HRG Membrane  10 
(0–30) 
HRG Nucleus  7.5 
(0-25) 
KI67   2.9% 
(1.2-6.4) 
TUNEL Assay  5.13% 
(2.0-17.7) 
 
3.3.1 ASSOCIATION OF MARKER EXPRESSION IN HSPC WITH GLEASON 
         SCORE AND METASTASIS 
Association  between  expression  and  high  Gleason  score  (8-10)  or  metastasis  at 
presentation  was  assessed  using  Mann-Whitney  analysis  with  p<0.05  representing 
significant association. No association was found in this group. 
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Table 3.5: Association of Markers in HSPC with high Gleason score and Metastasis 
Marker  High Gleason Score 
P-value for Mann Whitney 
Metastasis 
P-Value for Mann-Whitney 
HRG Cytoplasm  0.665  0.929 
HRG Membrane  0.112  0.732 
HRG Nucleus  0.903  0.856 
KI67  0.921  0.182 
TUNEL  0.376  0.421 
 
Figure 3.4: Boxplots of Marker expression in HSPC comparing patients with and without 
high Gleason score and Metastasis at presentation 
Not High Gleason    HighGleason
40.00
80.00
120.00
160.00
H
R
G
 
C
y
t
o
￿
￿
a) HRG Cyto and Gleason
No METS                         METS
40.00
80.00
120.00
160.00
H
R
G
 
C
y
t
o
￿
￿
b) HRG Cyto and Metastasis
 
 
Not High Gleason   HighGleason
0.00
40.00
80.00
120.00
H
R
G
 
M
e
m
b
￿
￿
c) HRG Memb and Gleason
No METS                   METS
0.00
40.00
80.00
120.00
H
R
G
 
M
e
m
b
￿
￿
d) HRG Memb and Metastasis
 
 
   115 
Not HighGleason    High Gleason
0.00
50.00
100.00
150.00
200.00
H
R
G
 
N
u
c
￿
￿
￿
￿
￿
￿
e) HRG Nuc and Gleason
No METS                   METS
0.00
50.00
100.00
150.00
200.00
h
R
G
 
N
u
c
￿
￿
￿
￿
￿ ￿
f) HRG Nuc and Metastasis
 
Not HighGleason   High Gleason
0.00
20.00
40.00
60.00
K
I
6
7
￿
￿
￿
￿
g) KI67 and Gleason
No METS                       METS
0.00
20.00
40.00
60.00
K
I
6
7
￿
￿
￿
￿
h) KI67 and Metastasis
 
 
Not High Gleason      HighGleason
0.00
25.00
50.00
75.00
100.00
T
U
N
E
L
￿
￿
￿
￿
￿
￿
i) TUNEL Assay and Gleason
No METS                   METS
0.00
25.00
50.00
75.00
100.00
T
U
N
E
L ￿
￿
￿
￿
￿
j) TUNEL Assay and Metastasis
 
a) Cytoplasmic HRG and Gleason Score, b) Cytoplasmic HRG and Metastasis, c) 
Membranous HRG and Gleason Score, d) Membranous HRG and Metastasis, e) Nuclear 
HRG and Gleason Score, f) Nuclear HRG and Metastasis g) KI67 and Gleason Score, h) 
KI67 and Metastasis, i) TUNEL Assay and Gleason Score, j) TUNEL Assay and 
Metastasis 
 
 
3.3.2 IMPACT OF MARKER EXPRESSION IN HSPC ON TIME TO RELAPSE 
        AND SURVIVAL 
Associations between upper quartile (very high) marker expression in HSPC samples and 
TTR, TTDFR and OS were assessed using Kaplan-Meier analysis the p-values of which   116 
are shown in table 3.6. Significant correlations were demonstrated between very high 
membranous HRG expression and increased TTR, TTDFR and OS. Patients with very 
high HRG membrane expression demonstrated a median time to relapse of 47.7 (27.4 – 
69.1) months compared to 27.8 (16.4 – 48.5) months in those with low membranous 
HRG expression. Therefore very high expressers suffered biochemical relapse 20 months 
after  low  expressers.  For  patients  with  high  HRG  membranous  expression  median 
TTRFR  was  30.7  (21  –  51.3)  months  compared  to  13.3  (6.9  –  23.2) months  in  low 
expressers – a difference of 17 months. Median OS was 85.9 (75.6 – 109.7) months 
compared  to  48  (29  –  74.1)  months,  a  difference  of  nearly  46  months.    KI67  was 
associated with reduced overall survival time but this did not quite achieve statistical 
significance (p=0.053). 
Table 3.6. Association between marker expression in HSPC specimens and TTR, TTDFR 
and OS. 
Markers  Time To Relapse 
Kaplan-Meier 
P- values 
Time To Death 
From Relapse 
Kaplan-Meier 
P- values 
Overall Survival 
Kaplan-Meier 
P- values 
HRG Cytoplasm  0.169  0.233  0.121 
HRG Membrane  0.036  0.002  0.001 
HRG Nucleus  0.076  0.297  0.115 
KI67  0.157  0.262  0.053 
TUNEL  0.308  0.168  0.295 
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Figure 3.5: Kaplan-Meier Analyses of significant associations between HSPC Marker 
expression and study outcomes. 
Time To Relapse (months)
125 100 75 50 25 0
C
u
m
 
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
p=0.036
Very High
Low
Memb HRG
a) HSPC Membranous HRG and TTR
TTDFR (months)
120.00 100.00 80.00 60.00 40.00 20.00 0.00
C
u
m
 
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
p=0.002
Very High
Low
Memb HRG
b) HSPC Membranous HRG and TTDFR
 
 
 
 
Survival (months)
300 250 200 150 100 50 0
C
u
m
 
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
p=0.001
Very High
Low
Memb HRG
c) HSPC Membranous HRG and Overall Survival
Survival (months)
300 250 200 150 100 50 0
C
u
m
 
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
p=0.053
Very High
Low
KI67 Nuclear 
Count
d) HSPC KI67 Nuclear Count and Overall Survival
 
 
a) Membranous HRG and TTR, b) Membranous HRG and TTDFR, c) Membranous HRG 
and OS, d) KI67 and OS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   118 
3.4 MARKER EXPRESSION IN HORMONE RESISTANT PROSTATE CANCER 
      SPECIMENS 
All 5 markers are expressed in HRPC specimens 
Table 3.7: Median and lower/upper quartile expression of HRG, KI67 and TUNEL assay 
in HSPC samples 
Marker  HRPC Expression 
HRG Cytoplasm  60 
(35-100) 
HRG Membrane  0 
(0 – 15) 
HRG Nucleus  5 
(0-27.5) 
KI67   7.7% 
(2.5-15.9) 
TUNEL Assay  6.6% 
(3.4-31.4) 
 
 
3.4.1 ASSOCIATION OF MARKER EXPRESSION IN HRPC WITH GLEASON 
         SCORE AND METASTASIS 
Association  between  expression  and  high  Gleason  score  (8-10)  or  metastasis  at 
presentation  was  assessed  using  Mann-Whitney  analysis  with  p<0.05  representing 
significant association. One significant result was found with high HRG membranous 
expression associated with reduced metastasis at diagnosis. This means that patients with 
no metastasis had a significantly higher HRG membranous expression than those without 
metastasis. 
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Table 3.8: Association of Markers in HRPC with high Gleason score and Metastasis 
Marker  High Gleason Score 
P-value for Mann Whitney 
Metastasis 
P-Value for Mann-Whitney 
HRG Cytoplasm  0.924  0.781 
HRG Membrane  0.799  0.043 
HRG Nucleus  0.273  0.268 
KI67  0.241  0.578 
TUNEL  0.829  0.363 
 
Figure 3.6: Boxplots of Marker expression in HSPC comparing patients with and without 
high Gleason score and Metastasis at presentation 
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a) Cytoplasmic HRG and Gleason Score, b) Cytoplasmic HRG and Metastasis, c) 
Membranous HRG and Gleason Score, d) Membranous HRG and Metastasis, e) Nuclear 
HRG and Gleason Score, f) Nuclear HRG and Metastasis g) KI67 and Gleason Score, h) 
KI67 and Metastasis, i) TUNEL Assay and Gleason Score, j) TUNEL Assay and 
Metastasis 
 
3.4.2 IMPACT OF MARKER EXPRESSION IN HRPC ON TIME TO RELAPSE 
        AND SURVIVAL 
Associations between marker expression in HRPC samples and TTR, TTDFR and OS 
were assessed using Kaplan-Meier analysis the p-values of which are shown in table 3.9. 
No significant associations were demonstrated. 
 
Table 3.9:Association between marker expression in HRPC specimens and TTR, TTDFR 
and OS. 
Markers  Time To Relapse 
Kaplan-Meier 
P- values 
Time To Death 
From Relapse 
Kaplan-Meier 
P- values 
Overall Survival 
Kaplan-Meier 
P- values 
HRG Cytoplasm  0.529  0.722  0.990 
HRG Membrane  0.977  0.834  0.906 
HRG Nucleus  0.997  0.802  0.943 
KI67  0.665  0.086  0.425 
TUNEL  0.417  0.106  0.219   122 
3.5 COMPARISON OF PRE AND POST HORMONE ESCAPE EXPRESSION 
Differences in pre and post hormone escape marker expression were assessed first by 
analysing the cohort as a whole then by determining the changes in individual sets of 
paired samples. 
3.5.1  COMPARISON  OF  PRE  AND  POST  HORMONE  ESCAPE  MARKER 
EXPRESSION IN FULL COHORT 
The mean histoscores/nuclear counts for pre and post hormone escape specimens in the 3 
markers not in the pilot study HRG, KI-67 and TUNEL Assay were analysed to assess 
any significant rise or fall in expression in the cohort as a whole following hormone 
escape. Due to limited slide numbers remaining none of the markers were available in all 
81  paired  sets  of  pre  and  post  hormone  escape  tissue.  Paired  stained  samples  were 
available for 45 patients in the case of Heregulin, 59 for KI67 and 45 for TUNEL. The 
Wilcoxen Signed Rank Test was used to determine if there had been a significant overall 
change in expression for each marker. HRG membrane staining was found to have fallen 
significantly  (p=0.012)  in HRPC  tissue  samples  compared to  HSPC  conversely  KI67 
nuclear staining was significantly raised in post hormone escape tissue (p<0.001). 
Table 3.10: Histoscores in Hormone Sensitive and Hormone Resistant Tumours for Study 
Markers not included in the Pilot Study.  
Marker  HSPC  HRPC  Wilcoxen 
p-value 
HRG Cytoplasm  75 
(50–100) 
60 
(35-100) 
0.116 
HRG Membrane  10 
(0–30) 
0 
(0 – 15) 
0.018 
HRG Nucleus  7.5 
(0-25) 
5 
(0-27.5) 
0.956 
KI67   2.9% 
(1.2-6.4) 
7.7% 
(2.5-15.9) 
<0.001 
TUNEL Assay  5.13% 
(2.0-17.7) 
6.6% 
(3.4-31.4) 
0.186   123 
 
Figure 3.7: Variation in Overall Cohort Histoscore/Nuclear Count between HSPC and 
HRPC Sections 
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a) Box plot of HRG Cytoplasmic staining in pre and post hormone escape samples.  
b) Box plot of HRG Membranous staining in pre and post hormone escape samples. 
c) Box plot of HRG Nuclear staining in pre and post hormone escape samples.d) Box plot 
of KI-67 Nuclear Count in pre and post hormone escape samples. e) Box plot of TUNEL 
Assay Nuclear Count in pre and post hormone escape samples. a-e significance p-value 
determined using Wilcoxen Signed Rank Test 
 
 
 
 
 
3.5.2 CHANGES IN EXPRESSION IN INDIVIDUAL PAIRED SAMPLES 
The  cohort  subjects  were  then  subdivided  according  to  whether  there  had  been  a 
significant  rise  or  fall  in  expression,  i.e.  a  change  of  greater  than  2  times  standard 
deviation of the ICCC, between the hormone sensitive and resistant samples in individual 
patients. Small changes in protein expression between paired ASPC and AIPC tumours 
could be due to random errors in the assessment of histoscores.  To identify individual 
patients in whom there was strong evidence of a genuine rise or fall in protein expression, 
it was required that the change in expression exceed a threshold equal to two standard 
deviations of the inter-observer difference for that protein.  This threshold was chosen 
because, if there was in reality no difference in protein expression between ASPC and 
AIPC tumours in a given patient, there would be only a 5% probability of an apparent 
difference being observed that exceeded the threshold due to random variation.  This 
assumes that the random variation between two different observers assessing the same 
tumour  is  of  a  similar  magnitude  to  the  random  variation  that  would  affect  a  single 
e) TUNEL Assay in HSPC and 
HRPC Specimens
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observer  assessing  two  different  tumours  with  the  same  level  of  protein  expression. 
Changes in protein expression in individual patients that exceeded this threshold were 
termed significant.    
Table  3.11:  Subgroubs  of  Cohort  1  demonstrating  significant  change  in  Marker 
expression between HSPC and HRPC 
Marker 
 
2×SD 
ICCC 
%Fall  %Unchanged  %Rise 
HRG  
Cytoplasm 
57.2  15.6%  76.5%  8.9% 
HRG 
 Membrane 
46.9  2.2%  97.8%  0% 
HRG  
Nucleus 
32.2  11.1%  73.3%  15.6% 
KI67  
 
3.47  5.1%  47.4%  47.5% 
TUNEL  
Assay 
13.5  17.8%  51.1%  31.1% 
 
 
Figure  3.8:  Histogram  Showing  Proportions  of  Cohort  Demonstrating  Significant 
Difference in Marker Expression Between HSPC and HRPC Samples 
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3.5.3 IMPACT OF DIFFERENTIAL EXPRESSION IN PRE AND POST HORMONE 
ESCAPE SAMPLES ON TIME TO RELAPSE AND SURVIVAL 
Using Kaplan-Meier analysis the impact of rise or fall in staining following hormone 
escape in individual paired samples on time to relapse, time to death from relapse and 
overall survival were investigated. Analyses were carried out comparing these outcomes 
in patients with a significant rise in expression between pre and post hormone escape 
samples  to  those  with  no  rise  (i.e.  no  change  or  a  fall  in expression)  and  separately 
comparing  those  with  a  significant  fall  in  expression  between  pre  and  post  hormone 
expression samples to those with no change or a rise. No correlation was seen between 
rise or fall in HRG staining after hormone escape at the cytoplasm or membrane and time 
to relapse, time to death from relapse and overall survival. A significant fall in HRG 
nuclear staining between HSPC and HRPC samples was associated with a reduced time 
to death following relapse (P=0.001) but this did not translate to reduced overall survival. 
Neither time to relapse nor overall survival were associated with changes in nuclear HRG 
staining. 
     A rise in KI67 expression following hormone escape was associated with increased 
time to relapse but this did not achieve significance (P=0.061). Neither time to death 
following relapse nor overall survival were associated with KI67 rise or fall. There was 
no association between changes in TUNEL Assay and any of the outcome measures. 
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Figure  3.9:  Changes  in  Pre  and  Post  Hormone  Escape  Marker  Expression  that 
demonstrated significant impact on TTR, TTDFR or OS 
 
a) Kaplan-Meier Graph showing Time To Death From Relapse Comparing Paired 
Samples with a significant fall in Nuclear HRG Expression following Hormone Escape to 
those with no change or a rise. b) Kaplan-Meier Graph showing Time To Biochemical 
Relapse Comparing Paired Samples with a significant Rise in KI67 Expression following 
Hormone Escape to those with no change or a fall 
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Table 3.12: Impact of changes in HRG, KI67 and TUNEL expression between Paired 
HSPC and HRPC samples on Time to Hormone Relapse (TTR) 
Marker 
 
Rise/Fall  Median TTR (mths)  P-value (Kaplan-Meier) 
HRG Cytoplasm  Risers 
 
Non-Risers 
51.3 
(30.3-73.5) 
30.26 
(21.1-55.5) 
0.518 
  Fallers 
 
Non-Fallers 
26.9 
(17.1-47.5) 
32.7 
(27.5-56.9) 
0.608 
HRG Membrane  Risers 
Non-Risers 
N/A 
31.5 
(21.1-57.4) 
N/A 
  Fallers 
 
Non-Fallers 
77.0 
(N/A) 
31.2 
(21.1-60.0) 
0.367 
HRG Nucleus  Risers 
 
Non-Risers 
28.3 
(20.2-50.7 
31.5 
(19.5-56.4) 
0.822 
  Fallers 
 
Non-Fallers 
22.3 
(16.8-47.1) 
31.5 
(22.8-57,4) 
0.834 
KI67  Risers 
 
Non-Risers 
47.4 
(26.5-64.1) 
23.0 
(14.0-35.1) 
0.061 
  Fallers 
 
Non-Fallers 
22.8 
(18.1-38.4) 
28.9 
(17.6-55.3) 
0.414 
TUNEL  Risers 
 
Non-Risers 
32.1 
(22.7-60.3) 
27.4 
(16.5-55.3) 
0.733 
  Fallers 
 
Non-Fallers 
41.0 
(23.0-49.7) 
27.5 
(16.8-57.4) 
0.457 
 
Median and interquartile ranges of changes in protein expression comparing risers to non-
risers and fallers to non-fallers. P-values were calculated using Kaplan-Meier analysis.   129 
Table 3.13: Impact of changes in HRG, KI67 and TUNEL expression between Paired 
HSPC and HRPC samples on Time To Death From Relapse (TTDFR) 
 
Marker 
 
Rise/Fall  Median TTDFR  P-value (Kaplan-Meier) 
HRG Cytoplasm  Risers 
 
Non-Risers 
11.1 
(8.3-18.9) 
16.4 
(11.0-32.1) 
0.266 
  Fallers 
 
Non-Fallers 
32.6 
(15.9-39.1) 
16.0 
(10.2-29.6) 
0.441 
HRG Membrane  Risers 
Non-Risers 
N/A 
16.1 
(10.9-32.1) 
N/A 
  Fallers 
 
Non-Fallers 
8.9 
(N/A) 
16.3 
(11.0-32.2) 
0.653 
HRG Nucleus  Risers 
 
Non-Risers 
13.0 
(6.0-38.7) 
16.4 
(10.9-30.2) 
0.816 
  Fallers 
 
Non-Fallers 
6.7 
(5.2-15.2) 
21.0 
(11.9-33.1) 
0.001 
KI67  Risers 
 
Non-Risers 
16.4 
(8.3-27.2) 
24.3 
(15.6-41.5) 
0.118 
  Fallers 
 
Non-Fallers 
26.2 
(21.1-43.4) 
19.2 
(10.6-33.1) 
0.858 
TUNEL  Risers 
 
Non-Risers 
16.8 
(9.2-36.3) 
23.4 
(15.1-33.3) 
0.308 
  Fallers 
 
Non-Fallers 
28.0 
(16.0-31.7) 
19.8 
(12.9-36.4) 
0.821 
Median and interquartile ranges of changes in protein expression comparing risers to non-
risers and fallers to non-fallers. P-values were calculated using Kaplan-Meier analysis.   130 
Table 3.14: Impact of changes in HRG, KI67 and TUNEL expression between Paired 
HSPC and HRPC samples on Overall Survival (OS) 
 
Marker 
 
Rise/Fall  Median OS (Mths)  P-value (Kaplan-Meier) 
HRG Cytoplasm  Risers 
 
Non-Risers 
77.4 
(64.3-81.8) 
59.1 
(40.4-83.4) 
0.758 
  Fallers 
 
Non-Fallers 
75.2 
(40.3-86.0) 
61.8 
(40.6-82.5) 
0.761 
HRG Membrane  Risers 
Non-Risers 
N/A 
64.5 
(40.4-83.4) 
N/A 
  Fallers 
 
Non-Fallers 
85.9 
(N/A) 
61.8 
(40.4-82.8) 
0.228 
HRG Nucleus  Risers 
 
Non-Risers 
76.0 
(32.1-88.8) 
59.1 
(40.3-82.3) 
0.972 
  Fallers 
 
Non-Fallers 
32.0 
(29.0-52.3) 
65.3 
(41.0-83.9) 
0.234 
KI67  Risers 
 
Non-Risers 
75.5 
(45.6-86.2) 
49.8 
(32.2-80.7) 
0.368 
  Fallers 
 
Non-Fallers 
69.9 
(54.8-76.6) 
57.0 
(39.3-85.6) 
0.578 
TUNEL  Risers 
 
Non-Risers 
68.7 
(46.3-81.7) 
54.9 
(38.4-85.0) 
0.445 
  Fallers 
 
Non-Fallers 
63.7 
(45.5-79.3) 
64.5 
(40.5-86.0) 
0.879 
Median and interquartile ranges of changes in protein expression comparing risers to non-
risers and fallers to non-fallers. P-values were calculated using Kaplan-Meier analysis.   131 
CHAPTER 4: RESULTS – COHORT 2 
4.1 PATIENTS 
This  patient  cohort  includes  the  HSPC  tumours  from  81  patients  from  cohort  1 
supplemented by 276 patients from 4 TMAs totalling 357 patients. Median age was 70.7 
years (range 39.0 – 103.4 years) mean age was 70.4 years (SD ± 9.2). At diagnosis 65 
(18.2%) of tumours were Stage T1, 53 (14.8%) T2, 86 (24.1%) T3, 30 (8.4%) T4 with the 
remainder of unknown/unrecorded stage. Gleason scores in HSPC specimens were 1-4 in 
4 (1.1%), 5-7 in 206 (57.7%), 8-10 in 94 (26.3%) and not recorded in the remainder. 74 
patients  (20.7%)  had  known  metastatic  disease  at  diagnosis,  187  (52.4%)  had  no 
metastases with the metastatic status of the remainder unknown.  
     Patients within the cohort underwent a variety of treatment modalities. 227 patients 
(63.3%) including all those from the pilot study cohort underwent hormone therapy – 
antiandrogens, GnRH analogues, maximal androgen blockade or bilateral orchidectomy. 
At  least  45  (12.6%)  underwent  radical  retropubic  prostatectomy.  Over  the  recorded 
course  of  their  disease  194  patients  (54.3%)  suffered  biochemical  relapse  as  defined 
above, 64 (17.9%) had no relapse and the relapse status was not recorded in 99 patients 
(27.7%). Mean time to relapse was 35.1 months (SD ± 32.3). At last known follow up 
213 patients (59.7%) patients were deceased, 110 patients (31.9%) were alive with the 
status of the remainder unclear. Mean time to death/last follow up was 69.8 months (SD 
± 54.0). 
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4.1.1 PATIENT DATA FOR COHORT 2 
Table 4.1: Summary Statistics for All Cohort 2 Patients with Hormone Treated Subgroup 
  HORMONE TREATED 
PATIENTS 
ALL PATIENTS 
N  227  357 
Age  71.4 ± 8.6 
(41.1 – 103.4) 
70.4 ± 9.2 
(39.0 – 103.4) 
Gleason Score 
￿  Low       (2-4) 
￿  Medium (5-7) 
￿  High       (8-10) 
 
4 
116 
69 
 
4 
206 
94 
T Stage at Diagnosis 
￿  T1 
￿  T2 
￿  T3 
￿  T4 
 
34 
26 
31 
25 
 
65 
54 
86 
30 
Metastasis at Diagnosis 
￿  Yes 
￿  No 
￿  Unknown 
 
57 
110 
60 
 
74 
187 
96 
Biochemical Relapse 
￿  Yes 
￿  No 
￿  Unknown 
 
182 
36 
12 
 
194 
64 
99 
Time to Relapse  34.1 ± 32.1  35.1 months ± 32.3 
Final Status 
￿  Alive 
￿  Deceased 
￿  Unknown 
 
43 
167 
17 
 
110 
213 
34 
 
Follow up  73.2 months ± 58.6  69.8 months ± 54.0 
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4.1.2 CORRELATION  OF GLEASON SCORE AND METASTASIS  WITH STUDY 
OUTCOMES IN COHORT 2 
In  this  cohort  High  Gleason  score  (8-10)  was  associated  with  reduced  time  to 
biochemical relapse (P<0.001) and overall survival (P<0.001). Metastasis at presentation 
was associated with reduced time to relapse (P<0.001) and survival (P<0.001). These 
values  are  in  accordance  with  known  prostate  cancer  natural  history  and  thus  help 
validate the database. 
Figure 4.1: Correlation of Gleason Score and Metastasis at Presentation with Time To 
Relapse and Overall Survival 
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a) Kaplan Meier Plot of Full Patient Cohort Comparing Patients with High Gleason Score 
(8-10) and those with Low-Medium (2-7) for Outcome Time to Biochemical Relapse. b) 
Kaplan Meier Plot of Full Patient Cohort Comparing Patients with High Gleason Score 
(8-10) and those with Low-Medium Score (2-7) for Outcome Overall Survival. c) Kaplan 
Meier Plot of Full Patient Cohort Comparing Patients with Distant Metastasis and No 
Metastasis  for  Outcome  Time  to  Biochemical  Relapse.  d)  Kaplan-Meier  Plot  of  Full 
Patient  Cohort  Comparing  Patients  with  Distant  Metastasis  and  No  Metastasis  for 
Outcome Overall Survival   134 
4.2  IMMUNOHISTOCHEMICAL  EXPRESSION  AND  INTER-OBSERVER 
CORRELATIONS IN TISSUE MICROARRAYS 
Staining of the TMAs revealed similar patterns to the single sample slides of the pilot 
group.  EGFR  staining  was  visible  at  the  membrane  and  cytoplasm,  HER2  at  the 
membrane  only,  HER3  and  HER4  at  cytoplasm  and  membrane.  Manufacture  of 
EGFRvIII antibody had been discontinued at the time of this therefore we were unable to 
stain  the  additional  samples  for  this  antigen..  Heregulin  staining  was  found 
predominantly in the cytoplasm but both nuclear and membrane staining were observed. 
As before KI67 and the TUNEL Assay are predominantly nuclear. The IHC and Inter-
observer scoring graphs for EGFR are shown here as an example, the remainder are listed 
in appendix 2. 
4.2.1 EGFR 
As  in  the  pilot  specimens,  relatively  little  EGFR  staining  was  seen  in  the  TMAs 
compared to HER3 and HER4. Both cytoplasmic and membranous staining was seen. 
 
Figure 4.2: Immunohistochemistry of EGFR. 
                                                                    
 
a) EGFR in Prostate Cancer  b) Negative Control for EGFR   135 
 
d) HSPC EGFR Membranous Score
25.00 50.00 75.00 100.00 125.00
Histocore
0
50
100
150
 
a) Specimen of Prostate Adenocarcinoma demonstrating EGFR staining b) Negative 
control for EGFR staining c) Histogram showing intensity of EGFR cytoplasmic 
expression. d) Histogram showing intensity of EGFR membranous expression 
 
All TMA specimens were double scored for EGFR. ICCCs were 0.77 for cytoplasmic 
EGFR and 0.99 for membranous EGFR 
Figure 4.3: Inter-Observer Variation in Heregulin Staining between double scored tissue 
sections in Tissue Microarrays 
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a)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Cytoplasmic  EGFR 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Cytoplasmic 
EGFR  Staining.  c)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in 
Membranous  EGFR  Staining.  d)  Bland-Altman  Plot  demonstrating  Inter-Observer 
Variation in Membranous EGFR Staining. 
 
 
4.2.2 HER2 
As in the pilot only membranous staining of HER2 was observed and little of this was 
present in comparison to HER3 and HER4. All TMA specimens were double scored for 
HER2. ICCCs was 0.99 for membranous HER2. 
 
4.2.3 HER3 
Both membranous and cytoplasmic HER3 staining were observed on TMAs. No nuclear 
staining was observed. All TMA specimens were double scored for HER3. ICCCs were 
0.99 for cytoplasmic HER3 and 0.93 for membranous HER3 
 
c) EGFR Membranous Staining  d) Inter-observer Difference Membranous EGFR   137 
4.2.4 HER4 
Both membranous and cytoplasmic HER3 staining were observed on TMAs. No nuclear 
staining was observed. All TMA specimens were double scored for HER4. ICCCs were 
0.90 for cytoplasmic HER3 and 0.96 for membranous HER4 
 
4.2.5 HEREGULIN 
As  in  the  pilot  study  specimens  stained  for  section  3  cytoplasmic,  membranous  and 
nuclear staining were seen in the TMAs with cytoplasmic most frequent and at greatest 
levels. 10% of TMA samples were double scored for HRG with ICCC >0.7 in each case 
taken as confirming the accuracy of the single scored specimens.  
 
4.2.6 KI-67 
KI-67 was expressed only in the nucleus with no membranous or cytoplasmic expression. 
Positive and negatively stained nuclei were clearly distinguishable allowing assessment 
via nuclear counting method. All tissue sections and TMAs stained for KI67 were scored 
as a whole by one single observer with 10% specimens stained for KI67 double scored by 
an independent observer to confirm accuracy of the first observer. All the double scored 
specimens were single tissue sections. ICCC score for double scored KI67 sections was 
0.95 confirming the accuracy of the first observer and reflecting the less subjective nature 
of nuclear counting compared to weighted histoscore.   
 
4.2.7 TUNEL ASSAY 
As  described  in  the  ApopTag®  instruction  manual  (Chemicon)  the  TUNEL  assay 
primarily causes staining only in the nucleus although there was some minor non-specific   138 
background staining. Positive and negatively stained nuclei were clearly distinguishable 
allowing assessment via nuclear counting method.  
 
All TUNEL Assay stained tissue sections and TMAs were viewed as a single group and 
scored by one observer with 10% double scored by an independent observer to ensure 
accuracy. All the double scored specimens for TUNEL assay were on the TMAs rather 
than tissue sections. Double scoring demonstrated an ICCC of 0.95  
Table 4.2: Summary of Inter-Class Correlation Coefficients 
Marker  2 Standard 
Deviations 
Inter class 
Correlation 
Coefficient 
Pearson 
Coefficient 
EGFR Cytoplasm  7.7  0.78  0.80 
EGFR Membrane  4.9  0.99  0.99 
HER2 Membrane  3.0  0.99  0.999 
HER3 Cytoplasm  10.5  0.99  0.996 
HER3 Membrane  31.9  0.93  0.93 
HER4 Cytoplasm  19.4  0.96  0.96 
HER4 Membrane  34.5  0.90  0.90 
HRG Cytoplasm  46.4  0.75  0.80 
HRG Membrane   46.9  0.83  0.83 
HRG Nucleus  12.5  0.72  0.75 
KI67  10.2  0.95  0.96 
TUNEL Assay  13.5  0.95  0.95 
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4.3 CORRELATION OF MARKER EXPRESSION WITH GLEASON SCORE AND 
      METASTASIS 
As with cohort 1 Mann-Whitney analyses were used to discern any association between 
expression of  markers  used  in  the study  and  high  Gleason score  (8-10)/metastasis  at 
presentation in the full cohort 2. In this cohort high cytoplasmic HER3 and membranous 
HRG are associated with lower Gleason score. A statistically significant association is 
also  seen  with  cytoplasmic  EGFR  but  as  there  is  very  little  positive  staining  of 
cytoplasmic  EGFR  the  significance  might  not  be  a  true  observation.  High  KI67  is 
associated with high Gleason score.  
 
Membranous  HER3,  HER4  and  HRG  are  all  associated  with  reduced  occurrence  of 
metastasis at presentation. Higher TUNEL assay score is associated with increased rate of 
metastasis but this does not quite reach statistical significance (p=0.051). 
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Table  4.3:  Associations  between  Marker  Expression  and  Gleason  Score/Metastasis  at 
Presentation 
Marker/Location  High Gleason Score 
Mann-Whitney P-value 
Metastasis 
Mann-Whitney P-Value 
EGFR – Cytoplasm 
 
0.013*  0.829 
EGFR – Membrane 
 
0.226  0.494 
EGFR variant III 
 
0.683  0.381 
HER2 (Herceptest) 
 
0.431  0.013 
HER3 – Cytoplasm 
 
0.007  0.147 
HER3 – Membrane 
 
0.381  0.018 
HER3 – Nucleus 
 
0.059  0.218 
HER4 – Cytoplasm 
 
0.608  0.926 
HER4 – Membrane 
 
0.430  0.017 
HER4 – Nucleus 
 
0.147  0.200 
HRG – Cytoplasm 
 
0.249  0.095 
HRG – Membrane 
 
<0.001  0.018 
HRG – Nucleus 
 
0.591  0.864 
KI67 Count 
 
0.002  0.333 
TUNEL Assay 
 
0.793  0.051 
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Figure  4.4:  Boxplots  of  Associations  between  Marker  Expression  and  High  Gleason 
Score/Metastasis that indicated significance 
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a) Cytoplasmic EGFR and Gleason, b) Membranous HER2 and Metastasis, c) 
Cytoplasmic HER3 and Gleason, d) Membranous HER3 and Metastasis, e) Membranous 
HER4 and Metastasis, f) Membranous HRG and Gleason, g) Membranous HRG and 
Metastasis, h) KI67 and Gleason 
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4.4 IMPACT OF MARKER EXPRESSION  IN PATIENT SUBCOHORT TREATED 
WITH ANDROGEN DEPRIVATION THERAPY 
4.4.1  IMPACT  OF  SINGLE  MARKER  VALUES  ON  TIME  TO  RELAPSE  AND 
SURVIVAL 
Using a sub-cohort of all patients who had been treated with ADT as previously defined, 
Kaplan-Meier  analyses  were  conducted  to  test  if  an  associated  with  TTR  or  OS  and 
expression of any of the markers studied was  observed. Expression was divided into 
those with high and low expression (divided by the median) and those with very high 
expression (divided by the 3
rd quartile). 
    Upper quartile (very high) membrane EGFR expression correlated with increased time 
to  relapse  (P=0.02)  as  did  above  the  median  (high)  HER2  (P=0.02).  Upper  quartile 
(P=0.002) HER2, upper quartile HER4 (P=0.009), above the median (P=0.033) and upper 
quartile membrane (P=0.004) HRG and upper quartile nuclear HRG (P=0.005) were all 
associated  with  increased  time  to  relapse.  Upper  quartile  EGFRvIII  expression  was 
associated with reduced time to relapse (P=0.027). 
     Upper  quartile  EGFR  membrane  expression  was  correlated  with  increased  overall 
survival (P=0.012) as were upper quartile HER2 (P=0.025), membrane HER4 (P=0.009) 
and membrane HRG (P=0.044). Above the median EGFRvIII expression was associated 
with reduced overall survival but this did not achieve significance (P=0.063) probably 
due to the unavailability of the antibody and consequent inability to expand the stained 
cohort.  
     To determine hazard ratios for all markers with a statistically significant influence 
COX regression analysis was performed for all markers with p<0.05 on Kaplan-Meier   144 
analysis.  Additionally  a  multivariate  backwards:  conditional  COX  analysis  utilising 
Gleason  score  and  Metastasis  at  presentation  was  performed  for  each  of  these  to 
determine if they were independently significant. 
Table 4.4: P-values for Kaplan-Meier Analyses of Time To Biochemical Relapse and 
Overall  Survival  for  all  Markers  in  HSPC  samples  from  patients  treated  with  ADT 
comparing those with high and low expression (divided by median) 
 
Protein/Location  Time To Relapse 
Kaplan Meier P-Value 
Overall Survival 
Kaplan Meier P-Value 
EGFR – Cytoplasm 
(High) 
0.548  0.407 
EGFR – Membrane 
(High) 
0.145  0.064 
EGFR variant III 
(High) 
0.998  0.962 
HER2 (Herceptest) 
(High) 
0.02  0.072 
HER3 – Cytoplasm 
(High) 
0.12  0.106 
HER3 – Membrane 
(High) 
0.282  0.47 
HER3 – Nucleus 
(High) 
0.8  0.783 
HER4 – Cytoplasm 
(High) 
0.986  0.361 
HER4 – Membrane 
(High) 
0.706  0.318 
HER4 – Nucleus 
(High) 
0.497  0.217 
HRG – Cytoplasm 
(High) 
0.519  0.679 
HRG – Membrane 
(High) 
0.033  0.858 
HRG – Nucleus 
(High) 
0.489  0.86 
KI67 Count 
(High) 
0.937  0.8334 
TUNEL Assay 
(High) 
0.295  0.227 
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Table 4.5: P-values for Kaplan-Meier Analyses of Time To Relapse and Overall Survival 
for all Markers in HSPC samples from patients treated with ADT comparing those with 
very high expression and those without (divided by third quartile) 
 
Protein/Location  Time To Relapse 
Kaplan Meier P-Value 
Overall Survival 
Kaplan Meier P-Value 
EGFR – Cytoplasm 
(Very High) 
0.548  0.407 
EGFR – Membrane 
(Very High) 
0.02  0.012 
EGFR variant III 
(Very High) 
0.027  0.063 
HER2 (Herceptest) 
(Very High) 
0.002  0.025 
HER3 – Cytoplasm 
(Very High) 
0.843  0.779 
HER3 – Membrane 
(Very High) 
0.797  0.574 
HER3 – Nucleus 
(Very High) 
0.898  0.491 
HER4 – Cytoplasm 
(Very High) 
0.993  0.604 
HER4 – Membrane 
(Very High) 
0.009  0.009 
HER4 – Nucleus 
(Very High) 
0.57  0.916 
HRG – Cytoplasm 
(Very High) 
0.115  0.235 
HRG – Membrane 
(Very High) 
0.004  0.044 
HRG – Nucleus 
(Very High) 
0.005  0.218 
KI67 Count 
(Very High) 
0.995  0.728 
TUNEL Assay 
(Very High) 
0.944  0.526 
 
It can be noted at this point that the upper quartile cut off gives a greater number of 
significant results both for TTR and OS indicating a gradation of increase likelihood of 
influence with increased expression of a given marker. It can also be seen that a greater   146 
number of significant results are seen for the outcome TTR with only a portion of these 
translating into a significant effect on OS. 
Figure 4.5: Correlations of Marker Expression with Time To Biochemical Relapse that 
show statistical significance in the Patient Subcohort treated with Androgen Deprivation 
Therapy 
a) Memb EGFR (upper quartile) and TTR
COX Regression Hazard Ratio: 1.84 (1.05-3.20) p=0.03
Multivariate COX Regression: N/A
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b) Memb EGFRvIII (upper quartile) and TTR
COX Regression Hazard Ratio: 0.46 (0.24-0.88) p=0.18
Multivariate COX Regression: N/A
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c) HER2 (Median) and TTR
COX Regression Hazard Ratio: 1.75 (1.01-3.02) p=0.044
Multifactorial COX Regression: p=0.645
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d) HER2 (upper quartile) and TTR
COX Regression Hazard Ratio: 2.53 (1.32-4.86) p=0.005
Multivariate COX Regression: p= 0.645
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e) Memb HER4 (upper quartile) and TTR
COX Regression Hazard Ratio:2.09 (1.19-3.67) p=0.01
Multivariate COX Regression: N/A
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f) Memb HRG (median) and TTR
COX Regression Hazard Ratio: 1.56 (1.05-2.30) p=0.027
Multivariate COX Regression: p=0.373
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g) Memb HRG (upper quartile) and TTR
COX Regression Hazard Ratio: 2.09 (1.30-3.37) p=0.002
Multivariate COX Regression: p=0.373
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h) Nuc HRG (upper quartile) and TTR
 COX Regression Hazard Ratio: 1.70 (1.13-2.54) p=0.01
Multivariate COX Regression: p=0.128
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a) Kaplan-Meier Plot comparing HSPC ADT patients with Very High Membrane 
expression of EGFR and those without (divided by Upper Quartile) for outcome Time To 
Biochemical Relapse. b) Kaplan-Meier Plot comparing HSPC ADT patients with Very 
High Membrane expression of EGFRvIII and those without (divided by median) for 
outcome Time To Biochemical Relapse. c) Kaplan-Meier Plot comparing HSPC ADT 
patients with High Membrane expression of HER2 and those without (divided by 
Median) for outcome Time To Biochemical Relapse. d) Kaplan-Meier Plot comparing 
HSPC ADT patients with Very High Membrane expression of HER2 and those without 
(divided by Upper Quartile) for outcome Time To Biochemical Relapse e) Kaplan-Meier 
Plot comparing HSPC ADT patients with Very High Membrane expression of HER4 and 
those without (divided by Upper Quartile) for outcome Time To Biochemical Relapse. f) 
Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane expression of 
HRG and those without (divided by Median) for outcome Time To Biochemical Relapse. 
g) Kaplan-Meier Plot comparing HSPC ADT patients with Very High Membrane 
expression of HRG and those without (divided by Upper Quartile) for outcome Time To 
Biochemical Relapse. h) Kaplan-Meier Plot comparing HSPC ADT patients with Very 
High Nuclear expression of HRG and those without (divided by Upper Quartile) for 
outcome Time To Biochemical Relapse 
 
Figure 4.6: Correlations of Marker Expression with Overall Survival that show statistical 
significance in the Patient Subcohort treated with Androgen Deprivation Therapy 
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a) Memb EGFR (upper quartile) and OS
COX Regression Hazard Ratio: 1.99 (1.14-3.46) p=0.015
Multivariate COX Regression: p=0.006
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b) EGFRvIII (upper quartile) and OS
COX Regression Hazard Ratio: 0.53 (0.28-1.01) p=0.052
Multifactorial COX Regression: N/A
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c) HER2 (upper quartile) and OS
COX Regression Hazard Ratio: 1.94 (1.06-3.56) p=0.032
Multifactorial COX Regression: 0.461
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d) Memb HER4 (upper quartile) and OS
COX Regression Hazard Ratio: 2.01 (1.16-3.47) p=0.012
Multifactorial COX Regression: p=0.089
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e) Memb HRG (upper quartile) and OS
COX Regression Hazard Ratio: 1.51 (1.00-2.29) p=0.0499
Multifactorial COX Regression: 0.290
Survival (months)
350 300 250 200 150 100 50 0
C
u
m
 
S
u
r
v
i
v
a
l
1.2
1.0
.8
.6
.4
.2
0.0
Memb HRG
Above Upper
Quartile
censored
Below Upper
Quartile
censored
 
a) Kaplan-Meier Plot comparing HSPC ADT patients with Very High Membrane 
expression of EGFR and those without (divided by Upper Quartile) for outcome Overall 
Survival. b) Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane 
expression of EGFRvIII and those without (divided by Upper Quartile) for outcome 
Overall Survival. c) Kaplan-Meier Plot comparing HSPC ADT patients with Very High 
Membrane expression of HER2 and those without (divided by Upper Quartile) for 
outcome Overall Survival. d) Kaplan-Meier Plot comparing HSPC ADT patients with 
High Membrane expression of HRG and those without (divided by Upper Quartile) for 
outcome Overall Survival. e) Kaplan-Meier Plot comparing HSPC ADT patients with 
High Membrane expression of HRG and those without (divided by Upper Quartile) for 
outcome Overall Survival    149 
4.4.2 IMPACT OF MARKER COMBINATIONS ON TIME TO RELAPSE AND 
         SURVIVAL 
The impact of high expression (high and low divided by the median) of combinations of 
markers in the HSPC patient sub cohort subsequently treated with ADT was assessed first 
by  grouping  markers  in  pairs  then  by  more  general  combinations  –  ≥1  marker,  ≥2 
markers,  ≥3  markers  and  4  markers.  For  a  given  marker,  if  expression  had  been 
demonstrated in more than 1 cell site (EGFR, HER3, HER4) markers were grouped with 
like site with like site (e.g. cytoplasmic EGFR and cytoplasmic HER3, membrane EGFR 
with  membrane  HER3).  Where  expression  had  been  demonstrated  in  only  one  site 
(HER2, EGFRvIII) the marker was matched with all sites (e.g. HER2 with cytoplasmic 
HER3, HER2  with  membrane  HER3).  The  general analyses  were  performed  on  both 
HER1-3 only (given HER1-3 having different prognostic actions in breast cancer) and 
HER1-4.  Analysis  was  repeated  with  EGFRvIII  included  i.e. high score  in  EGFR  or 
variant  III  with  others  and  again  with  HRG  high  score  required  in  addition  to  other 
markers. 
     Increased time to relapse correlated with a number of HER family high expression 
combinations;  memb  EGFR/HER2  (P=0.008),  memb  EGFR/HER3  (0.03),  memb 
EGFR/HER4  (0.013),  HER2/cyto  HER3  (0.006),  HER2/memb  HER3  (0.047), 
HER2/cyto HER4 (0.017), HER2/memb HER4, all 3 membranous markers from HER1-3 
(0.006), all 4 membranous HER1-4 (0.001). If EGFRvIII was included any 1 cytoplasmic 
maker from HER1-4 (0.022), all membranous HER1-3 (0.021), and membranous (0.003) 
HER1-4 were  correlated with increased time to relapse.  If HRG  and EGFRvIII  were   150 
included  high  expression  of  a  single  cytoplasmic  marker  was  also  correlated  with 
increased time to relapse.  
     Increased  overall  survival  was  correlated  with  high  memb  EGFR/HER2  (0.012), 
memb  EGFR/HER3  (0.015),  memb  EGFR/HER4  (0.023),  HER2/cyto  HER3  (0.019), 
HER2/memb HER3 (0.019), at least 2 cytoplasmic markers from HER1-3 (0.015), all 3 
membranous  HER1-3  (0.004),  at  least  3  cytoplasmic  from  HER1-4  (0.012),  all  4 
membranous HER1-4 (0.001). If EGFRvIII was included high expression of at least 2 
cytoplasmic markers from HER1-3 (0.037), all 3 membranous (0.005) from HER1-3 and 
all 4 membranous HER1-4 (0.005) were correlated with increased overall survival.  
     To determine hazard ratios for all markers with a statistically significant influence 
COX regression analysis was performed for all markers with p<0.05 on Kaplan-Meier 
analysis.  Additionally  a  multivariate  backwards:  conditional  COX  analysis  utilising 
Gleason score and Metastasis at presentation was performed for each of these. 
Table 4.6: P-values for Kaplan-Meier Analyses of Time To Relapse in HSPC samples 
from  patients  treated  with  ADT  comparing those  with  high  expression  in  2  different 
markers to those without   
  EGFRC  EGFRM  EGFR 
VIII 
HER2  HER3C  HER3M  HER4C  HER4M  HRGC  HRGM  HRGN 
EGFRC  ND  ND  ND  Nil  Nil  ND  0.078  ND  Nil  ND  ND 
EGFRM    ND  ND  0.008  ND  0.03  ND  0.013  ND  0.399  ND 
EGFR 
vIII 
    ND  0.513  0.908  0.072  0.944  0.879  0.51  0.569  0.385 
HER2        ND  0.006  0.047  0.017  0.046  0.601  0.222  0.322 
HER3C          ND  ND  0.228  ND  0.104  ND  ND 
HER3M            ND  ND  0.084  ND  0.171  ND 
HER4C              ND  ND  0.327  ND  ND 
HER4M                ND  ND  0.958  ND 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table  4.7:  P-values  for  Kaplan-Meier  Analyses  of  Time  To  Biochemical  Relapse  in 
HSPC samples from patients treated with ADT comparing those with high expression in 
different combinations of markers to those without 
 
  Any1C  Any1M  Any2C  Any2M  Any3C  Any3M  4M 
HER1-3  0.187  0.404  Nil  0.145  N/A  0.006  N/A 
HER1-4  0.330  0.951  0.346  0.618  Nil  0.075  0.001 
EGFR/vIII 
+HER2-3 
0.062  0.092  0.192  0.098  N/A  0.021  N/A 
EGFR/vIII 
+HER2-4 
0.022  0.326  0.667  0.128  0.112  0.276  0.003 
HER1-3 
+HRG 
0.123  0.445  Nil  0.303  N/A  0.076  N/A 
HER1-4 
+HRG 
0.537  0.971  0.488  0.546  Nil  0.363  0.077 
EGFR/vIII 
+HER2-3 
+HRG 
0.018  0.477  0.155  0.302  N/A  0.186  N/A 
EGFR/vIII 
+HER2-4 
+HRG 
0.098  0.739  0.522  0.592  0.155  0.499  0.183 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table 4.8: P-values for Kaplan-Meier Analyses of Overall Survival in HSPC samples 
from  patients  treated  with  ADT  comparing those  with  high  expression  in  2  different 
markers to those without  
  EGFRC  EGFRM  EGFR 
VIII 
HER2  HER3C  HER3M  HER4C  HER4M  HRGC  HRGM  HRGN 
EGFRC  ND  ND  ND  Nil  0.475  ND  0.803  ND  Nil  ND  ND 
EGFRM    ND  ND  0.012  ND  0.015  ND  0.01  ND  0.29  ND 
EGFR 
vIII 
    ND  0.288  0.437  0.564  0.341  0.951  0.276  0.183  0.272 
HER2        ND  0.023  0.019  0.195  0.053  0.972  0.252  0.621 
HER3C          ND  ND  0.682  ND  0.214  ND  ND 
HER3M            ND  ND  0.219  ND  0.4  ND 
HER4C              ND  ND  0.383  ND  ND 
HER4M                ND  ND  0.539  ND 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table 4.9: P-values for Kaplan-Meier Analyses of Overall Survival in HSPC samples 
from  patients  treated  with  ADT  comparing  those  with  high  expression  in  different 
combinations of markers to those without 
  Any1C  Any1M  Any2C  Any2M  Any3C  Any3M  4M 
HER1-3  0.155  0.365  0.472  0.083  N/A  0.004  N/A 
HER1-4  0.521  0.269  0.868  0.431  0.499  0.07  0.001 
EGFR/vIII 
+HER2-3 
0.068  0.276  0.037  0.063  N/A  0.005  N/A 
EGFR/vIII 
+HER2-4 
0.140  0.247  0.415  0.09  0.241  0.153  0.005 
HER1-3 
+HRG 
0.303  0.671  Nil  0.298  N/A  0.03*  N/A 
HER1-4 
+HRG 
0.840  0.583  0.922  0.578  Nil  0.32  0.03* 
EGFR/vIII 
+HER2-3 
+HRG 
0.172  0.417  0.047  0.186  N/A  0.107  N/A 
EGFR/vIII 
+HER2-4 
+HRG 
0.433  0.515  0.544  0.219  0.284  0.439  0.109 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.7:  Correlations  of  Expression  of  combinations  of  Markers  with  Time  To 
Biochemical Relapse that show statistical significance in the Patient Subcohort treated 
with Androgen Deprivation Therapy. 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
   154 
 
a) Memb EGFR/HER2 and TTR
COX Regression Hazard Ratio: 2.38 (1.19-4.78) p=0.014
Multifactorial COX Regression: N/A
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b) Memb EGFR/HER3 and TTR
COX Regression Hazard Ratio: 2.11 (1.02-4.36) p=0.072
Multivariate COX Regression: N/A
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c) Memb EGFR/HER4 and TTR
COX Regression Hazard Ratio: 2.04 (1.11-3.73) p=0.021
Multivariate COX Regression: N/A
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d) HER2/Cyto HER3 and TTR
COX Regression Hazard Ratio: 2.64 (1.23-5.67) p=0.013
Multivariate COX Regression: N/A
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e) HER2/Memb HER3 and TTR
COX Regression Hazard Ratio: 1.76 (0.93-3.32) p=0.08
Multivariate COX Regression: N/A
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f) HER2/Cyto HER4 and TTR
COX Regression Hazard Ratio: 2.10 (1.07-4.12) p=0.032
Multivariate COX Regression: N/A
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g) HER2/Memb HER4 and TTR
COX Regression Hazard Ratio: 1.81 (0.94-3.47) p=0.077
Multivariate COX Regression: N/A
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j) Memb HER1-3 and TTR
COX Regression Hazard Ratio: 3.09 (1.29-7.38) p=0.011
Multivariate COX Regression: N/A
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k) Memb HER1-4 and TTR
COX Regression Hazard Ratio: 4.07 (1.57-10.52) p=0.004
Multivariate COX Regression: N/A
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m) Memb HER1(vII)-3 and TTR
COX Regression Hazard Ratio: 2.22 (1.07-4.60) p=0.033
Multivariate COX Regression: N/A
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o) HER1(vIII)-4 and TTR
COX Regression Hazard Ratio: 3.08 (1.36-7.00) p=0.007
Multivariate COX Regression: N/A
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h) HER1-3 and TTR 
i) HER1-4 and TTR  j) Memb HER1(vIII)-3 and TTR 
k) Memb HER1(vIII)-4 and TTR 
COX Regression Hazard Ratio: 2.39 (1.21-3.09) p=0.04 
Multivariate COX Regression: N/A   156 
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a) Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane expression of 
both EGFR and HER2 and those without for outcome Time To Biochemical Relapse. b) 
Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane expression of 
both EGFR and HER3 and those without for outcome Time To Biochemical Relapse. c)  
Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane expression of 
both EGFR and HER4 those without for outcome Time To Biochemical Relapse. d) 
Kaplan-Meier Plot comparing HSPC ADT patients with High expression of both HER2 
and Membrane HER3 and those without for outcome Time To Biochemical Relapse. e) 
Kaplan-Meier Plot comparing HSPC ADT patients with High Membrane expression of 
both HER2 and HER3 and those without for outcome Time To Biochemical Relapse. f) 
Kaplan-Meier Plot comparing HSPC ADT patients with High expression of both HER2 
and Membrane HER4 and those without for outcome Time To Biochemical Relapse. g) 
Kaplan-Meier Plot comparing HSPC patients with High Membrane expression of both 
HER2 and HER4 and those without for outcome Time To Biochemical Relapse. h) 
Kaplan-Meier Plot comparing HSPC ADT patients with high expression of membranous 
HER 1-3 proteins and those without for outcome Time To Biochemical Relapse. i) 
Kaplan-Meier Plot comparing HSPC ADT patients with high expression of all 4 
membranous HER 1-4 proteins and those without for outcome Time To Biochemical 
Relapse j) Kaplan-Meier Plot comparing HSPC ADT patients with high expression of all 
membranous HER 1-3 proteins (where EGFR can be normal or variant III) and those 
without for outcome Time To Biochemical Relapse. k) Kaplan-Meier Plot comparing 
HSPC ADT patients with high expression of membranous HER 1-4 proteins (where 
EGFR can be normal or variant III) and those without for outcome Time To Biochemical 
Relapse . l) Kaplan-Meier Plot comparing HSPC ADT patients with high expression of 
any 1 cytoplasmic HER 1-4 proteins (where EGFR can be normal or variant III) and 
those without for outcome Time To Biochemical Relapse. l) Kaplan-Meier Plot 
comparing HSPC ADT patients with high expression of HRG and any 1 cytoplasmic 
HER 1-4 proteins (where EGFR can be normal or variant III) and those without for 
outcome Time To Biochemical Relapse. 
 
COX Regression Hazard Ratio: 2.8 (1.41 -4.1) p=0.021 
Multivariate COX Regression: N/A   157 
Figure 4.8: Correlations of Expression of combinations of Markers with Overall Survival 
that  show  statistical  significance  in  the  Patient  Subcohort  treated  with  Androgen 
Deprivation Therapy. 
 
a) Memb EGFR/HER2 and OS
COX Regression Hazard Ratio: 2.43 (1.17-5.01) p=0.017
Multivariate COX Regression: p=0.006
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b) Memb EGFR/HER3 and OS
COX Regression Hazard Ratio: 2.78 (1.16-6.62) p=0.021
Multivariate COX Regression: N/A
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c) Memb EGFR/HER4 and OS
COX Regression Hazard Ratio: 2.37 (1.20-4.71) p=0.013
Multivariate COX Regression: p=0.783
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d) HER2/Cyto HER3 and OS
COX Regression Hazard Ratio: 2.17 (1.08-4.34) p=0.029
Multivariate COX Regression: p=0.015
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e) HER2/Memb HER3 and OS
COX Regression Hazard Ratio: 2.13 (1.10-4.15) p=0.025
Multivariate COX Regression: p=0.027
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f) HER2/Memb HER4 and OS
COX Regression Hazard Ratio: 1.99 (0.96-4.11) p=0.064
Multivariate COX Regression: p=0.031
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h) Memb HER1-3 and OS
COX Regression Hazard Ratio: 4.11 (1.44-11.69) p=0.008
Multivariate COX Regression: N/A
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j) Memb HER1-4 and OS
COX Regression Hazard Ratio: 5.57 (1.69-18.41) p=0.005
Multivariate COX Regression: N/A
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k) 2+ Cyto of HER1(vIII)-3 and OS
COX Regression Hazard Ratio: 1.80 (1.08-2.99) p=0.024
Multivariate COX Regression: p=0.664
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m) Memb HER1(vIII)-3 and OS
COX Regression Hazard Ratio: 2.97 (1.32-6.69) p=0.008
Multivariate COX Regression: N/A
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n) Memb HER1(vIII)-4 and OS
COX Regression Hazard Ratio: 3.54 (1.38-9.08) p=0.009
Multivariate COX Regression: N/A
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a)  Kaplan-Meier  Plot  comparing  HSPC  ADT  patients  with  high  expression  of 
membranous EGFR and HER2 and those without for outcome Overall Survival. 
b)  Kaplan-Meier  Plot  comparing  HSPC  ADT  patients  with  high  expression  of 
membranous EGFR and HER3 and those without for outcome Overall Survival. 
c)  Kaplan-Meier  Plot  comparing  HSPC  ADT  patients  with  high  expression  of 
membranous EGFR and HER4 and those without for outcome Overall Survival.  
d) Kaplan-Meier Plot comparing HSPC ADT patients with high expression of HER2 and 
membranous HER3 and those without for outcome Overall Survival. e) Kaplan-Meier 
g) Memb HER1-3 and OS  h) Memb HER1-4 and OS 
i) 2+ Cyto of HER1(vIII)-3 and OS  j) Memb HER1(vIII)-3 and OS 
k) Memb HER1(vIII)-4 and OS 
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Plot comparing HSPC ADT patients with high expression of HER2 and membranous 
HER3 and those without for outcome Overall Survival. f) Kaplan-Meier Plot comparing 
HSPC ADT patients with high expression of HER2 and membranous HER4 and those 
without for outcome Overall Survival. g) Kaplan-Meier Plot comparing HSPC ADT 
patients with high expression of membranous HER1, 2 and 3 proteins and those without 
for outcome Overall Survival. h) Kaplan-Meier Plot comparing HSPC ADT patients with 
high expression of all membranous HER1-4 proteins and those without for outcome 
Overall Survival. i) Kaplan-Meier Plot comparing HSPC ADT patients with high 
expression of at least 2 cytoplasmic HER1-3 proteins (where EGFR can be normal or 
variant III) and those without for outcome Overall Survival. j) Kaplan-Meier Plot 
comparing HSPC ADT patients with high expression of  all membranous HER1-3 
proteins (where EGFR can be normal or variant III) and those without for outcome 
Overall Survival. k) Kaplan-Meier Plot comparing HSPC ADT patients with high 
expression of all membranous HER1-4 proteins (where EGFR can be normal or variant 
III) and those without for outcome Overall Survival. 
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4.5 IMPACT OF MARKER EXPRESSION IN FULL PATIENT COHORT 
4.5.1  IMPACT  OF  SINGLE  MARKER  VALUES  ON  TIME  TO  RELAPSE  AND 
SURVIVAL 
Using  the  full  patient  cohort  of  Kaplan-Meier  analyses  were  conducted  correlating 
expression of each of the markers used in HSPC samples with time to relapse and overall 
survival  comparing  those  with  high  and  low  expression  (divided  by  the  median)  and 
those with very high expression and those without (divided by the 3
rd quartile). 
     Upper  quartile  (Very  high)  membrane  EGFR  expression  correlated  with  increased 
time to relapse  (P=0.049) as were upper quartile HER2 (0.02), above  median (High) 
cytoplasmic HER3 (0.006) and upper quartile HER4 (<0.001). Above median membrane 
HER4 was also associated with increased time to relapse but did not achieve significance 
(P=0.051).  Upper  quartile  EGFRvIII  expression  was  associated  with  reduced  time  to 
relapse (P=0.027). 
     Above median (0.03) and upper quartile HER3 (0.002) cytoplasm expression were 
correlated  with  increased  overall  survival  as  were  upper  quartile  cytoplasmic  HER4 
(0.022),  above  median  (0.008)  and  upper  quartile  (<0.001)  membrane  HER4  and 
membrane HRG (P=0.002). Upper quartile KI67 expression was associated with reduced 
overall survival (P=0.022). 
     To determine hazard ratios for all markers with a statistically significant influence 
COX regression analysis was performed for all markers with p<0.05 on Kaplan-Meier 
analysis.  Additionally  a  multivariate  backwards:  conditional  COX  analysis  utilising 
Gleason score and Metastasis at presentation was performed for each of these. 
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Table 4.10: P-values for Kaplan-Meier Analyses of Time To Biochemical Relapse and 
Overall Survival for all Markers in HSPC samples from all patients comparing those with 
high and low expression (divided by median) 
 
Protein/Location  Time To Relapse 
Kaplan Meier P-Value 
Overall Survival 
Kaplan Meier P-Value 
EGFR – Cytoplasm 
(High) 
0.211  0.096 
EGFR – Membrane 
(High) 
0.32  0.444 
EGFR variant III 
(High) 
0.998  0.962 
HER2 (Herceptest) 
(High) 
0.139  0.067 
HER3 – Cytoplasm 
(High) 
0.006  0.03 
HER3 – Membrane 
(High) 
0.448  0.783 
HER3 – Nucleus 
(High) 
0.8  0.783 
HER4 – Cytoplasm 
(High) 
0.322  0.753 
HER4 – Membrane 
(High) 
0.051  0.008 
HER4 – Nucleus 
(High) 
0.864  0.413 
HRG – Cytoplasm 
(High) 
0.214  0.385 
HRG – Membrane 
(High) 
0.063  0.101 
HRG – Nucleus 
(High) 
0.76  0.2 
KI67 Count 
(High) 
0.238  0.022 
TUNEL Assay 
(High) 
0.321  0.436 
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Table  4.11:  P-values  for  Kaplan-Meier  Analyses  of  Time  To  Relapse  and  Overall 
Survival for all Markers in All HSPC samples comparing those with very high expression 
to those without (divided by the Third Quartile) 
 
Protein/Location  Time To Relapse 
Kaplan Meier P-Value 
Overall Survival 
Kaplan Meier P-Value 
EGFR – Cytoplasm 
(Very High) 
0.211  0.096 
EGFR – Membrane 
(Very High) 
0.049  0.902 
EGFR variant III 
(Very High) 
0.027  0.063 
HER2 (Herceptest) 
(Very High) 
0.02  0.347 
HER3 – Cytoplasm 
(Very High) 
0.106  0.002 
HER3 – Membrane 
(Very High) 
0.86  0.321 
HER3 – Nucleus 
(Very High) 
0.898  0.491 
HER4 – Cytoplasm 
(Very High) 
0.093  0.022 
HER4 – Membrane 
(Very High) 
<0.001  <0.001 
HER4 – Nucleus 
(Very High) 
0.497  0.217 
HRG – Cytoplasm 
(Very High) 
0.078  0.434 
HRG – Membrane 
(Very High) 
0.094  0.002 
HRG – Nucleus 
(Very High) 
0.228  0.2 
KI67 Count 
(Very High) 
0.77  0.159 
TUNEL Assay 
(Very High) 
0.748  0.601 
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Figure 4.9: Correlations of Marker Expression with Time To Biochemical Relapse that 
show statistical significance in the Full Patient Cohort 
  
a) Memb EGFR (upper quartile) and TTR
COX Regression Hazard Ratio: 1.62 (0.96-2.73) p=0.070
Multivariate COX Regression: p=0.089
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b) EGFRvIII (upper quartile) and TTR
COX Regression Hazard Ratio: 0.46 (0.24-0.88) p=0.018
Multivariate COX Regression: p=0.033
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c) HER2 (upper quartile) and TTR
COX Regression Hazard Ratio: 1.90 (1.05-4.56) p=0.033
Multivariate COX Regression: p=0.130
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d) Cyto HER3 (median) and TTR
COX Regression Hazard Ratio: 1.77 (1.11-2.85) p=0.017
Multivariate COX Regression: p=0.035
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f) Memb HER4 (upper quartile) and TTR
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a) Kaplan-Meier Plot comparing all HSPC patients with very high membrane expression 
of EGFR and those without (divided by Upper Quartile) for outcome Time To 
Biochemical Relapse b) Kaplan-Meier Plot comparing all HSPC patients with very high 
membrane expression of EGFR variant III and those without (divided by Upper Quartile) 
for outcome Time To Biochemical Relapse. c) Kaplan-Meier Plot comparing all HSPC 
e) Memb HER4 (upper quartile) and TTR 
COX Regression Hazard Ratio: 2.30 (1.21-4.29) p=0.001 
Multivariate COX Regression: p=0.401 
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patients with very high membrane expression of HER2 and those without (divided by 
Upper Quartile) for outcome Time To Biochemical Relapse  
d) Kaplan-Meier Plot comparing all HSPC patients with high cytoplasm expression of 
HER3  and  those  without  (divided  by  median)  for  outcome  Time  To  Biochemical 
Relapse. e) Kaplan-Meier Plot comparing all HSPC patients with very high membrane 
expression of HER4 and those without (divided by Upper Quartile) for outcome Time To 
Biochemical Relapse 
 
 
 
Figure  4.10:  Correlations  of  Marker  Expression  with  Overall  Survival  that  show 
statistical significance in the Full Patient Cohort 
 
a) Cyto HER3 (median) and OS
COX Regression Hazard Ratio: 1.64 (1.07-2.51) p=0.024
Multivariate COX Regression: p=0.769
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b) Cyto HER3 (upper quartile) and OS
COX Regression Hazard Ratio: 1.64 (1.07-2.51) p=0.024
Multivariate COX Regression: p=0.769
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c) Cyto HER4 (upper quartile) and OS
COX Regression Hazard Ratio: 1.71 (1.06-2.75) p=0.027
Multivariate COX Regression: p=0.315
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d) Memb HER4 (median) and OS
COX Regression Hazard Ratio: 1.72 (1.13-2.63) p=0.012
Multivariate COX Regression: p=0.014
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e) Memb HER4 (upper quartile) and OS
COX Regression Hazard Ratio: 2.52 (1.57-4.05) p<0.001
Multivariate COX Regression: p=0.414
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f) Memb HRG (upper quartile) and OS
COX Regression Hazard Ratio: 1.77 (1.22-2.58) p=0.003
Multivariate COX Regression: p=0.791
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g) KI-67 (median) and OS
COX Regression Hazard Ratio: 0.71 (0.53-0.95) p=0.023
Multivariate COX Regression: p=0.411
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a) Kaplan-Meier Plot comparing all HSPC patients with high cytoplasm expression of 
HER3 and those without (divided by median) for outcome Overall Survival b)Kaplan-
Meier Plot comparing all HSPC patients with very high cytoplasm expression of HER3 
and those without (divided by upper quartile) for outcome Overall Survival.  
c)  Kaplan-Meier Plot comparing all HSPC patients with very high cytoplasm expression 
of HER4 and those without (divided by upper quartile) for outcome Overall Survival d) 
Kaplan-Meier  Plot  comparing  all  HSPC  patients  with  high  membrane  expression  of 
HER4 and those without (divided by median) for outcome Overall Survival. e) Kaplan-
Meier Plot comparing all HSPC patients with very high membrane expression of HER4 
and those without (divided by upper quartile) for outcome Overall Survival. f) Kaplan-
Meier Plot comparing all HSPC patients with very high membrane expression of HRG 
and those without (divided by upper quartile) for outcome Overall Survival. g) Kaplan-
Meier Plot comparing all HSPC patients with high expression of KI67 and those without 
(divided by median) for outcome Overall Survival. 
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4.5.2  IMPACT  OF  MARKER  COMBINATIONS  ON  TIME  TO  RELAPSE  AND 
SURVIVAL 
The impact of high expression (high and low divided by the median) of combinations of 
markers in the full HSPC patient cohort was assessed first by grouping markers in pairs 
then by more general combinations – ≥1 marker, ≥2 markers, ≥3 markers and 4 markers. 
For a given marker, if expression had been demonstrated in more than 1 cell site (EGFR, 
HER3, HER4) markers were grouped like site with like site (e.g. cytoplasmic EGFR and 
cytoplasmic  HER3,  membrane  EGFR  with  membrane  HER3).  Where  expression  had 
been demonstrated in only one site (HER2, EGFRvIII) the marker was matched with all 
sites (e.g. HER2 with cytoplasmic HER3, HER2 with membrane HER3). The general 
analyses  were  performed  on  both  HER1-3  only  (given  HER1-3  having  different 
prognostic actions in breast cancer) and HER1-4. Analysis was repeated with EGFRvIII 
included i.e. high score in EGFR or variant III with others and again with HRG high 
score required in addition to other markers. 
     Increased  time  to  relapse  correlated  with  high  memb  EGFR/HER2  (0.0332, 
HER2/cyto HER3 (0.03), all 3 membranous markers from HER1-3 and all 4 membranous 
markers  HER1-4  (0.001).  If  EGFRvIII  was  included  high  expression  of  all  one 
cytoplasmic of HER1-3 (0.013), one of HER1-4 (0.004) or all 4 membranous (0.015) 
HER1-4 were correlated with increased time to relapse. No significant correlations were 
found if HRG was included.  
     Increased overall survival was correlated with high cyto HER3/HRG (0.025), high 
expression of at least 1 cytoplasmic marker from HER1-3 (0.036), HER1-4 (0.030) and 
with high expression of at least 1 memb marker from HER1-4. If EGFRvIII was included   167 
high expression of at least 2 membranous markers of HER1-3 (0.026) was correlated with 
decreased  overall  survival.  With  HRG  included  again  increased  overall  survival  was 
correlated with at least one highly expressed cytoplasmic marker. 
     To determine hazard ratios for all markers with a statistically significant influence 
COX regression analysis was performed for all markers with p<0.05 on Kaplan-Meier 
analysis.  Additionally  a  multivariate  backwards:  conditional  COX  analysis  utilising 
Gleason score and Metastasis at presentation was performed for each of these. 
 
Table 4.12: P-values for Kaplan-Meier Analyses of Time To Biochemical Relapse in 
HSPC samples from all patients comparing those with high expression in 2 different 
markers to those without 
 
  EGFRC  EGFRM  EGFR 
VIII 
HER2  HER3C  HER3M  HER4C  HER4M  HRGC  HRGM  HRGN 
EGFRC    ND  ND  Nil  Nil  ND  0.5*  ND  Nil  ND  ND 
EGFRM      ND  0.033  ND  0.069  ND  0.053  ND  0.459  ND 
EGFR 
vIII 
      0.513  0.907  0.972  0.944  0.879  0.51  0.569  0.385 
HER2          0.02  0.142  0.082  0.095  0.927  0.27  0.375 
HER3C            ND  0.005  ND  0.027  ND  ND 
HER3M              ND  0.074  ND  0.408  ND 
HER4C                ND  0.738  ND  ND 
HER4M                  ND  0.724  ND 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table 4.13: P-values for Kaplan-Meier Analyses of Time To Biochemical Relapse in 
HSPC  samples  from  all  patients  comparing  those  with  high  expression  in  different 
combinations of markers to those without 
 
  Any1C  Any1M  Any2C  Any2M  Any3C  Any3M  4M 
HER1-3  0.109  0.791  Nil  0.337  N/A  0.019  N/A 
HER1-4  0.189  0.355  0.124  0.814  Nil  0.113  0.007 
EGFR/vIII 
+HER2-3 
0.035  0.531  0.335  0.307  N/A  0.062  N/A 
EGFR/vIII 
+HER2-4 
0.004  0.055  0.317  0.596  0.135  0.384  0.015 
HER1-3 
+HRG 
0.051  0.77  Nil  0.343  N/A  0.075  N/A 
HER1-4 
+HRG 
0.438  0.901  0.468  0.692  Nil  0.402  0.076 
EGFR/vIII 
+HER2-3 
+HRG 
0.017  0.891  0.136  0.368  N/A  0.214  N/A 
EGFR/vIII 
+HER2-4 
+HRG 
0.114  0.748  0.463  0.817  0.210  0.561  0.209 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table 4.14: P-values for Kaplan-Meier Analyses of Overall Survival in HSPC samples 
from all patients comparing those with high expression in 2 different markers to those 
without 
 
  EGFRC  EGFRM  EGFR 
VIII 
HER2  HER3C  HER3M  HER4C  HER4M  HRGC  HRGM  HRGN 
EGFRC  ND  ND  ND  0.031*  0.177  ND  0.619  ND  0.196  ND  ND 
EGFRM    ND  ND  0.7135  ND  0.95  ND  0.745  ND  0.251  ND 
EGFR 
vIII 
    ND  0.288  0.437  0.564  0.341  0.951  0.276  0.183  0.272 
HER2        ND  0.776  0.435  0.21  0.673  0.164  0.76  0,427 
HER3C          ND  ND  0.511  ND  0.025  ND  ND 
HER3M            ND  ND  0.404  ND  0.662  ND 
HER4C              ND  ND  0.74  ND  ND 
HER4M                ND  ND  0.108  ND 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Table 4.15: P-values for Kaplan-Meier Analyses of Overall Survival in HSPC samples 
from  all  patients  comparing  those  with  high  expression  in  different  combinations  of 
markers to those without 
 
  Any1C  Any1M  Any2C  Any2M  Any3C  Any3M  4M 
HER1-3  0.036  0.913  0.177  0.087  N/A  0.486  N/A 
HER1-4  0.030  0.044  0.677  0.542  0.516  0.462  0.322 
EGFR/vIII 
+HER2-3 
0.215  0.206  0.312  0.026  N/A  0.819  N/A 
EGFR/vIII 
+HER2-4 
0.062  0.233  0.716  0.417  0.581  0.151  0.598 
HER1-3 
+HRG 
0.031  0.848  Nil  0.277  N/A  0.113  N/A 
HER1-4 
+HRG 
0.050  0.348  0.945  0.835  Nil  0.843  0.112 
EGFR/vIII 
+HER2-3 
+HRG 
0.106  0.448  0.772  0.243  N/A  0.536  N/A 
EGFR/vIII 
+HER2-4 
+HRG 
0.067  0.5  0.753  0.63  0.775  0.605  0.518 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key 
ND – Not Done – Markers not paired with themselves, staining sites (cytoplasm/membrane) 
paired like with like where possible 
N/A – Not possible 
Nil – No patients had relevant combination 
* - Statistical significance but too few patients had relevant combination for real significance 
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Figure  4.11:  Correlations  of  Expression  of  combinations  of  Markers  with  Time  To 
Biochemical Relapse that show statistical significance in the Full Patient Cohort. 
 
a) Memb EGFR/HER2 and TTR
COX Regression Hazard Ratio: 1.95 (1.01-3.76) p=0.045
Multivariate COX Regression: p=0.106
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b) Memb EGFR/HER4 and TTR
COX Regression Hazard Ratio: 1.70 (0.95-3.01) p=0.071
Multivariate COX Regression: p=0.235
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c) HER2/Cyto HER3 and TTR
COX Regression Hazard Ratio: 2.19 (1.07-4.48) p=0.032
Multivariate COX Regression: p=0.049
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d) Cyto HER3/HRG and TTR
COX Regression Hazard Ratio: 1.90 (1.01-3.57) p=0.048
Multivariate COX Regression: p=0.807
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g) Memb HER1-3 and TTR
COX Regression Hazard Ratio: 2.46 (1.10-5.50) p=0.028
Multivariate COX Regression: p=0.041
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i) Memb HER1-4 and TTR
COX Regression Hazard Ratio: 2.99 (1.26-7.08) p=0.013
Multivariate COX Regression: p=0.045
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e) Memb HER1-3 and TTR  f) Memb HER1-4 and TTR   172 
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l) Memb HER1(vIII)-4 and TTR
COX Regression Hazard Ratio: 2.37 (1.11-5.06) p=0.026
Multivariate COX Regression: p=0.598
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a) Kaplan-Meier Plot comparing all HSPC patients with high membrane expression of 
EGFR and HER2 and those without for outcome Time To Biochemical Relapse.  
b) Kaplan-Meier Plot comparing all HSPC patients with high membrane expression of 
EGFR and HER4 and those without for outcome Time To Biochemical Relapse  
c) Kaplan-Meier Plot comparing all HSPC patients with high expression of HER2 and 
cytoplasmic HER3 and those without for outcome Time To Biochemical Relapse.  
d) Kaplan-Meier Plot comparing all HSPC patients with high cytoplasmic expression of 
HER3 and HRG and those without for outcome Time To Biochemical Relapse 
e) Kaplan-Meier Plot comparing all HSPC patients with high membrane expression of all 
HER1-3 proteins and those without for outcome Time To Biochemical Relapse. f) 
Kaplan-Meier Plot comparing all HSPC patients with high membrane expression of all 
HER1-4 proteins and those without for outcome Time To Biochemical Relapse. g) 
Kaplan-Meier Plot comparing all HSPC patients with high expression of at least 1 
cytoplasmic HER1-3 proteins (where EGFR can be normal or variant III) and those 
without for outcome Time to Biochemical Relapse. h) Kaplan-Meier Plot comparing all 
HSPC patients with high expression of at least 1 cytoplasmic HER1-4 proteins (where 
EGFR can be normal or variant III) and those without for outcome Time to Biochemical 
Relapse i) Kaplan-Meier Plot comparing all HSPC patients with high membrane 
expression of all HER1-4 proteins (where EGFR can be normal or variant III) and those 
without for outcome Time To Biochemical Relapse.  
 
 
 
 
h) 1+ Cyto HER1(vIII)-4 and TTR 
COX Regression Hazard Ratio: 2.10 (1.01-4.09) p=0.03 
Multivariate COX Regression: p=0.521 
P=0.004   173 
Figure  4.12:  Correlations  of  Expression  of  combinations  of  Markers  with  Overall 
Survival that show statistical significance in the Full Patient Cohort. 
 
a) Cyto HER3/HRGC and OS
COX Regression Hazard Ratio: 1.87 (1.06-3.34) p=0.032
Multivariate COX Regression: p=0.270
Survival (months)
300 250 200 150 100 50 0
C
u
m
 
S
u
r
v
i
v
a
l
1.2
1.0
.8
.6
.4
.2
0.0
CytoHER3/HRG
Both High
censored
Not Both High
censored
P=0.025
Survival (months)
300 250 200 150 100 50 0
C
u
m
 
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
p=0.036
censored
.censored
1+ Cyto
.<1 Cyto
AnyCyto HER1-
3
b) 1+ Cyro from HER1-3 and OS
 
 
 
 
 
 
b) 1+ Cyto of HER1-4 and OS
COX Regression Hazard Ratio: 1.61 (1.07-2.41) p=0.023
Multivariate COX Regression: p=0.739
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c) 1+ Memb of HER1-4 and TTR
COX Regression Hazard Ratio: 1.55 (1.02-2.35) p=0.038
Multivariate COX Regression: p=0.051
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d) 2+ Memb of HER1(vIII)-3 and TTR
COX Regression Hazard Ratio: 0.61 (0.39-0.93) p=0.023
Multivariate COX Regression: p=0.164
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c) 1+ Cyto of HER1-4 and OS 
P=0.03 
d) 1+Memb of HER1-4 and OS 
e) 2+ Memb of HER1(vIII)-3 and OS 
COX Regression Hazard Ratio: 1.81 (1.01 - 3.52) p=0.049 
Multivariate COX Regression p= 0.423 
COX Regression Hazard Ratio: 
Multivariate COX Regression 
COX Regression Hazard Ratio: 2.02 (1.01 - 4.14) p=0.04 
Multivariate COX Regression p= 0.821   174 
 
a) Kaplan-Meier Plot comparing all HSPC patients with high cytoplasmic expression of 
HER3 and HRG and those without for outcome Overall Survival. b) Kaplan-Meier Plot 
comparing all HSPC patients with high expression of at least 1 cytoplasmic HER1-3 
protein and those without for outcome Overall Survival. c) Kaplan-Meier Plot comparing 
all HSPC patients with high expression of at least 1 cytoplasmic HER1-4 protein and 
those without for outcome Overall Survival. d) Kaplan-Meier Plot comparing all HSPC 
patients with high membrane expression of at least 1 HER1-4 protein those without for 
outcome Overall Survival. e) Kaplan-Meier Plot comparing all HSPC patients with high 
membrane  expression of at least 2 HER1-3 proteins (where EGFR can  be normal or 
variant  III)  and  those  without  for  outcome  Overall  Survival.  f)  Kaplan-Meier  Plot 
comparing all HSPC patients with high expression of HRG and at least 1 cytoplasmic 
HER1-4 protein and those without for outcome Overall Survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   175 
4.6 CORRELATIONS OF DIFFERENT MARKER EXPRESSION IN FULL COHORT 
Correlation  analyses  were  performed  comparing  expression  of  each  marker  with  all 
others in all HSPC samples. A correlation coefficient of >0.4 and p<0.05 were taken as 
indicating a statistically significant correlation. 
     In  this  cohort  statistically  significant  correlations  were  found  between  EGFR 
membrane  and  cytoplasmic  expression,  HRG  cytoplasmic  and  HRG  membranous 
expression, HRG cytoplasmic and HRG nuclear expression.  
Table  4.16:  Correlation  Coefficients  and  P-values  for  Inter-Marker  Expression 
Correlation Analyses 
 
  EGFR 
M 
EGFR 
vIII 
HER2  HER3 
C 
HER3 
M 
HER4 
C 
HER4 
M 
HRGC  HRGM  HRGN  KI67  TUNEL 
EGFR 
C 
.533 
<.001 
N/A  .009 
929 
.018 
.852 
.036 
.712 
.156 
.117 
.002 
.985 
.193 
.047 
.073 
.455 
.042 
.666 
.052 
.597 
.041 
.694 
EGFR 
M 
  .25 
.846 
.358 
.000 
.079 
.329 
.116 
.15 
.222 
.006 
.115 
.154 
.56 
.491 
.224 
.005 
.168 
.038 
.115 
.146 
.042 
.613 
EGFR 
vIII 
    .126 
.401 
.081 
.583 
.121 
.415 
.043 
.764 
.115 
.423 
.061 
.686 
.016 
.914 
.233 
.118 
.083 
.567 
.068 
.652 
HER2 
 
      .162 
.048 
.220 
.007 
.225 
.006 
.109 
.188 
.166 
.045 
.137 
.099 
.024 
.775 
.087 
.299 
.044 
.612 
HER3 
C 
        .388 
.000 
.179 
.031 
.147 
.077 
.207 
.015 
.109 
.206 
.083 
.336 
.06 
.483 
.006 
.947 
HER3 
M 
          .238 
.004 
.3 
<.001 
.099 
.249 
.114 
.186 
.082 
.34 
.08 
.35 
.026 
.77 
HER4 
C 
            .216 
.006 
.001 
.992 
.000 
.997 
.049 
.573 
.055 
.521 
.145 
.099 
HER4 
M 
              .115 
.18 
.083 
.334 
.025 
.775 
.059 
.485 
.008 
.925 
HRGC 
 
                .418 
<.001 
.601 
<.001 
.055 
.355 
.088 
.156 
HRGM 
 
                  .329 
<.001 
.219 
<.001 
.048 
.443 
HRGN 
 
                    .015 
.797 
.122 
.05 
KI67 
 
                      .036 
.556 
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Figure 4.13: Significant Inter-Marker Expression Correlations 
 
a) Cytoplasmic and Membranous EGFR
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b) Cytoplasmic and Membranous HRG
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c) Cytoplasmic and Nuclear HRG Score
HRG Nuclear Score
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a) Scatter Graph of EGFR cytoplasmic and EGFR Membranous Expression in Full 
Patient Cohort. b) Scatter Graph of HRG cytoplasmic and HRG Membranous Expression 
in Full Patient Cohort c) Scatter Graph of HRG cytoplasmic and HRG Nuclear 
Expression in Full Patient Cohort     
 
It should be noted that the EGFR scatter graph is not as convincing as the other 2 given 
the fewer number of stained specimens and the large proportion which are 0 value and 
the wide spacing of the remainder. 
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4.7  MULTIVARIATE  COX  REGRESSION  ANALYSIS  IN  MARKERS  SHOWING 
SIGNIFICANT IMPACT ON TIME TO RELAPSE OR SURVIVAL 
4.7.1 PATIENT SUBCOHORT ON ANDROGEN DEPRIVATION THERAPY 
Summarising  the  individual  multivariate  COX  analyses  with  outcome  time  to 
biochemical relapse no factor was found to have a significant influence independent of 
Gleason score and metastasis at presentation. 
Several markers/marker combinations had an independent influence on outcome Overall 
Survival in multivariate COX analysis with Gleason Score and Metastasis at presentation. 
These  were  very  high  Membrane  expression  of  EGFR,  high  expression  membranous 
EGFR and HER2, high expression HER2 and Cytoplasmic HER3, high expression HER2 
and membranous HER3, high expression HER2 and membranous HER4. 
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4.7.2 FULL PATIENT COHORT 
     Several  markers/marker  combinations  had  and  independent  influence  on  outcome 
Time to Relapse in multivariate COX analysis with Gleason Score and Metastasis at 
presentation.  These  were  very  high  membrane  expression  of  EGFR  variant  III,  high 
cytoplasm  expression  of  HER3,  high  expression  HER2  and  cytoplasmic  HER3,  high 
expression HER1, 2 and 3 proteins, high membrane expression of HER1, 2, 3 and 4 
proteins. A multivariate analysis including Gleason score, metastases, high HER3 and 
very  high  EGFRvIII  indicates EGFRvIII  (p=0.038)  is  a  greater  influence  than  HER3 
(p=0.051) 
     High  membrane  expression  of  HER4  was  the  only  factor  significantly  influencing 
overall survival independently of Gleason score and Metastasis at presentation in this 
cohort. 
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4.8 SUMMARY 
Univariate analysis of an expanded cohort of HSPC patients with outcomes TTR and OS 
has yielded a large number of statistically significant results with a clear trend towards 
positive prognosis with increased marker expression. Several trends within this data are 
apparent e.g. greater influence of membranous staining, a larger number of significant 
results  in  the  ADT  subgroup  and  more  significant  p-values  with  multiple  markers 
expressed concomitantly – these will be reviewed in the discussion. There are markedly 
fewer  significant  results  following  multivariate  analysis  with  Gleason  score  and 
metastasis at presentation but some independent predictors remain.  
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5. DISCUSSION 
5.1 RATIONALE FOR STUDY 
With  the  rising  incidence  and  high  contribution  to  cancer  mortality,  Prostate 
Adenocarcinoma is an important health issue in the UK and elsewhere. It has become a 
significant priority to distinguish those patients with disease that is likely to progress and 
metastasise  from those  whose disease  will  remain  quiescent throughout their lifetime 
allowing  radical  therapy,  with  all  its  associated  side  effects  and  complications  to  be 
appropriately utilised.  
 
Hormone therapy with antiandrogens and GnRH analogues have long been a mainstay of 
treatment of both locally advanced and metastatic prostatic adenocarcinoma but while 
initial  tumour  response  is  good  in  the  majority  of  patients  eventual  development  of 
hormone resistance is common and heralds further progression, metastasis and death. It 
thus becomes clinically advantageous to discern which patients will have a poor initial 
hormonal response and which will undergo hormone relapse/clinical progression early. 
Such  patients  could  thus  be  targeted  with  adjuvant  therapies  earlier  including 
radiotherapy,  targeted  biological  therapies  and  newer/currently  evolving 
chemotherapeutic agents.  
 
While chemotherapy trials are ongoing agents used in hormone refractory disease are still 
in their infancy. The immunotherapeutic agent Herceptin (Trastuzamab) targeting HER2 
in breast cancer has been used in widespread clinical practice and multiple similar agents 
have been used in clinical trials however no such agent is currently available for CaP   181 
whether  hormone  sensitive  or  refractory.  There  is  a  clinical  need  for  such  agents 
particularly in HRPC which has a poor prognosis and limited clinical options.  
 
As  explored  in  the  background  a  multitude  of  extracellular,  transmembrane  and 
intracellular signalling molecules have been investigated for their potential as prognostic 
markers and treatment targets in CaP, the HER family is one of many investigated in this 
context.  
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5.2 COMPARISON OF RESULTS WITH PREVIOUS LITERATURE 
5.2.1 EGFR 
In  this  study  univariate  analysis  of  expression  of  EGFR  in  HSPC  specimens  was 
performed in cohort 2. High membranous EGFR expression was correlated with positive 
outcomes in both the full cohort and the ADT subcohort. This contrasts with existing 
literature where EGFR expression in CaP has been linked to either negative outcome or 
having  no  effect.  The  pilot  study  for  this  project  showed  no  influence  of  EGFR 
expression on TTR/OS but this was limited by a relatively small patient cohort. (2004) et 
al.  which  similarly  used  IHC  demonstrated  a  significant  rise  in  expression  following 
hormone escape but no correlation between expression and clinical outcome. Bartlett et 
al. utilised IHC and FISH to demonstrate a negative impact on prognosis of EGFR gene 
copy number an HRPC expression. Again no impact was seen with HSPC expression. Di 
Lorenzo et al (2002) demonstrated decreased time to hormone escape and relapse with 
high  expression  of  EGFR.    Multiple  single  marker  EGFR  studies  –Maddy  (1989), 
Glynne-Jones (1996), Myers 1997, Fowler (1998), De Miguel (1999), Zellweger (2005) 
have demonstrated increased expression post hormone escape and/or a negative impact 
on prognosis of increased EGFR expression 
The reason for the difference between this study and others may involve subject numbers 
– the most closely related studies showing no influence had significantly fewer subjects 
and,  like  the  pilot,  a  larger  patient  cohort  may  be  required  to  demonstrate  a  trend. 
Differences in technique may also have influenced the disparity, this study unlike some 
others  has  clearly  divided  membranous  and  cytoplasmic  expression  and  increased 
cytoplasmic expression has not shown an influence. Additionally this study has focussed   183 
on HSPC whereas negative effects have rather been seen in HRPC in some previous 
studies.  Given  previously  noted  significant  increases  in  EGFR  expression  following 
hormone  escape  increased  expression  may  have  different  implications  for  HSPC  and 
HRPC tissue.  
 
In CaP and other solid tumours EGFR has been associated with negative prognosis and 
its activity within the signal transduction network particularly via MAP kinase and PI3K-
Akt pathways to stimulate cell proliferation and decrease apoptosis are in keeping with an 
oncogenic role. The results of this study are at odds with this and counter-intuitive. One 
possible explanation is suggested by the clear demonstration in this study that in CaP 
EGFR and HER2 expression is low and infrequent compared to HER3, HER4 and HRG 
and the fact that expression of multiple HER family members is correlated with improved 
outcome most particularly in the ADT subcohort where expression of all 4 HER family 
members improves outcome to a greater degree of significance than EGFR alone. This 
importance of co-expression was noted in the pilot where high expression of 3+ markers 
gave a significantly longer TTR (p=0.012) than 2 or fewer. It may be that those tumours 
in  which  EGFR  is  detectable  represent  a  subset  in  which  HER  family  expression  is 
generally  higher  but  the  influence  of  HER4  which  has  a  previously  demonstrated 
antiproliferative action (see below) is the most dominant, noting that in the full cohort 
high HER4 expression gives the lowest p-values. In effect EGFR is acting as a surrogate 
for very high HER4 activity. However it should be noted that no correlation was found 
between HER4 expression and that of other markers. 
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5.2.2 HER2 
In  this  study  the  correlations  between  high  HER2  expression  and  prognosis  were 
determined in cohort 2. Univariate analysis indicated high membranous HER2 expression 
had a positive impact on prognosis in both the full cohort and ADT subcohort. This 
conflicts  with  previous  studies  which  have  shown  a  negative  impact  or  no  effect.  In 
Hernes (2004) high HER2 expression in HRPC samples significantly  associated with 
outcome – reduced time to death from relapse. Bartlett et al. demonstrated correlations 
between increased HER2 gene copy number and reduced survival and reduced time to 
death  from  relapse  with  a  rise  in  HER2 following  hormone  escape.  In  this  study  an 
increased significance was noted in reduced TTDFR if both EGFR and HER2 expression 
were increased in the HRPC specimen.  
 
Multiple studies have demonstrated greater HER2 expression in HRPC than HSPC in 
non-paired  samples  Xie  (1995),  Signoretti  (2000),  Shi  (2001),  Di  Lorenzo  (2002). 
Alternatively Lara et al. (2002) demonstrated no link between HER2 overexpression and 
hormone escape. Agus et al (1999) demonstrated greater HER2 expression in androgen 
independent compared to androgen dependent human CaP cells. HER2 expression has 
been correlated with poor prognosis in multiple studies Zhau (1992), Sadasivan (1993), 
Di Lorenzo (2004), Okegawa (2006) and Morote (1999) the last demonstrating HER2 
expression as an independent predictor of worse prognosis on multivariate analysis Other 
studies have shown no relationship of HER2 with prognosis – Ware 1991, Mellon 1992,  
Ross 1997. 
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Possible explanations for this disparity are similar to those for EGFR – limited numbers, 
differing techniques, including HRPC specimens in other studies.  
 
Like EGFR, where HER2 has been found to influence prognosis in CaP and other tumour 
types this influence has been negative the most prominent example being in breast CA. 
Like EGFR, HER2 is involved in signalling pathways that generally result in increased 
proliferation/decreased apoptosis. How then can the positive influence demonstrated in 
this study be explained?  One possible explanation is involvement in alternative pathways 
having  the  opposite  effect  e.g.  HER2  activating  apoptosis  via  a  caspase  independent 
mechanism (Tikhomirov ). However, as noted for EGFR, in this study HER2 expression 
is  low  and  infrequent  compared  to  HER3,  HER4  and  HRG and it  is  also  noted  that 
expression of multiple HER family members is correlated with improved outcome most 
particularly  in  the  ADT  subcohort  where  expression  of  all  4  HER  family  members 
improves  outcome  to  a  greater  degree  of  significance  than  HER2  alone.  In  a similar 
fashion to EGFR tumours where HER2 is detectable represent a subset in which HER 
family expression is generally higher but the anti-oncogenic influence of HER4 is the 
most dominant (noting that in the full cohort high HER4 expression gives the lowest p-
values);- HER2 acting as a surrogate for very high HER4 activity. Again it should be 
noted that no correlation was found between HER4 expression and that of other markers.  
 
5.2.3 HER3 
Univariate  analysis  of HER3  expression  in  cohort  2  demonstrated  improved  outcome 
with high cytoplasmic expression in the full cohort only not the ADT subcohort. There is   186 
a good deal less previous literature regarding HER3 in CaP compared to EGFR/HER2. 
HER3 expression in HRPC cell line has been shown to be significantly higher than that 
of HSPC tissue (Koumakpayi 2006). In this study higher HER3 nuclear expression was 
correlated with higher Gleason score indicating poorer prognosis. Leung 1997 showed 
HER3 expression in abut not benign prostate tissue. Western blotting showed greater 
nuclear HER3 expression in HSPC cell lines as than HRPC contradicting IHC results. 
Hernes et al demonstrated no significant influence of HER3 expression on outcome. In 
Gregory et al. (2005) HER2 and HER3 expression, stimulated by HRG, was shown to 
increase AR transactivation and tumour proliferation in a recurrent CaP cell line in the 
absence of androgen – a possible route of hormone escape. Leung et al demonstrated 
HER3 expression linked to poor response to androgen therapy and decreased survival, 
however more recently Koumakpayi et al (2006) have demonstrated low nuclear HER3 
as a predictor of biochemical recurrence in CaP. There is therefore no consistent position 
in terms of positive or negative prognosis in high HER3 expression even within the small 
number of existing studies however this is the first study to cytoplasmic expression so 
strongly to positive outcome. This may be due to higher patient numbers and the few 
studies using similar IHC methods targeting HER3. 
 
In explaining this studies positive results it can be noted that HER3 along with HER4 and 
HRG has been shown to be positively prognostic in bladder Ca and Koumakpayi has 
indicated  that  low  nuclear  HER3  is  negatively  prognostic  in  CAP)  therefore  it  is 
reasonable  to  conclude  that  HER3  is  involved  in  antioncogenic  signal  transduction. 
Koumakpayi  suggests  HER3  interaction  with  Erb3  binding  protein  1  (EBP1)  which   187 
suppresses AR mediated gene transcription. In this study while it is usually membranous 
expression of HER markers that has the greatest influence on outcome it is cytoplasmic 
rather than membranous HER3 expression that is linked to improved TTR/OS in the full 
cohort. This may reflect that only HER3 in a heterodimer with HER4 is anti-oncogenic 
although  there  is  no  correlation  between  HER3  and  HER4  expression  and  it  is 
membranous  HER4  that  is  efficacious.  It  may  be  that  membranous  HER4  and 
cytoplasmic HER3 are both surrogate markers for the apoptotic activity of the HER4 
intracellular domain. 
 
5.2.4 HER4 
Univariate analysis of HER4 expression and outcome in cohort 2 demonstrated strong 
correlations of high expression of membranous HER4 and improved outcome in both the 
full  cohort  and  the  ADT  subcohort.  This  is  in  keeping  with  Hernes  (2004)  which 
demonstrated  high  expression  of  HER4  in  the  HRPC  sample  was  correlated  with 
improved 2 year survival to a degree nearly achieving statistical significance (p=0.054). 
This  was  in  contrast  to  prognosis  HER1-3  in  Hernes  as  expression  of  these  was 
associated with worse prognosis (although of these statistical significance occurred only 
with HER2). There is little else in the way of IHC studies of HER4 in CaP. 
 
HER4 has previously been shown to be positively prognostic in cancers including breast 
(Tovey  2004)  and  bladder  (Memon  et  al.  2004)  with  Hernes  et  al.  (2004)  noting  a 
positive effect on survival that nearly reached significance. HER4 transfection results in 
reduced proliferation/increased apoptosis in breast Ca cells (Earp et al. 2003, Barnes et al   188 
2005) and growth arrest in prostate Ca lines (Williams 2003). In fact HER4 involvement 
in signal transduction has been defined as antiproliferative in breast Ca studies with the 
HER4 intracellular domain released following HER4 degradation and accumulating in 
mitochondria  to  induce  apoptosis  (Vidal  2005).  The  HER4  results  in  this  study  are 
therefore in keeping with the majority of other literature – HER4 expression correlated to 
improved outcome due to its involvement in antiproliferative pathways. 
 
5.2.5 EGFRvIII 
As mentioned above EGFRvIII commercial antibody was unavailable at the time of this 
study but data from the pilot study was used in the analysis. Single marker EGFRvIII as 
in the pilot data was associated with poor prognosis.  In combinations EGFRvIII  was 
associated  with  some  significant  positive  outcomes  but  in  most  cases  the  same 
combination  without  EGFRvIII  was  also  significant  with  a  smaller  p-value  again 
indicating a negative influence on prognosis. This is in keeping with previous literature 
where EGFRvIII gives a non-conflicted message. It has been detected only in malignant 
and not in benign prostate tissue with greatest expression in metastatic and high grade 
disease. EGFRvIII expression is greater in HRPC than HSPC and associated with high 
serum PSA and disease progression. 
 
5.2.6 HRG 
In this study HRG expression was analysed in cohort 1 and cohort 2. In both cohorts 
increased membranous HRG expression in HSPC is correlated with improved outcome 
with no effect noted in the HRPC specimens in cohort1. While there is a paucity of IHC   189 
based  studies  of  HRG  in  prostate  CA  these  results  are  in  keeping  with  the  previous 
observations that HRG stimulation of HSPC cell lines is associated with antiproliferation 
(Lyne 1997) and that high levels of HRG are associated with growth inhibition (Sartor 
2001). This study would appear to support the hypothesis that high HRG expression is 
positively  prognostic.  The  fall  in  HRG  membranous  staining  has  not  been  noted 
specifically in previous literature but may tie in with previously noted greater expression 
in benign than malignant tissue i.e. greater malignancy – lesser expression (Lyne 1997). 
 
5.2.7 MULTIPLE MARKERS 
In  both  the  ADT  subcohort  and  full  cohort  2  high  expression  of  multiple  marker 
combinations showed significant correlation with improved outcome as listed in chapter 
4.    The  most  notable  combination  was  high  expression  of  HER  1-4  combined 
significantly correlated with both TTR and OS in the ADT subcohort and with TTR alone 
in the full cohort. The results borne out in univariate COX analysis. A small number of 
combinations with positive correlation involved EGFRvIII however in most such cases 
the  same  combination  without  EGFRvIII  (involving  EGFR-WT  only)  also  showed  a 
similar correlation with a more significant p-value confirming the negative influence of 
EGFRvIII. There are few studies in the literature involving HER marker combinations for 
comparison. Hernes (2004) used HER1-4 as markers but did not explore the effect of 
high expression of combinations of theses markers. Bartlett et al had noted significantly 
reduced TTDFR in patients with increased EGFR or HER2 following hormone escape 
but for patients with raised EGFR and HER2 the significance of correlation with reduced 
TTDFR was increased indicating  an  additive effect. Di  Lorenzo (2002) demonstrated   190 
decreased time to hormone escape and relapse with high expression of EGFR also with 
an  additive  effect  of  increased  HER2  expression.  While  these  papers  indicate 
EGFR/HER2 as having the converse effect to the present study they agree that increased 
expression of more than one marker together has an additive effect.  
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5.3. MULTIVARIATE ANALYSIS 
All markers  and  marker  combinations  significant  on  univariate  COX regression  were 
analysed  with  multivariate COX  regression  including  tumour  grade  and  metastasis  at 
diagnosis both for the ADT subcohort and full patient cohort 2. Only a relatively small 
proportion of the single markers and marker combinations found to be significant on 
univariate analysis and these are listed in chapter 4.  
The most obvious reason for this reduction of significant associations on multivariate 
analysis  would  be  that  the  significant  results  on  univariate  analysis  were  due  to 
association between marker expression and Gleason/metastasis and indeed, within cohort 
2 several of these associations are seen most notably high HER3, HER4 and HRG are all 
associated with either low/medium Gleason score or absence of metastases. Additionally 
there  is  the  effect  of  attrition  of  subjects  for  each  multivariate  analysis  making 
significance harder to achieve e.g. for a subject to be included in analysis for a given 
marker/TTR and metastasis in the ADT subcohort a subject must have 1) been stained for 
the correct marker 2) been treated with ADT, 3) had a biochemical relapse, 4) have the 
information available regarding metastasis at presentation; even with a starting cohort of 
over 350 subjects this number of requirements can reduce the pool of subjects to such 
low levels that significance is hard to achieve.  
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5.4 ANSWERS TO STUDY QUESTIONS 
1. Are expression of HER 1-4 and EGFRvIII correlated with response to therapy/ time to 
relapse/time to death in prostate cancer? 
Within this study there are multiple instances of expression of HER family members 
correlating with outcomes TTR and OS on Kaplan-Meier analysis with most of these also 
significant on univariate COX regression and a small proportion of these on mutivariate 
analysis. Not all HER family marker expressions investigated are significantly associated 
with outcomes and some trends are apparent 
·  High/Very  High  HER1-4  expression  are  associated  with  positive  outcomes, 
EGFRvIII with negative 
·  Very  High  (Upper  Quartile)  expression  is  more  likely  to  be  associated  with  a 
significant outcome than high expression (above median) 
·  The most significant results on univariate analysis are seen with HER4 expression 
and a combination of all 4 main markers On multivariate analysis both HER4 and 
HER1-4 gave significant results for OS and TTR respectively in the full cohort.  
·  The majority of single Markers that give significant results are membranous staining 
rather than cytoplasmic or nuclear. As detailed in the background the membrane is the 
primary  site  where  HER  family  receptors  are  activated  before  dimerisation  and 
internalisation/signal transduction therefore membrane. Membrane expression could 
represent level of the receptor available for signal transduction hence a surrogate for 
activity.  Alternatively  high  membrane  expression  could  represent  a  lack  of 
internalisation  and  therefore  pathway  activity.  While  few  correlations  in  marker 
expression were seen the fact all correlations between membrane and cytoplasmic   193 
expression that were demonstrated were positive rather than negative would suggest 
the former explanation rather than the latter. A nuclear role for HER3 have been 
noted  earlier  in  this  discussion  (Koumakpayi  2006)  but  few  correlations  between 
prognosis and nuclear expression were seen in this study. 
·  Particularly  with  regard  to  Marker  combinations  there  are  a  greater  number  of 
significant results within the ADT subcohort than in the full cohort 2. As detailed in 
the background HER family affects cellular activity via both pathways that interact 
with AR (Yeh 1999, Rochette-Egly 2003, Mellinghoff 2004) and those that do not 
(Lin  1999).  One  could  hypothesise  that  given  the  increased  time  to  biochemical 
recurrence  and  greater  action  in  the  ADT  subcohort  family  pathway  is  acting  to 
potentiate ADT or that it acts to block mechanisms that effect hormone escape. 
·  With outcomes TTR and OS in the ADT subgroup and TTR in the full cohort there is 
a general trend towards falling p-values with increased numbers of highly expressed 
HER  family  members.  Notably  the  lowest  p-values  are  seen  where  there  is  high 
membranous  expression  of  all  4  HER  family  members.  This  gives  a  general 
indication  of  increased  significance  and  an  additive  effect  in  terms  of  positive 
outcome the more HER family members are highly expressed. Additive effects of 
multiple HER family members have been noted in Bartlett (2005) and Di Lorenzo 
(2003). Witton et al. (2003) noted that in breast cancer patients HER1-3 were often 
co-expressed but rarely co-expressed with HER4. In ER positive patients with high 
expression  of  HER1-3  had  a  significantly  worse  prognosis  than  those  expressing  
HER4 – HER1-3 acting in concert but in opposition to HER4 differing with this study 
which  demonstrated  all  4  markers  correlated  with  positive  outcome  .    194 
Heterodimerisation  as  a precursor  to  cellular  action  implies  different  HER  family 
member expression can be associated with similar pathway activation and cellular 
effects  hence  increased  expression  of  any  is  associated  with  increased  pathway 
activity. 
2. Is Heregulin (HRG) involved in mechanisms by which HER family proteins affect 
cancer progression? 
Membranous HRG and in one experiment Nuclear HRG expression are associated with 
some positive outcomes in a similar fashion to HER1-4 however there is no correlation 
between HRG and individual HER family member expression. In cohort 1 high HRG 
expression in HSPC but not in HRPC is associated with improved outcome in terms of 
TTR/TTDFR/OS. In the full cohort 2 a combination of cytoplasmic HER3 and HRG 
improved outcome in terms of both TTR and OS. HRG is a primary ligand of HER3 and 
HER4 which are both associated with positive outcome as well. The greater significance 
values for HER4 would suggest that this is the most important factor and suggests it is via 
this  that  HRG  has  its  positive  effect.  It  could  be  hypothesised  that  the  HRG-HER4 
pathway  acts to block  mechanisms that bypass ADT but once this itself in bypassed 
hormone escape can occur and HRG-HER4 no longer has a protective effect.  
3. Do HER family proteins effect oncogenesis via cell proliferation or reduced cell death? 
In contrast to previous research, aside from EGFRvIII, the HER family members do not 
increase oncogenesis however there are significant correlations with positive outcomes. 
In the regression analyses neither KI67 nor TUNEL assay correlate with expression of 
any of the HER family members, additionally there is only one instance of expression of 
KI67 or TUNEL being associated with outcome and this was a negative one (High KI67   195 
expression associated with decreased overall survival). Therefore there is no evidence 
within this study indicating that HER family members exert their influence primarily by 
either proliferation or apoptosis. This could be due to problems with the staining/scoring 
of the proliferation or apoptotic measures; – although the KI67 staining does give some 
expected results the TUNEL assay gave no significant results whatsoever indicating no 
influence of apoptosis on outcomes or that the assay itself was inaccurate. Alternatively it 
could be that proliferation and apoptosis as endpoints are too general to pick up subtle 
cellular  effects  of  the  HER  family  or  that  the  HER  pathways  act  via  other  cell 
mechanisms entirely.  
4. Are trends seen in the pilot study borne out with a larger patient base? 
The  general  trends  of  the  pilot  study  within  HSPC  patients  –  positive  outcomes 
associated  with  high  HER2  and  HER4  expression  with  negative outcomes  associated 
with EGFRvIII are borne out in the larger patient base. In fact high expression of other 
family members EGFR and HER3 was also correlated with positive outcomes as well as 
some combinations of family members. In terms of specific conclusions some are carried 
over but the most notable HER 2 as an independent positive predictive marker of time to 
relapse  in  hormone  sensitive  tumours  was  not  confirmed  on  multivariate  analysis 
(although  significant  on  Kaplan-Meier,  univariate  COX  and  in  combination  with 
cytoplasmic HER3 which was an independent predictor in this study).  
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5.5 IMPLICATIONS OF RESULTS  
As was suggested by the pilot study HER family members are associated with positive 
outcomes in hormone sensitive prostate cancer and as such are not suitable for targeting 
with immunotherapy in this patient group. This also provides an explanation as to why no 
antitumour agents targeting HER family members have emerged as clinically viable in 
CaP. EGFRvIII remains the only negatively prognostic family member but given the lack 
of EGFRvIII staining possible in this study, it is difficult to draw conclusions regarding 
EGFRvIII targeting. Where HRG expression is associated with significant results high 
expression is positively prognostic therefore might be involved with activation of the 
HER family in this scenario. 
High expression of HER family members is positively prognostic and there is evidence 
within this study that there is an additive effect with increased numbers of HER protein 
markers  positively  expressed.  This  effect  is  more  profound  in  patients  who  have 
undergone  ADT.  Membranous  expression  of  all  4  HER  family  members  is  an 
independent  predictor  of  delayed  TTR.  Individual  markers  that  have  emerged  as 
independent predictors within this study are 
·  Very High Membrane expression of EGFR in ADT patients 
·  Very high membrane expression of EGFRvIII, High cytoplasm expression of HER3, 
High membrane expression of HER4 in all patients 
The possibility is raised for HER family member expression to be used as a prognostic 
test to indicate those most likely to respond well to ADT and therefore not require other 
treatments. 
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5.6 LIMITATIONS OF STUDY 
The  principle  limitations  to  this  study  are  incomplete  staining  of  the  full  cohort  and 
incomplete patient information. While the full cohort number of n=357 is high  for  a 
tissue based study, limitations in availability of all TMAs and commercial antibodies 
reduce the patient numbers for each specific marker reducing the statistical power of the 
study below its apparent level.  
 
Despite rigorous data collection it is not possible to obtain all relevant information for 
each patient due to the limitations of availability of patient records, the large number of 
patients,  the  extensive  duration  over  which  original  data  was  collected  given  the 
prolonged course of CaP and inconsistent completeness of computer records the further 
back in history you go. The incompleteness of information is apparent in the recorded 
demographics of the patient cohorts in this study where a proportion of patients have no 
recorded  stage,  Gleason  score,  metastasis  status,  hormone  escape  stage  etc.  again 
reducing the statistical power of the conclusions based on this data. The high number of 
subjects is, in itself, an attempt to compensate for the anticipated gaps in patient data.  
 
The heart of this study is the modified histoscore – a subjective assessment of staining. 
The  methods by  which  this  subjective  method  is  addressed  and  compensated  for  are 
detailed in this and previous studies (Kirkegarrd 2006). 
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5.7 CONCLUSION 
In this study high expression of EGFR, HER2-4 and HRG in Hormone Sensitive Prostate 
Cancer were correlated with improved prognosis in terms of time to biochemical relapse 
and  overall  survival.  EGFRvIII  was  correlated  with  poor  prognosis.  Several  marker 
expression combinations were also correlated with improved prognosis including high 
expression of all 4 main family members together. Significant results are more common 
in  a  subcohort  of  patients  treated  with  ADT.  High  expression  of  HER4  and  high 
expression of HER1-4 together give the most significant results. While HER4 and HRG 
have previously been associated with positive outcome this study contradicts previous 
literature regarding EGFR and HER2 which have previously been associated with poor 
prognosis. The possibility is raised that HER family member expression be used as a 
prognostic test to indicate those most likely to respond well to ADT.  
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APPENDIX 1: IMMUNOHISTOCHEMISTRY AND INTER-OBSERVER SCORING 
                         FOR CHAPTER 3 
 
AP1.1: KI-67 
Figure AP1-1: KI-67 Immunohistochemistry 
a1) KI67 Stained Prostate Tumour           b) Negative Control for KI67 
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a1) Prostate Tumour stained with KI-67. b) Prostate Tumour Negative for KI-67 Staining 
c) Histogram showing distribution of KI-67 nuclear count in HSPC samples. d) 
Histogram showing distribution of KI-67 nuclear count in HRPC samples. 
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Figure AP1-2: Inter-Observer Variation in KI-67 Staining between double scored tissue 
sections in Cohort 1 
 
a) Scatter Graph Plot demonstrating Inter-Observer Variation in KI-67 Nuclear Count b) 
Bland-Altman Plot demonstrating Inter-Observer Variation in KI-67 Nuclear Count 
 
AP1.2: TUNEL ASSAY 
Figure AP1-3: TUNEL ASSAY Immunohistochemistry 
a1) TUNEL Assay Staining in Prostate   b) Negative control for TUNEL Assay 
       cancer 
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a1)  Prostate  Tumour  stained  with  TUNEL  Assay.  b)  Prostate  Tumour  Negative  for 
TUNEL  Assay Staining  c)  Histogram  showing  distribution  of TUNEL  Assay  nuclear 
count in HSPC samples. d) Histogram showing distribution of TUNEL Assay nuclear 
count in HRPC samples 
 
Figure  AP1-4:  Inter-Observer  Variation  in  TUNEL  Assay  Staining  between  double 
scored tissue sections in Cohort 1 
  
a) Scatter Graph Plot demonstrating Inter-Observer Variation in TUNEL Assay Nuclear 
count. b) Bland-Altman Plot demonstrating Inter-Observer Variation in TUNEL Assay 
Nuclear Count 
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APPENDIX 2: IMMUNOHISTOCHEMISTRY AND INTER-OBSERVER SCORING 
                        FOR CHAPTER 4 
 
AP2.1: HER2 
 
Figure AP2-1: Immunohistochemistry of HER2 
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a) Specimen of Prostate Adenocarcinoma demonstrating HER2 staining b) Negative 
control for HER2 staining c) Histogram showing intensity of HER2 membranous 
expression. 
 
 
 
 
 
 
 
 
a) HER2 in Prostate Cancer  b) Negative Control for HER2   231 
Figure  AP2-2:  Inter-Observer  Variation  in Heregulin  Staining  between double  scored 
tissue sections in Tissue Microarrays 
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a)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Membranous  HER2 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Membranous 
HER2 Staining. 
AP2.2 HER3 
 
Figure AP2-3: Immunohistochemistry of HER3 
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a) Specimen of Prostate Adenocarcinoma demonstrating HER3 staining b) Negative 
control for HER3 staining c) Histogram showing intensity of HER3 cytoplasmic 
expression. d) Histogram showing intensity of HER3 membranous expression. 
Figure  AP2-4:  Inter-Observer  Variation  in Heregulin  Staining  between double  scored 
tissue sections in Tissue Microarrays 
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a)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Cytoplasmic  HER3 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Cytoplasmic 
HER3  Staining.  c)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in 
Membranous  HER3  Staining.  d)  Bland-Altman  Plot  demonstrating  Inter-Observer 
Variation in Membranous HER3 Staining. 
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AP2.3: HER4 
 
Figure AP2-5: Immunohistochemistry of HER 
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a)  Specimen  of  Prostate  Adenocarcinoma  demonstrating  HER4  staining  b)  Negative 
control  for  HER4  staining  c)  Histogram  showing  intensity  of  HER4  cytoplasmic 
expression. d) Histogram showing intensity of HER4 membranous expression. 
 
 
 
 
 
 
b) Negative Control for HER4 
a) HER4 in Prostate Cancer   234 
Figure AP2-6: Inter-Observer Variation in HER4 Staining between double scored tissue 
sections in Tissue Microarrays 
 
 
 
 
0 50 100 150
HER4C Scorer 2
0
50
100
150
H
E
R
4
C
 
S
c
o
r
e
r
 
1
￿ ￿ ￿
￿
￿
￿ ￿ ￿
￿
￿
￿ ￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿ ￿
￿ ￿
￿
￿
￿ ￿ ￿
￿
￿ ￿ ￿ ￿
￿
￿ ￿
￿ ￿ ￿ ￿
￿
￿
￿
￿
￿ ￿ ￿
￿
￿
￿
￿
￿ ￿ ￿ ￿ ￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿ ￿ ￿ ￿ ￿
￿ ￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿ ￿ ￿ ￿
￿
￿
￿
￿
￿ ￿
￿ ￿
￿ ￿ ￿
￿ ￿ ￿ ￿ ￿ ￿
￿
￿
￿ ￿ ￿ ￿
￿ ￿ ￿ ￿
￿
￿
￿
￿ ￿
￿ ￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿ ￿
￿
￿
￿ ￿
￿
￿
￿
￿
R-square=0.92
 
 
0 25 50 75 100
HER4M Scorer 2
0
25
50
75
100
H
E
R
4
M
 
S
c
o
r
e
r
 
1
￿
￿
￿
￿ ￿ ￿ ￿ ￿
￿
￿ ￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿ ￿
￿ ￿
￿
￿
￿ ￿ ￿
￿
￿ ￿
￿
￿
￿
￿
￿ ￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿ ￿
￿
￿
￿ ￿
￿ ￿
￿
￿
￿
￿ ￿ ￿ ￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿ ￿ ￿ ￿ ￿
￿
￿
￿
￿
￿ ￿
￿ ￿
￿ ￿ ￿
￿ ￿ ￿
￿
￿ ￿
￿
￿ ￿
￿ ￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿
￿
￿
￿
￿
￿
￿
￿
￿ ￿ ￿
￿
￿
￿ ￿
￿
￿
￿
￿
R-square=0.80
 
 
 
a)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Cytoplasmic  HER4 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Cytoplasmic 
HER4  Staining.  c)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in 
Membranous  HER4  Staining.  d)  Bland-Altman  Plot  demonstrating  Inter-Observer 
Variation in Membranous HER4 Staining. 
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AP2.4: Heregulin 
 
Figure AP2-7: Immunohistochemistry of HRG 
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a) Histogram showing intensity of HRG cytoplasmic expression. b) Histogram showing 
intensity of HRG membranous expression. c) Histogram showing intensity of HRG 
Nuclear Expression 
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Figure  AP2.8:  Inter-Observer  Variation  in  Heregulin  Staining  between  double  scored 
tissue sections in Tissue Microarrays 
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a)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in  Cytoplasmic  HRG 
Staining. b) Bland-Altman Plot demonstrating Inter-Observer Variation in Cytoplasmic 
HRG  Staining.  c)  Scatter  Graph  Plot  demonstrating  Inter-Observer  Variation  in 
Membranous  HRG  Staining.  d)  Bland-Altman  Plot  demonstrating  Inter-Observer 
Variation  in  Membranous  HRG  Staining.  e)  Scatter  Graph  Plot  demonstrating  Inter-
Observer Variation in Nuclear HRG Staining. f) Bland-Altman Plot demonstrating Inter-
Observer Variation in Nuclear HRG Staining. 
 
AP2.5: KI67 
 
Figure AP2-9: KI67 Immunohistochemistry 
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a) Histogram showing distribution of KI67 nuclear count in Full Cohort. 
 
 
f) Inter-Observer Difference HRG Nuclear  e) HRG Nuclear Staining   238 
Figure AP2-10: Inter-Observer Variation in KI67 Staining between double scored tissue 
sections in Cohort  
 
a) Scatter Graph Plot demonstrating Inter-Observer Variation in KI67 Nuclear Count b) 
Bland-Altman Plot demonstrating Inter-Observer Variation in KI67 Nuclear Count  
 
 
AP2.6: TUNEL ASSAY 
 
Figure AP2-11: TUNEL ASSAY Immunohistochemistry 
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a) Histogram showing distribution of TUNEL Assay nuclear count in Full Patient Cohort 
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Figure  AP2-12:  Inter-Observer  Variation  in  TUNEL  Assay  Staining  between  double 
scored tissue sections in Cohort 1 
a) Scatter Graph Plot demonstrating Inter-Observer Variation in TUNEL Assay Nuclear 
count. b) Bland-Altman Plot demonstrating Inter-Observer Variation in TUNEL Assay 
Nuclear Count 
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SUMMARY 
 
Prostate  Adenocarcinoma  is  a  significant  issue  facing  UK  healthcare  today  with 
incidence growing to the level that it is the most commonly diagnosed cancer in males. 
Research has focussed on signal transduction molecules that may underlie progression of 
CaP allowing the development of prognostic markers to guide therapy and anti-tumour 
therapies  that  may  complement  or  replace  current  treatments  -  radical  and  hormonal 
therapy.  
The HER tyrosine kinase family  - EGFR, HER2, HER3 and HER4 - has proved fruitful 
in breast cancer research but currently evidence regarding influence of these receptors 
during  disease  progression  in  prostate  adenocarcinoma  is  conflicting  –  both  poor 
prognosis and no influence on outcome are reported. Few studies have considered the 
family as a whole. A small cohort pilot study of paired hormone sensitive (HSPC) and 
refractory  (HRPC)  specimens  demonstrated  HER2/HER4  as  positively  prognostic  in 
HSPC. While  HER4  has  been  demonstrated as  positively  prognostic  in  breast  cancer 
previously, HER2 has been shown to have a negative influence in many cancer types and 
this apparent positive correlation is a rare finding. In accordance with previous studies the 
constitutively  active  variant  EGFRvIII  was  seen  in  the  pilot  to  negatively  influence 
prognosis 
Attention  has  also  focused  on  Heregulin  (a  principle  HER  family  ligand,  which  has 
previously been noted to have a differential effect on HSPC (decreased proliferation) and 
HRPC (increased proliferation) cell lines. This study determines influence of HER family 
and  HRG  in  a  larger  HSPC  cohort  and  whether  downstream  influence  mechanisms 
involve proliferation or apoptosis.   241 
Patients and Methods 
Immunohistochemical staining for HRG, KI67 (proliferation), TUNEL (apoptosis) was 
performed on pilot study specimens with  Further IHC for EGFR, HER2, HER3, HER4, 
HRG,  KI67  and  TUNEL  was  performed  on  HSPC  tissue  microarrays.  Correlations 
between  target  protein  expression  and  the  outcomes  time  to  biochemical  relapse  and 
overall survival were determined. 
 
Result 
On univariate analysis high expression of all 4 main HER was correlated with improved 
prognosis particularly in androgen deprivation treated subcohort (examples include high 
EGFR and longer time to relapse p=0.02, high HER2 and delayed relapse p=0.002, high 
HRG  and  delayed  relapse  p=0.004).  Concurrent  high  expression  of  several  marker 
combinations was also correlated with improved outcome and high expression of all 4 
main members increased association significance (e.g. high HER1-4 and delayed relapse 
p=0.001).  
Several  trends  were  seen  within the data;-  if samples  were  divide into high  and  low 
expression by the upper quartile rather than the median more significant results were 
seen,  membranous  marker  expression  gave  more  significant  correlations  than  other 
cellular  locations  and  more  significant  results  were  seen  in  the  subcohort  of patients 
treated with Androgen Deprivation Therapy. Membranous HRG was seen to be positively 
prognostic if highly expressed in HSPC but not HRPC tissue. 
With multivariate analysis a small number of these markers remained significant if the 
influence  of  Gleason  Score  and  Metastasis  at  presentation  were  included.  Markers   242 
retaining significance on multivariate analysis included cytoplasmic HER3 (p=0.035), 
membranous HER4 (p=0.014) and membranous HER1-4 (p=0.045) combined 
No correlations between HER/HRG expression and proliferation or apoptosis were seen. 
 
Conclusion 
The  HER  family  and  HRG  are  positively  prognostic  in  prostate  adenocarcinoma.  In 
keeping with previous literature high HER4 appears to have the most significant positive 
influence but high expression of other markers is also seen to have a positive influence 
counter to previous studies. HRG positive influence is in keeping with its action as a 
HER4 ligand.  
These results provide an explanation as to why efficacy of HER family based anti-tumour 
agents have had limited efficacy in CaP. These results have implications for the use of 
HER family as outcome predictors to guide management possibly in relation to predicting 
good response to Androgen Deprivation Therapy.  
 
 